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 1 
Abstract 
 
Development of chiral ligands capable of achieving high selectivity for various 
asymmetric catalytic reactions has been an important aim of both academia and 
industry. Nature is capable to selectively catalyze chemical reactions by using 
enzymes. An ideal catalyst would combine the selectivity of nature and the reactivity 
of man-made catalysts based on transition metal complexes. The two biomolecules 
chosen to achieve this are DNA and PNA. DNA is a chiral molecule with high 
binding selectivity towards small molecules and has been used as ligand for 
asymmetric catalysis. PNA is an achiral structural analogue of DNA that can form 
duplexes with DNA. To produce DNA based catalysts it is necessary to introduce a 
ligand such as a phosphine that will strongly coordinate to transition metals. To 
achieve this, functionalized linkers need to be introduced into a DNA strand, to 
covalently couple the phosphine moiety at a specific location of the DNA strand. 
Amine linkers and several modified nucleosides have been prepared containing thiol 
and amine functionalities and some of them were successfully introduced into DNA 
strands to function as linkers for the introduction of phosphine functionalities. Those 
strands were purified and an adequate procedure was developed for their analysis by 
MALDI-TOF. Diphenylphosphino carboxylic acids have been coupled to amine 
modified deoxyuridines by amide bond formation. The same coupling method has 
been used for oligonucleotides. DNA strands containing phosphine moieties were 
characterized by MALDI-TOF and 
31
P NMR spectrometry. 
31
P NMR spectroscopy 
was also used to confirm coordination of a phosphine modified 15-mer to [PdCl(3-
allyl)]2. The phosphine modified nucleobases were also tested as ligands for 
palladium catalyzed allylic alkylation and allylic amination with diphenylallyl acetate 
as substrate although no enantioselectivity was observed. A PNA monomer was also 
modified with a bidentate sulfur protected phosphine and successfully introduced into 
a short PNA strand using manual solid phase synthesis. This strand was analyzed by 
MALDI-TOF. Moreover, preliminary studies were performed to test the use of 
aptamers as scaffolds for targets containing a ligand functionality.  
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Chapter 1: General Introduction 
 
1. Introduction 
1.1 Need for catalysis 
Fine chemical manufacturers rely on catalytic reactions for the production of the 
majority of their chemicals, although many chemicals are still made by using 
stochiometric amounts of activators. Those stochiometric reactions produce large 
amounts of waste per kilogram of product synthesized and the majority of those waste 
products are inorganic salts. For a sustainable development it is necessary to 
minimize the environmental damage by eliminating waste formation and the use of 
toxic materials during chemical production. This concept is known as green chemistry 
and was first introduced by Anastas in 1994 at the Environmental Protection Agency 
(EPA) in the United States.
1
 To quantify the efficiency and environmental impact of a 
chemical reaction two parameters have been defined. The E factor is defined as the 
mass ratio of waste to desired product, the higher the E factor the larger the waste 
production
1
. The atom economy is calculated by dividing the molecular weight of the 
desired product by the sum of the molecular weight of all the products of the 
reaction.
2-4
 A large scale process like oil refining has an E factor of ˂0.1, the E factor 
of Bulk chemicals increases to <5 while fine chemicals industries can reach an E 
factor of 50 whereas the production of pharmaceuticals can reach an E factor larger 
than 500.
3
 Those two measurements for waste production only take into account the 
amount of waste produced. Since the environmental impact of this waste depends on 
its toxicity and potential danger, Sheldon et al have introduced the environmental 
quotient (EQ) which is the E factor multiplied by an unfriendliness quotient Q.
5
 For 
example, NaCl can have a value of 1 compared to a heavy metal salt which would 
have a Q of 100-1000. Those values are only an estimate and are meant to give a 
general idea about the toxicity of a substance and its environmental damage. To 
reduce the EQ and increase the atom economy chemical industries are striving to 
develop processes based on the use of H2, O2, H2O2, CO, CO2 and NH3 as sources of 
H, O, C and N.
1
 Catalysts can decrease the amount of waste production, prevent the 
use of dangerous chemicals and decrease the use of starting material. Figure 1 shows 
the drastic improvement in atom economy for several representative reactions by 
going from the use of a stoichiometric system to a catalytic one. Different types of 
catalysis are distinguished comprising organocatalysis, biocatalysis, homogeneous 
 3 
and heterogeneous catalysis. Transition metal complexes have been used for catalytic 
processes because of their ability to activate organic molecules. An example is the 
synthesis toward the commonly used analgesic ibuprofen which has an annual 
production of several thousand tons. This drug is produced from p-
isobutylacetophenone by hydrogenation and carbonylation and it is produced with an 
atom economy of 100% (Scheme 1).
1
 
 
 
 
Scheme 1. Hoechst Celanese process for ibuprofen, 99% conv., 96% selectivity, 100% atom 
economy.
1
 
 
 
Figure 1. Atom economy of stochiometric process versus catalytic process for various 
reactions.
2
 
 
1.2 Hybrid Catalysts 
1.2.1 Artificial metalloenzymes   
Enzymes, nature‟s catalysts, are essential molecules present in all living organisms 
that are able to largely increase the speed of a reaction. They have been thought to be 
exclusively proteins but only a few decades ago it was discovered that RNA can also 
function as a catalyst. They stabilize the transition states of the various reactions 
performed in a living organism.
6
 Enzymes are composed of L-amino acids and have 
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an active binding site where a substrate is catalytically transformed. Enzymes are 
highly specific towards the identity of the substrate, the section of the substrate to be 
transformed and the course of the reaction toward the formation of a specific product. 
An enzyme generally binds the molecules undergoing the catalytic change and can 
distinguish the two sides of a prochiral molecule to give exceptionally high 
enantiomeric excess (ee).
7
 Those chemical transformations are performed in the 
active site of the enzyme. An assembly of strategically placed amino acids in the 
active site weakly binds to a specific substrate and makes the desired reaction occur. 
This binding is possible through various noncovalent interactions such as hydrogen 
bonding, van der Waals forces, electrostatic bonds, and hydrophobic interactions.
6
 
Because of their high selectivity, specificity and control of both first and second 
coordination spheres, enzymes have a high potential for being used as catalysts for 
asymmetric reactions. The drawback of enzymatic catalysis is that enzymes are made 
for specific reactions that do not include many of the various chemical reactions 
performed in industry. The combination of biocatalysis with transition metal catalysis 
would ideally give life to the perfect catalyst for highly selective asymmetric 
reactions. Whitesides and Wilson were the first to combine the selectivity of enzymes 
with transition metal catalysis. Whitesides synthesized a modified biotin with a 
diphosphine ligand complexed to rhodium(I) to noncovalently bind it to the protein 
avidin (Figure 2). This new biocatalyst was then used for the asymmetric 
hydrogenation of α-acetamidoacrylic acid to N-acetylalanine (Scheme 2). Modified 
biotin with avidin gave ee up to 40% (S) while biotin alone gave no enantioselectivity 
proving that the protein was capable of transferring its chirality to the catalytic 
reaction.
8
 
 
(strept)avidin
 
Figure 2. Biotin-(stept)avidin catalyst engineered by Whitesides for enantioselective 
hydrogenation reactions.
9
 Reprinted from J. Steinreiber and T. R. Ward, Coordination Chemistry Reviews, 
 2008, 252, 751-766. Copyright 2008, with permission from Elsevier. 
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Scheme 2. Enantioselective hydrogenation of α-acetamidoacrylic acid to N-acetylalanine 
using a protein based catalyst.
9
 
 
Inspired by Whitesides‟ work, Thomas Ward has further investigated the use of the 
biotin-avidin biocatalyst for enantioselective hydrogenation reactions. By changing 
avidin to streptavidin Ward was able to obtain ees as high as 94% (R) with 85% 
conversion for the hydrogenation of acetamidoacrylic acid and acetamidocinnamic 
acid. The advantage of streptavidin over avidin is a deeper binding pocket. For the 
purpose of optimizing the selectivity of the catalyst, Ward has used the 
“chemogenetic approach” which involves modifying both the biotin and the protein 
parts. The biotin was modified by changing the metal, the phosphine ligands and the 
spacer between ligand and protein. The protein itself was modified by using 
saturation mutagenesis at a specific position of the scaffold.
9
 Eight spacers between 
ligand and biotin were tested; five alkylamino acids and three arylamino acids and 
they were used for both steptavidin and avidin (Scheme 3). Avidin Biot-3-2 
represented in Scheme 3 gives 80% ee (S) for the production of amidoalanine while 
the biotin 1 gives only 39% ee. The protein modification increased slightly the 
enatioselectivity of both enantiomers.
9,10
 By changing the ligand scaffold to amino-
sulfonamide ruthenium and rhodium complexes Humbert et al were able to catalyze 
the oxidation of secondary alcohols
11
 and the reduction of ketones by transfer 
hydrogenation.
12
 Figure 3 shows how the protein and the metal complex are 
positioned in the appropriate orientation towards the substrate for the hydrogenation 
reaction. The protein has a cavity where the biotin anchor is bound, this anchor 
contains a spacer and a bidentate for metal coordination. The substrate is introduced 
in the cavity and the hydrogen is transferred from the metal complex to the substrate 
without any coordination of the substrate with the metal to give enantioselectivities 
up to 97% (R).
13
 Further modifications of the active site slightly increased the 
enantioselectivities to 98% (R).
14
  
 6 
 
 
Scheme 3. Enantioselective hydrogenation with eight different ligands.
9
 Reprinted from J.  
Steinreiber and T. R. Ward, Coordination Chemistry Reviews, 2008, 252, 751-766. Copyright 2008, with  
permission from Elsevier. 
 
hn-CnRn
(strept)avidin
M=Ru(II); n=6 
M=Rh(III), Ir(III); n=5
artificial metalloenzyme
*
 
 
Figure 3. Artificial metalloenzymes used for the enantioselective transfer hydrogenation 
reactions.
13 Reprinted with permission from C. Letondor et al. Journal of the American Chemical Society, 2006, 
128, 8320-8328. Copyright 2006 American Chemical Society. 
 
Streptavidin was also used with biotin modified with manganese-salen complexes to 
catalyze the aqueous sulfoxidation of thioanisole using hydrogen peroxide. Although 
enantioselectivities were not high (up to 56%) those findings show the transfer of 
chirality from the protein to the catalytic reaction.
15
 Those examples show how ligand 
 7 
design combined with biomolecular tuning can produce a large number of catalysts 
with varying activities in a short period of time.  
Reetz and co-workes have used a Darwinistic approach to genetically modify proteins 
to better fit their enantioselective reactions and to be more stable in the presence of 
non-natural substrates. This method is called directed evolution and implies random 
mutagenesis of the gene of an enzyme, giving a library of numerous genes which are 
then expressed into enzymes. The size of the library, n, can be calculated by using the 
formula n=19
M
 x 285/[(285-M) x M], where M is the number of amino acids 
substituted in the enzyme. Once the enzymes are produced, they are ready to be 
screened as enantioselective catalysts. Once a few improved mutants have been 
detected they go through the same cycle until the optimal enzyme is produced (Figure 
4).
16
 Several other approaches were used for proteins mutation and another common 
method is the combinational active-site saturation test (CAST). This method uses the 
3D structure of the wild type protein containing a substrate to locate the amino acids 
that can participate to the substrate binding. Depending on the secondary structure of 
the protein the spatially close amino acids can be located in locations such as a loop, 
β–sheet or α helix. This method consists of randomly mutating specific pairs of 
amino acids to enhance the enantioselectivity and catalytic properties of the 
protein.
17,18
 
 
 
Figure 4. Directed evolution of an enantioselective enzyme.
19,20
 Reprinted from M. T. Reetz et al.  
Tetrahedron 2007, 63, 6404-6414. Copyright 2007, with permission from Elsevier. 
 
Reetz et al have used the CASTing approach for the optimization of streptavidin and 
the Rh(diphosphine) modified biotin cofactor to improve the 23% enantioselectivity 
 8 
for (R) achieved by Thomas Ward in the hydrogenation of α–acetamido-acrylic acid. 
The protein cavity was modified in the proximity of Rh (I) and further away from the 
metal to give an enantioselectivity of 65% for the (R) product. Although the 
selectivity improved with respect to Ward‟s catalyst, not all 200-300 clones that were 
synthesized could be tested for catalysis because of the low clone yield. In theory, the 
mutant with the highest enantioselectivity might not have been the best mutant of the 
screening process.
20,21
 Nevertheless, this study clearly shows the proof of principle 
that advanced techniques such as directed evolution combined with screening can be 
applied to improve the selectivity of a hybrid catalyst.   
Kaiser et al in 1988 were the first to covalently modify the active site of a protein.
22
 
This approach was later used by Reetz to covalently introduce a coenzyme in a 
protein‟s scaffold. In this case papain was modified by addition of the thiol of cys25 
to a maleimide containing a Mn/salen ligand (Scheme 4). This hybrid catalyst was 
used in asymmetric epoxidation which gave only 10% ee.
20,23
  
 
 
 
Scheme 4. Schematic representation of covalently bonded ligand to a protein and Mn/Salen 
ligand coupled to papain.
20
 
 
In 1996 Distefano et al covalently bonded a phenantroline moiety to a cysteine 
located inside the active site of Adipocyte Lipid Binding Protein (ALBP) for the 
coordination with Cu (II). This metalloenzyme was used for the enantioselective 
hydrolysis of various unactivated amino acid esters. High enantioselectivity was 
achieved with the racemic mixture of alanine isopropyl ester where the L enantiomer 
was hydrolyzed 13 times as faster than the D isomer giving 86% ee.
24,25
 Several other 
groups have used anchoring methods to bind their ligand to a protein for catalytic 
purposes. Lu has used a methane thiosulphonate group for dual anchoring of a 
 9 
Mn/Salen complex into apo sperm whale myoglobin for the enantioselective 
sulfoxidation of thioanisole. Figure 5 shows the dual anchoring by formation of 
disulfide bridges between the ligands and the protein. With his dual anchoring 
strategy, Lu achieved 51% ee without any need of protein modification. By using a 
double anchor, conformational states available for the metal complex are limited 
leading to better reaction rate and higher enantioselectivity.
26
  
 
 
 
 
Figure 5. A) computer model of ligand 1 attached to myoglobin, B) Mn/Salen ligand.
26
 
Reprinted with permission from J. R. Carey et al. Journal of the American Chemical Society, 2004, 126, 10812- 
10813. Copyright 2004 American Chemical Society." 
 
1.2.2 Peptides as catalysts  
Proteins are not the only biomolecules used for catalytic reactions. In 1970 the amino 
acid proline was used for the first time as a catalyst for the Robinson annulation 
reaction.
27,28
 Since then other researchers have been using proline and small peptide 
molecules as biocatalysts.
29 
Miller at al. have been using small and large 
oligopeptides for various asymmetric reactions. An example is an oligopeptide with a 
β-Turn and a stereogenic centre that can catalyze asymmetric aziridation.30 Longer 
peptides have also been used for regioselective reactions such as the acylation of 
carbohydrate compounds
31
 and even peptide containing phosphines have been used 
for enantioselective cycloadditions.
32
 It is important to underline that all the catalysts 
used by Miller are organocatalysts that can produce high selectivities without the 
presence of transition metals. Gilbertson combined the special properties of amino 
acids with metal based catalysis producing metal-peptide complexes as catalysts for 
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asymmetric reactions. Since 1994, Gilbertson and co-workers have been studying the 
use of phosphine modified amino acids-metal complexes for asymmetric catalysis. 
Their first studies were focused on the addition of amino acids containing a protected 
phosphine moiety (diphenylphoshino-alanine sulfide) into a peptide chain with high 
helix content. Two phosphine moieties were placed with a four amino acid distance 
from each other in a solid supported peptide and later deprotected with Raney nickel. 
Owing to the helical structure of the peptide the two phosphine moieties were at the 
optimum distance from each other to coordinate as a bidentate to a metal, such as 
rhodium, forming a metal-peptide complex. (Figure 6)
33
 
 
 
Figure 6. 
31
P NMR representing: a) sulfur protected phosphine moiety introduced in a 
 peptide, b) deprotectedPhosphine moiety, c) Rhodium complex of the phosphine modified  
peptide.
33
 Reprinted withpermission from S. R.Gilbertson, G. Chen and M. McLoughlin, Journal of the 
American Chemical Society, 1994, 116, 4481-4482. Copyright 1994 American Chemical Society. 
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The peptide ligand can be modified giving a large variety of catalysts in a relatively 
short time. In fact, Gilbertson has continued his study in peptide catalysis by 
introducing two electronically different phosphine moieties into a peptide. Since the 
peptide favours only one conformation, it is not necessary to use phosphine ligands 
with C2 symmetry and it is possible to introduce (dicyclohexylphosphino)-alanine 
sulfide and the previously used diphenylphosphino-alanine sulphide ligands in the 
peptide. (Figure 7)
34
 
 
 
 
Figure 7. 
31
P NMR of rhodium complex with two different phosphine moieties.
34
 Reprinted 
with permission from S. R. Gilbertson and X. Wang, J. Org. Chem. 1996, 61, 434-435. Copyright 1996 American 
Chemical Society. 
 
The fist attempt of Gilbertson to use the metal complex in catalysis was in 1996 with 
peptide-rhodium complexes on solid support.
35, 36
 63 different phosphine modified 
peptides were synthesized on solid support. The phosphines were located at three 
different distances from each other (i+4, i+3, i+1, i=modified peptide) and tested for 
the hydrogenation of an enamide but enantioselectivities were lower than 20%. The S 
enantiomer reached an ee higher than 10% when dicyclohexylphosphinoalanine was 
present and when the distance between the two phosphines was i+3. For the R 
enantiomer an ee greater than 10 % was only achieved when the distance between the 
two phosphines was i+1.
36
 More recently, Gilbertson has studied different 
asymmetric catalytic reactions obtaining higher enantiomeric excesses. The catalyst 
that he used for those reactions is a peptide with a derivative of proline inside a β-turn 
motive between the two phosphine groups. These turns increased the vicinity of the 
two phosphine moieties and favoured hydrogen bonding between the amino acids 
near the turns. (Figure 8) 
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Figure 8. Peptides containing a proline inside β-turns between the two phosphine groups.37,38 
 
The addition of dimethyl malonate to cyclopentenyl acetate (Scheme 5) with a 
palladium complex of the proline modified peptide with two diphenylphosphines as 
ligands (#1 in Figure 8) gave ee ranging from 34 to 80%.
37
 For the same catalytic 
reaction it was possible to achieve up to 95% ee by using a different phosphine 
moiety on a peptide in solution (#2 in Figure 8).
38,39
 
 
 
 
Scheme 5. Addition of dimethyl malonate to cyclopentenyl acetate. 
 
1.3 DNA 
As stated before, the presence of a chiral ligand is a prerequisite for asymmetric 
catalysis. Chirality is also present in all life forms. The chiral molecule DNA contains 
genes which have the hereditary information that is carried on from generation to 
generation in all living organisms. Deoxyribonucleic acid (DNA) consists of a series 
of coupled deoxynucleotides. A nucleotide is composed of a base, a ribose, and a 
phosphoric acid residue. The bases are purine bases, adenine (A) and guanine (G), 
and pyrimidine bases, cytosine (C) and thymine (T). Following the well known 
Watson-Crick rules for double helix formation, adenine pairs with thymine and 
cytosine pairs with guanine through hydrogen bonding. Two single complementary 
strands form a double helix because of interactions between complementary bases 
and π-π stacking. Base pairing is perpendicular to the helix central axis and the two 
 13 
strands are antiparallel to each other, one going from 3‟ to 5‟ and the other going 
from 5‟ to 3‟ (Figure 9). 
 
This material is unavailable due to copyright restrictions 
 
Figure 9. DNA double helix with base pairings. Taken from the U. S. National Library of Medicine. 
 
There are three main types of double helices. A, B and Z-DNA, (Figure 10). 
 
This material is unavailable due to copyright restrictions 
 
Figure 10. A, B, and Z-DNA double helix. Taken from www.oregonstate.edu 
 
The B-DNA helix is the most common form of DNA found in nature and it contains a 
major and a minor groove which give the shape of the spiral double helix. The width 
of the double helix is around 20 Å (2 nm), the distance between bases is 3.4 Å, and 
one turn of the double helix consists of 10 to 10.5 bases or about 3.5 nm.
40
 In A-
DNA, the base pairs lie at a 20˚ angle with respect to the helix central axis. Both A 
and B DNA helixes wind upwards going from the left to the right and therefore are 
called right handed helices (Figure 11) In contrast Z-DNA is left handed and occurs 
when G-C base pairs frequently repeat each other. In fact, the base sequences in the 
strand can influence several parameters such as curvature, helical twist, rigidity of the 
duplex and groove width. An example is the propeller twist which happens when a 
base rotate between 5̊ and 25̊ with respect to their complementary base. This is 
common when a series of A residues are located next to each other.
41
  
 
This material is unavailable due to copyright restrictions 
 
Figure 11. Right and left handed double helixes. Taken from web.uconn.ed 
 
In addition to these helices, formation of triple and quadruple helical DNA is also 
possible.
42
 In triple or quadruple stranded DNA the third strand is placed in the major 
groove of a double helix. Hydrogen bonds between the purines and pyridines of the 
double helix and single strand give stable triplexes. Two types of triplexes are 
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possible. The first type is a py(pu-py) (py:pyrimidines, pu: purines) triplex where the 
additional strand is pyrimidine rich. The most stable triplexes of this kind are T(A-T) 
and C(G-C), often amines are required to overcome charge repulsion of phosphates. 
The base interactions between the triplexes are of the Hoogsteen type which means 
that the third strand is parallel to the purine strand of the double helix and forms 
hydrogen bonds between the pyrimidines of the third strand and the N7 group of the 
purine strand of the double strand (Figure 12a). The second type is a pu(pu-py) triplex 
where G(G-C) and A(A-T) triplexes stabilize the triple strand. The third strand is also 
antiparallel but to the purine strand of the duplex and it forms reverse Hoogsteen pairs 
(Figure 12b).
43
 The stability of the triple helix not only depends on the base 
interactions but also on the DNA length, temperature, pH, and salt concentration.
44  
The unique proprieties of DNA have been used not only in biochemical research but 
also in nanotechnology to form DNA strands with supramolecular structures such as 
branches and 3-dimensional shapes.
40,45,46
 DNA has also been manipulated to design 
origami type shapes.
47
 The engineered DNA strands with three-dimensional shapes 
and ramifications can give rise to pockets that could be used as hosts or nanoreactors 
for catalytic reactions.  
 
This material is unavailable due to copyright restrictions 
 
Figure 12. Represenation of Hoogsteen and Watson-Creek base pairs.
43
 
 
Artificial DNA using the phosphoramidite method can be synthesized manually or by 
using a DNA synthesizer. The automated synthesis of DNA begins with a 3‟-
hydroxyl nucleotide attached to a solid support by a succinate ester bond. All 5‟-OH 
of the sugar are protected with DMT, therefore the first step during the synthesis is 
the deprotection of DMT by TCA (trichloroacetic acid). The phosphoramidite 
nucleotide is added with tetrazole as the activating agent. All the unreacted 
nucleotides are capped with acetic anhydride and 1-methylimidazole and flushed 
away with acetonitrile. Finally P
(III)
 is oxidized with iodine and water to give a 
phosphatetriester bond. This procedure is repeated until the desired sequence is 
formed. The DNA strand is cleaved from the solid support by using a strong base that 
will also cleave the cyanoethyl group of the phosphodiester groups and all other 
protecting groups of the bases (Scheme 6). The DNA synthesizer calculates the 
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coupling efficiency of the synthesis by measuring the DMT cation release by 
conductivity. The more modern DNA synthesizers can synthesize sequences of up to 
175 bases. The positions and the frequency of the bases in the strand are inserted into 
the DNA synthesizer by the operator
48
 so that the strand can be engineered to better 
fit its purpose. 
 
 
Scheme 6. Automated DNA synthesis.  
 
One draw back of solid phase synthesis is that it is limited to 15μm per preparation. 
Solution phase DNA synthesis is also possible for short sequences
49
 and will be 
discussed later in Chapter 2.  
 
1.3.1. Aptamers 
DNA and RNA sequences have extremely high recognition properties towards small 
organic molecules. Those biomolecules are called aptamers which are single or 
double stranded oligonucleotides that bind to their target by folding around it through 
hydrogen bonding and π-π stacking. The molecular weight range of the target is 
typically between 100 to 1000 Dalton.
50
 Polynucleotide library pools are used to 
generate aptamers which can vary in size and diversity. The more common length for 
an aptamer is about 70 nt (nucleotides) but smaller aptamers can still have the same 
functions. For instance, a 14nt aptamer that binds to flavin mononucleotide (FMN) 
still holds all the properties of its longer version of 35nt and it is still able to 
selectively recognize its target even in the presence of structurally similar 
molecules.
51 
Aptamers can bind to a variety of molecules such as organic dyes, 
antibiotics, amino acids, peptides, proteins, and vitamins.
52,53
 Because of their wide 
binding range, aptamers have been used in therapeutics,
54-56
 as biosensors,
57-62
 
analytical tools,
63,50,58
 antiviral agents,
64
 and as catalysts.
65-67
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Aptamers are produced by a technique called the Systematic Evolution of Ligands by 
EXponential enrichment (SELEX) (Figure 13) developed by Joyce, Szostak, and 
Gold in the late 1980s early 1990s.
67
 
 
 
Figure 13. Systematic Evolution of Ligands by Exponential Enrichment. 1) synthesis of 
random DNA sequences, 2)conversion to RNA by transcription using T7 RNA polymerase, 
3) introduction of target into the DNA pool, 4) removal of low affinity binders, 5) recovery of 
ssDNA and RNA strands, 6) PCR amplification.
68 Reprinted from T. Sampson, World Pat. Inf. 2003, 
25, 123-129.Copyright 2003, with permission from Elsevier. 
 
Each oligonucleotide in the library is composed of a defined region containing 
primers and restriction sites at each end and a randomized region in the centre. 
Taking into account that „n‟ nucleotides yield 4n DNA molecules; the complexity of 
the library depends on the number of nucleotides used. Two different screening 
processes can be performed. The first screening process consists of incubating the 
random polynucleotide mixture and the target molecule in a buffer. The aptamers that 
bind to the target are filtered by using a nitrocellulose filter partitioning, the aptamers 
that are not selective to the target elute first, the aptamers bound to the target elute 
last. The second process to screen aptamers involves immobilizing the target 
molecule on a solid support. All the sequences that do not bind to the target are 
washed away. This step is less common because the aptamer can not always properly 
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fold around the molecule because one part of the molecules is attached to the solid 
support.
68-72
 The bound sequences are eluted and used for the amplification step, 
during this step the previously selected aptamers are enriched for another cycle of 
selection and amplification. The affinity enrichment step is usually completed in 8-15 
cycles depending on the binding target. Once the desired aptamer is selected it can be 
reproduced synthetically. It is often not necessary to use the whole aptamer length but 
it can be shortened to better fit its purpose. The entire cycle of SELEX manually 
would take 2 days but nowadays an automated system can complete 12 rounds of 
selection.
69,71
 Aptamer-binding target studies done by Hermann and Patel
72
 show that 
interaction between aptamers and aromatic ligands is highly specific. Hydrogen 
bonding together with π-π stacking interactions improves binding affinity and 
selectivity for these types of compounds. For example, Theophylline has the same 
molecular structure as caffeine except for an NH group instead of an N–methyl group 
and has 10,000 times more affinity to the aptamer than caffeine (Figure 14). This is 
because theophylline is stacked between two consecutive base-paired nucleotides and 
interacts with a cytosine base by hydrogen bonding. The methyl group in caffeine 
disrupts this interaction.  
 
 
 
Figure 14. A) theophylline molecule, B) 3D image of theophylline in aptamer cavity.
72
  
From T. Hermann and D. J. Patel, Science (Washington, D. C.) 2000, 287, 820-825. Reprinted with permission 
from AAAS. 
 
The selectivity of aptamers is not limited to cyclic compounds. Mann et al
73
 have 
found that ssDNA aptamers that contained G-quadruplexes (guanine rich sequences) 
with potassium cations as stabilizers easily bind to ethanolamine located on magnetic 
beads or in solution. Ethanolamine is the smallest molecule used as an aptamer target 
and this discovery showed that aptamers can be used for clinical and environmental 
analysis. Another example of the high selectivity of aptamers is the RNA aptamer that 
recognizes L-arginine over D-arginine with a 12000-fold difference in binding 
constant.
74
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The selectivity of aptamers is improved by introducing small modifications to 
nucleotide structures that do not interfere with hydrogen bonding and aptamer 
folding. Those modifications have to be compatible with nucleic acids replicating 
enzymes or DNA and RNA polymerases. The preferred location for nucleotide 
modifications are the 5-position of pyrimidines, the 8-position of purines, and the 2‟-
position of all nucleotides.
75
 Small chemical modifications such as the introduction of 
2‟-fluoro and 2‟-amino can improve selectivity and sequence stability53,76,77 An 
example is the aptamer developed for the endothelial growth factor (VEGF). This 
RNA aptamer has 2‟-fluoro pyrimidine and 3‟-O-methyl purine modifications. One 
isoform of the VEGF induces abnormal blood vessel growth and age related macular 
degradation which is a vascular disease that leads to blindness. VEGF is composed of 
a receptor binding domain and a hairpin binding domain. Its aptamer derived from the 
SELEX process specifically recognize this isoform and does not bind to any of the 
other four isoforms.
78
 
The high selectivity of aptamers towards their target molecule combined with 
transition metal complexes can give rise to a hybrid catalyst capable of selectively 
recognizing the substrate by folding around the substrate by hydrogen and π-π 
interactions, thereby positioning it correctly for a selective modification. 
 
1.3.3 DNA in Catalysis 
DNA has been used in hybrid catalysis for a range of asymmetric reactions. Two 
methods have been used for the interaction of the ligand moiety with the DNA, the 
covalent and non covalent approach. The first method developed by Roelfes is the 
non covalent approach where the ligand is located on a DNA intercalator. This 
method places the metal complex in close proximity to the chiral environment of the 
helix without being coupled to a specific part of the DNA strands. This DNA/metal 
complex was used as catalyst for Diels-Alder reactions and Michael additions. For the 
Diels-Alder reaction the catalyst consisted initially of an intercalator such as 9-
aminoacridine with a spacer and a metal binding group which gave 
enantioselectivities up to 90% for the reaction between cyclopentadiene and aza 
chalcone.
79
 In more recent work the spacer has been removed and bipyridine ligands 
have been used to increase the proximity of the copper complex to the DNA for better 
transfer of chirality. Several intercalators with achiral bypyridine ligands were tested 
and the most selective was 4,4‟-dimethyl-2,2‟bypiridine give which gave 99% ee for 
 19 
the endo isomer (Figure 15).
80,81
 Roelfes and coworkers have also used α,β-
unsaturated 2-acryl imidazoles as dienophile for its better solubility in water but this 
resulted in a slightly lower enantioselectivity (83-98% ee for the endo isomer).
82
 The 
same imidazoles were also tested for enantioselective Michael reactions in water with 
the same bipyridine ligand (#5 in Figure 15) which resulted in 99% ee with 
nitromethane and dimethyl malonate as nucleophiles.
83
 It has been also proven that 
for the Diels-Alder reactions changing the DNA sequence can result in a positive 
improvement of enantioselectivity and reactivity. Small changes such as shorter GC 
alternating sequences and two consecutive G‟s can improve the ee from 80% to more 
than 99% for the endo isomer. This is an illustrative example on how small changes 
in the microenvironment of the ligand can largely improve its properties.
84
 
 
        
 
Figure 15. Asymmetric Diels-Alder reaction of cyclopentadiene (1) with aza-chalcone (2), 
using DNA metal complexes as catalysts. Dienophile 2b gave the highest enantioselectivity 
using ligands 7 (92% ee), 10 (95% ee), and 11 (>99% ee).
80
 Reprinted with permission from G. 
Roelfes, A. J. Boersma and B. L. Feringa, Chem. Commun. (Cambridge, U. K.)2006, 635-637. Copyright 2006 
The Royal Society of Chemistry. 
 
To understand the mode of action of a hybrid catalyst that uses the chirality and 
molecular recognition of DNA combined with the activity of transition metal 
catalysts it is important to know where the metal interacts with the DNA ligand. One 
way to introduce the ligand in a well defined position of the DNA strand is to have a 
covalent bond formation between the ligand and the DNA. More recently, Roelfes 
and Jäschke have explored the covalent approach. Roelfes has introduced an amine 
linker of different lengths into the terminal position of the DNA and has introduced a 
bipyridine ligand through amide bond formation. This oligonucleotide is then 
assembled with a second oligonucleotide on a complementary template strand that 
holds both oligonucleotides together. (Scheme 7) The bipyridine ligand was 
complexed with Cu and used for Diels-Alder reaction. Modification of the DNA 
 20 
strands fine tuned the enantioselectivity and a three carbon linker also increased 
enantioselectivity suggesting that a close proximity to the chiral double helix 
improves the ee of the reaction. This great advantage of this method is that several 
ligands could be engineered just by changing the sequence of the complementary 
strand.
85
 
 
 
Scheme 7. Coupling of bipyridine ligand to DNA and its use in Diels-Alder.
85
 
 
Jäschke et al explored DNA transition metal hybrid catalysts for asymmetric allylic 
substitution. An imidazole modified nucleoside was introduced in the central position 
of an oligonucleotide. The imidazole moiety was made to react with amine 
functionalities during the basic DNA cleavage from solid support giving DNA 
modification and cleavage in one pot. In this way amine linkers can be introduced 
into the DNA strand and those linkers can later be coupled to ligands containing a 
carboxylic acid moiety or alternatively ligands with an amine moiety can be directly 
introduced on the DNA strand (Scheme 8). Bicyclo[2.2.2]octadiene was modified 
with a carboxylic acid or an amine moiety and both methods were used for 
introduction of the diene ligands into the DNA strand. The complementary strand was 
varied forming loops in the opposite strand of the ligand or on the strand of the 
ligand. The diene ligand was complexed with iridium and used for asymmetric allylic 
alkylation. The enantioselectivity was slightly higher with the DNA ligand than only 
with the diene ligand, but it is important to mention that the engineering of the 
complementary strand gave definite changes in enantioselectivity
86
 which was also 
observed by Roelfes.  
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Scheme 8. Coupling of diene ligand to DNA strands. a is the coupling of a diamine to the 
modified monomer and b is the coupling of a diene carboxylic acid to the amine functionality. 
C is the coupling of a diene amine modified directly on the modified monomer.
86
 P. Fournier, R. 
Fiammengo and A. Jaeschke, Angewandte Chemie, International Edition, 2009, 48, 4426-4429. Copyright Wiley- 
VCH Verlag GmbH & Co. KGaA. Reproduced with permission. 
 
Phosphine modified nucleosides and a short oligonucleotide have also been used as 
ligands for asymmetric allylic substitution. Ropartz et al
87
 have synthesized a trimer 
with a diphenylphosphine moiety. An 5-iodouridine has been introduced into the 
trimer using automated solid phase synthesis and diphenylphosphine has been 
introduced via palladium catalyzed phosphinylation (Scheme 9).  
 
 
 
Scheme 9. Synthesis of modified monomers and trimers, in dppdU R1 and R2 = H, in 
AcdppdU R1 and R2 = Ac, in dAdppdUdT R1= deoxyadenosine-3-phosphate and R2 = 
deoxythymidine-5-phosphate.
87
 
 
The monomer was tested with acetyl protected and free hydroxyl groups. Table 2 
shows that the unprotected monomer in THF results in the highest enantioselectivity 
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(80%) and that when the hydroxyl groups are protected or the solvent is changed the 
enantioselectivity drastically decreases even resulting in change of absolute product 
configuration. This effect could be explained by possible hydrogen bonding 
interactions of the hydroxyl groups with the structure of the ligand. Trimers show 
much lower selectivity and conversion but they represent a good study for the use of 
larger DNA sequences with modified phosphine moieties.
87
 
 
 
 
Scheme 10. Assymetric Allylic amination using monomers and tirmers as ligands.
87
 
 
Ligand (L) Solvent L:Pd 
ratio 
Incubation 
time/h 
Conversion 
(%) 
ee 
(%) 
Absolute 
Configuration 
dppdU
a
 THF 0.5 0.5-4 >99 62 S 
dppdU
a
 THF 2 2 >99 72 S 
dppdU
a
 THF 2 4-16 >99 80 S 
dppdU
a
 THF 4 4 >99 79 S 
dppdU
a
 CH3CN-
THF 
2 4 >99 16 R 
dppdU
a
 DMF 2 4 >99 14 R 
AcdppdU
a
 THF 2 2 >99 8 S 
AcppdU
a
 DCM 2 2 >99 21 R 
AcppdU
a
 DCM 2 2 83 23 R 
dAdppdUdT
b
 THF-H2O 
3:1 
4 8-24 15 8-12 R 
dAdppdUdT
b
 H2O 4 24 30 - - 
aReaction conditions: 7.5 μmol [Pd(allyl)Cl]2, benzylamine:propenyl acetate: Pd = 120:40:1, solvent 2 cm
3, 25 ˚C, 
24 h. bReaction conditions: 0.5μmol [Pd(allyl)Cl]2, benzylamine:propenyl acetate: Pd: K2CO3 = 120:40:1:120, 
solvent 1 cm3, 25 ˚C, 36 h. 
 
Table 2. Allylic amination of 1,3-diphenyl-2-propenyl acetate with benzylamine with 
monomers and trimers as ligands.
87
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1.3.4 Introduction of transition metals into DNA      
Linkers in DNA can be placed at different locations of the DNA. Amine and thiol 
linkers have been introduced directly on a nucleoside,
88-94
 or as a carbon linker at the 
terminal positions of a DNA strand.
95
 Propargyl linkers have been introduced on 
thymidine and have also been used to couple moieties through click chemistry.
96
 
Covalent bonding with DNA has been used in the past to introduce ligands for 
transition metals. Ferrocene ligand has been introduced into DNA strands as a tool for 
labelling by two different methods. It can be introduced on the monomer prior to 
DNA synthesis or during DNA synthesis. A ferrocene with a propargyl functionality 
can be coupled to iodo/bromo-uridine
97
 or a 5‟ amine modified thymidine can be 
coupled by amide bond formation with a carboxylic acid modified ferrocene.
98
 
Introduction of ferrocene during DNA synthesis is achieved by introducing iodo-
uridine or bromo-adenosine monomers directly on the DNA. DNA Synthesis is 
interrupted after the introduction of the halogenated monomer and the ferrocene 
ligand is attached using sonagashira coupling. All the excess reagents are easily 
washed away while the DNA stays attached on solid support. After that DNA 
synthesis is continued using the standard procedure (Scheme 11).
98,99
 
 
 
 
Scheme 11. a) ODN (oligodeoxynucleotide) synthesis; b) Pd(Ph3)4, CuI, DMF; c) ODN 
deprotection.
98
 Reprinted from A. E. Beilstein and M. W. Grinstaff, Journal of Organometallic Chemistry, 
2001, 637-639, 398-406. Copyright 2001, with permission from Elsevier. 
 
Ruthenium complexes have also been introduced into DNA during solid phase 
synthesis on amine modified bases at the 3‟ position100 or directly on the modified 
base prior to DNA synthesis.
101,102
 Ligands coordinated to ruthenium have been 
widely used to probe the electron transfer capabilities of DNA.
103
 They are known to 
give photo cross-linking with guanine bases of complementary strands. Guanine is the 
most reductive base present in the DNA and when the metal complex is excited by 
illumination it is capable to abstract an electron from dG. Those metal complexes 
have potential for a wide range of applications in therapeutics. To covalently attach 
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the Ru complex to DNA, aliphatic chains with terminal amine have been introduced 
into the 5‟ and 3‟ terminal position of DNA strands and nucleotides have been 
modified also with amine functionalities at the central position. The desired Ru 
complex is attached to the DNA via amide bond formation.
100,104-110
 
Ligands typically used to coordinate to the metal are phenanthrene diimine, 
phenanthroline, and bipyridyl derivatives, some examples are shown in Figure 16. 
 
 
 
Figure 16. Ru and Rh complexes with bipyridine ligands.
100,105,106
  
 
Bipyridyl ligands are not only used with Rh metal
111,112
 but also with Cu as shown in 
Roelfes work.
79
 Several of those methods used for ligand binding to DNA can be 
adopted for the introduction of phosphine moieties into DNA, two very good 
examples are the work done by Ropartz et al.
87
 explained in the previous section 
(Scheme 9) and Jäschke.
113
 Jäschke was capable of introducing several phosphine 
moieties into longer DNA strands using the same method used for the introduction of 
diene ligands. With this method four different phosphine moieties shown in Scheme 
12 were introduced in the DNA strand by amide bond formation using EDC and NHS 
as the coupling agents under basic conditions (Scheme 12).
113
 
 
Scheme 12. Introduction of phosphine moieties into DNA after its synthesis.
113
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1.4 Peptide Nucleic Acids (PNA) 
After the discovery of DNA several artificial nucleic acids mimics have been 
synthesized. One of them is Peptide Nucleic Acids (PNA) developed in 1991 by 
Nielsen et al PNA has an N-(2-aminoethyl)glycine backbone with a DNA base 
attached to the central amine.
114 
 Those bases can form Watson-Crick and Hoogsteen 
duplexes with DNA single and double strands (Figure 17) or with other PNA 
strands.
115
 
 
 
 
Figure 17. Example of a PNA DNA duplex.
114
 Reprinted from L. Bialy et al. Tetrahedron 2005, 61,  
8295-8305. Copyright 2005, with permission from Elsevier. 
 
Since its first preparation, PNA has been extensively used in several different 
scientific fields such as in molecular biology as genome cutter, in drug discovery as 
an antigen
116
 or as mRNA inhibitor for therapeutic drugs; and in detection as 
biosensor for nucleic acids.
117 
Because of its similarity with DNA, PNA has been used to make chimeras by itself or 
with DNA if better solubility in water is needed. This field has been studied by 
Messere and co-workers who produced chimeras for the recognition of nucleic acids 
and proteins. Chimeras are composed of two parallel strands of PNA or DNA and 
PNA connected at the ends with an alkyl chain forming a closed circle. (Figure 18)
118
 
With this shape the PNA or DNA could be modified to covalently introduce metal 
complexes in the chimeras to benefit the chirality and steric hindrance of those 
modified biomolecules. 
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Figure 18. PNA chimeras, (I) only PNA strand, (II) PNA and DNA, (III) two PNA strands.
118
 
Reprinted with permission from L. Moggio et al. Org. Lett. , 2006, 8, 2015-2018. Copyright 2006 Chemical 
 Society. 
 
PNA has also been used to form duplexes and triplexes with DNA.
115,119-121
 PNA has 
the same ability to recognize DNA as DNA has with itself. Not only the base pairing 
between the two different strands for duplex formation is similar but also the neutral 
backbone of PNA gives less repulsion between the two strands in comparison to two 
negatively charged DNA strands. This high affinity of PNA to DNA results in duplex 
formation with a helical structure similar to type A or B form of DNA which means 
that a single DNA strand is able to transfer its chirality to an achiral PNA strand.
119-121
 
Further work by Nielsen showed that PNA-DNA duplexes are even more stabilized 
when PNA strands contain a relatively large number of purines.
122
 Double stranded 
PNA can also form a helical structure because of the helical stacking of the 
nucleobases although due to the non chiral backbone the helical structure can 
interchange between the right and left handed structures. It is possible to induce 
chirality in a PNA double strand by introducing a chiral amino acid instead of glycine 
at the terminal monomer of the PNA single strand. The amino acid usually used is L-
lysine. This approach eliminates the need for a DNA strand to produce chirality but it 
has its limitations. With a chiral amino acid the chirality can be transferred only to a 
strand that has a maximum number of ten nucleobases and the choice of the 
nucleobase nearest the amino acid is very important to obtain only one helical 
structure. Guanine or cytosine need to be near the chiral amino acid. Because of the 
different structure of the two bases it is believed that is the thermal stability of their 
G-C base pair that induces a specific handedness and not their possible interaction 
with the amino acid.
123 
Chirality also depends on where the monomer with the 
introduced amino acid is located in the strand and the hydrophilicity of the amino acid 
side chains. Modified monomers introduced in the central position of the strand give 
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the strongest effect for chirality and hydrophobic amino acid side chains give one 
handedness while hydrophilic chains give the other handedness.
124
  
PNA is not only capable of forming duplexes and triplexes with DNA but it can also 
invade a DNA double helix to form a triplex, duplex or a double duplex invasion. 
(Figure 19)  
 
Triplex Triplex  Invasion Duplex Invasion Double Duplex 
Invasion
(a) (b) (c) (d)
= DNA
= PNA
 
 
Figure 19. Representative drawing of PNA invasion of a DNA double strand.
125
 P. E. Nielsen, 
Methods in Enzymology, 2001, 340, 329-340. Copyright 2008, with permission from Elsevier. 
 
For triplex invasion one PNA strand binds to one strand of a DNA duplex through 
Watson-Crick base pairing while the other PNA strand binds to the same DNA strand 
through Hoogsteen base pairing (b). A single stranded homopurine PNA strand can 
give rise to duplex invasion (c) although it is not as strong an interaction as the triplex 
invasion. Modifications of adenine and thymine to form diaminopurine and thiouracil 
have improved DNA invasion especially for a double duplex invasion (d) where the 
two PNA strands prefer to bind to the target DNA over binding each other due to the 
steric hindrance formed by the altered adenine and thymine. This ability to invade 
DNA strands makes PNA highly valuable in molecular biology and medicinal 
applications.
125
 
The chirality and selectivity of DNA and the vast use of PNA are very important 
qualities for ligands to make selective transition metal complexes. As previously 
showed DNA has been already successfully used together with transition metals as 
catalyst for several asymmetric reactions. 
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1.5 Asymmetric Catalysis 
A chiral compound is defined as a compound whose mirror image can not be 
superimposed to the original molecule. Chirality can be attributed to the presence of 
one or more stereogenic elements which can be centres, axes, and planes. A carbon 
with four different substituents is a chiral centre. When two optical isomers are mirror 
images they are called enantiomers which have the same properties but can behave 
differently in a chiral environment. In contrast, diastereomers have different 
physicochemical properties and are not mirror images of each other. An example of 
different behaviour of enantiomers is the pharmaceutical drug thalidomide of which 
its S isomer appeared to be teratogenic while his R isomer is an effective sedative. In 
spite of this many drugs are still sold in their racemic form because of the laborious 
production of enantiopure compounds and high costs involved. About 80% of 
industrial processes use catalysts to increase the yield of their products, the reaction 
rates and the selectivity to the desired compound. The products resulting from the 
catalytic reaction can be chiral or not. There are three different techniques to produce 
only one enantiomer of chiral compounds: resolution of racemic mixtures, 
stereoselective synthesis and asymmetric catalysis.
126
 This section will focus on 
asymmetric homogeneous catalysis. 
A catalyst does not alter the equilibrium constant of a reaction but lowers its 
activation energy making the reaction faster or creates another reaction pathway.
7
 
Generally, several types of selectivity can be distinguished for a chemical reaction 
(Table 2). In homogeneous catalysis the reagents and the catalyst are in the same 
phase usually the liquid phase. For asymmetric catalysis, transition metal complexes 
have proved to be highly efficient and have been widely studied by both industry and 
academia. To design efficient catalysts for asymmetric transformations it is necessary 
to have metal complexes which create a chiral environment. This is possible by using 
chiral ligands. It is important to emphasise that the main challenging goal in 
homogeneous catalysis is to design complexes capable to selectively produce only 
one isomer of the desired compound.  
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Reaction selectivity Definition 
Chemoselectivity  One functional group of the substrate is altered over the other 
functional groups present in the substrate  
Regioselectivity  The alteration is preferred at one location of the substrate over other 
possible locations. 
Diastereoselectivity  Only one diastereoisomer is formed out of an enantiomer  
Enantioselectivity The formation of one enantiomer over the other 
 
Table 2. Definition of the four possible types of selectivity.
127
 
 
Metal-catalysed allylic substitution is an indispensable tool in organic synthesis and 
has mainly been used at laboratory scale. Because of the extensive studies done on 
this reaction and its complexity it was chosen as a catalytic model reaction. A brief 
overview of this reaction is given in the next section. 
 
1.5.1 Allylic Substitution 
Stoichiometric allylic substitution was first discovered by Tsuji in 1965
128
 and in 
1977 Trost
129
 developed the first asymmetric Pd catalysed version. This reaction 
consists of the replacement of a leaving group in an allylic position by a nucleophile. 
The most common transition metal used for those reactions is palladium but many 
others such as Cu, Ir, Pt and Mo have also been employed. The general cycle of 
palladium catalyzed allylic substitution for a soft and hard nucleophile is represented 
in Scheme 13. The first step of a palladium catalyzed allylic substitution is 
coordination of the allyl substrate to the metal, the second step is an oxidative 
addition of the allylic substrate to the metal, in this case Pd(0), to give rise to a π-
allyl-Pd(II) complex.
127
 The third step is the nucleophilic attack, which happens 
directly on the coordinated allyl group outside the primary coordination sphere of the 
metal for soft nucleophiles (A).
132
 The forth step is dissociation of the desired product 
and reduction to Pd(0), which can re-enter the catalytic cycle.
127
 When hard 
nucleophiles are used (B), the nucleophilic attack takes place on the metal instead of 
the allyl ligand and the product is formed by reductive elimination.
131
 This section 
will focus on soft nucleophiles because they are most commonly used in allylic 
substitution reactions. 
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Scheme 13. General catalytic cycle for Pd catalyzed allylic substitution with soft (A) and 
hard (B) nucleophiles.
133
  
 
The mechanism of regio- and enantioselection for this reaction depends on the 
substrate and nucleophile used and is controlled by the chiral ligands coordinated to 
the metal. For example, the enantioselectivity of products which are generated from 
an asymmetric allylic fragment depends among other things on the differentiation 
between the two carbons on the allyl group.
134
 This selectivity is controlled by the 
ligands via steric and electronic effects. Successful examples are the chiral 
phosphino-oxazoline ligands synthesized by Pfaltz as in the metal allyl complexes 
represented in Figure 20.
135
  
 
 
 
Figure 20. allyl metal complex using phosphino-oxazoline ligands
135
  
 
This metal complex contains P and N donor atoms which create electronic and steric 
dissymmetry into the coordinated allylic group. Consequently, the C3-M bond length 
of the allyl complex is increased compared to the C1-M bond length therefore 
favouring the nucleophile attack on the carbon trans to the P atom. This is also called 
“trans influence” which is defined as “the extent to which a ligand weakens the bond 
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trans to itself”.136 The phosphorous atom makes a strong π-bond with the metal 
resulting in an increase in electrophilicity in the carbon at its trans position. In 
addition to this electronic effect steric effects can also apply. An example is the 
ligand shown in Figure 20 where the cis position to the nitrogen atom is less sterically 
hindered.
133
  
For monosubstituted allylic substrates, the less hindered termini of the allyl-metal 
complex is more prone to nucleophilic attack for steric reasons resulting in the mostly 
linear product which is achiral. In spite of that, nucleophilic attack can be directed 
toward the more substituted termini by choosing the appropriate catalyst. Pfaltz et al 
prepared chiral phosphite-oxazoline ligands favouring the branched product. That was 
achieved by introducing electronegative substituents at the phosphorus atom and 
changing the R group of the oxazoline ligand to adjust the steric repulsions. With the 
optimized system, it was possible to achieve a branched:linear ratio of 76:24 with 
90% ee.
137
 Depending on the catalyst employed it is also possible to direct the 
regioselectivity of the linear product toward the E or Z regioisomer.
127,133
 Many other 
types of substrates are used which require specific ligand design to accommodate the 
desired regio and enantioselectivities.
133 
To produce enantiopure products an additional complication found in allylic 
substitution reactions are the rearrangements of the π-allyl-Pd intermediates.  
 
 
 
Scheme 14. 1) π-rotation, 2) π-σ-π isomerization.127 
 
Two principal mechanisms of rearrangement have been described; the first one 
(Scheme 14, 1)) consists of a formal allyl rotation, which interchanges only the 
terminal substituents without changing the face of the allyl group which is 
coordinated to the metal although it changes the enantioselectivity of the reaction. 
The second mechanism (Scheme 14, 2)) known as π-σ-π isomerization occurs 
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thorough a σ-bound intermediate and implies a change in the face of the allyl group 
coordinated to the metal. Once the σ-bond is formed between C1 and Pd the alkene 
rotates at the C1-C2 bond and coordinates again to the Pd at the opposite face. 
Moreover, the methyl substituent at the C1 carbon changes from a syn position to an 
anti position.
127,138
  
The mechanistic examples of asymmetric allylic substitution explained above 
demonstrate the complexity of this reaction and the demand of ligands capable of 
modifying different types of substrates without the need of elaborate changes in the 
structure of the ligand.  
 
1.6 Project Aim 
To reduce the amount of industrial chemical waste it is mandatory to design catalysts 
with high selectivity and efficiency for a range of chemical reactions. It is well known 
that metal atoms bound to a chiral organic molecule can form effective catalysts for 
the production of enantiomerically pure compounds.
7 
Nature uses enzymes which are 
the most efficient and selective catalysts known. If nature‟s properties could be 
combined with transition metals reactivity it would be possible to form highly 
selective hybrid catalysts. Because of their chirality and selectivity those catalysts 
could be applied for asymmetric reactions. The two biomolecules chosen for this 
hybrid catalyst are DNA and PNA which is a peptide mimic of DNA that forms 
duplexes with DNA. DNA is chosen because of its chirality and selective binding 
toward small molecules. The first step towards the production of DNA based catalysts 
is to introduce a moiety such as phosphine ligands that will strongly coordinate to 
transition metals. To achieve this, functionalized nucleosides will have to be 
introduced into a DNA strand, which can be covalently linked to the phosphine 
moiety in a specific location of the DNA strand. (Figure 21) 
 
 33 
AGCTCAMTGCGTA AGCTCAMTGCGTA
P
P
AGCTCMAMTGCGT
AGCTCMAMTGCGT
P P
AGCTCATGCGTAM
MAGCTCATGCGTA
AGCTCATGCGTAM MAGCTCATGCGTA
P P
AGCTCATGCGTAM
TCGAGTACGCATM
AGCTCATGCGTAM
P
TCGAGTACGCATM
P
P
M= modified monomer,  P= phosphine moiety, A=adenine, G= guanine, T= thymidine, C= cytosine
 
 
Figure 21. Introduction of phosphine moieties into DNA. 
 
As can be seen in Figure 21 the modified nucleotide can be introduced in the central 
or terminal position of a DNA single strand. By changing the position and 
characteristics of the phosphine moiety and by changing the complementary strands it 
could be possible to produce a variety of modified double helix DNA. An amine or 
thiol linker can be introduced into a modified oligonucleotide for the introduction of 
the phosphine moiety. This approach can be used for both DNA and PNA and 
because of their affinity to each other it would be possible to combine PNA and DNA 
single strands therefore increasing the variety of ligands produced. Once the strands 
have been functionalized with phosphine moieties they will be complexed to a 
transition metal and their enantioselective properties will be tested in asymmetric 
reactions such as hydrogenation, hydroformylation, and allylic substitution.   
A noncovalent approach is also possible. As seen in the work of Thomas Ward it is 
possible to couple the ligand to a molecule that is well recognized by the biomolecule 
of interest. In our case the biomolecule of interest is DNA and the well recognized 
molecule is L-arginine. In the literature several aptamers of arginine have been 
studied and we plan to couple a bipyridine ligand to arginine and use its aptamer as 
the source of chirality. Those types of ligands can be tested as catalysts for Michael 
additions or Diels-Alder reactions.   
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Chapter 2: Synthesis of Thiol Modified Monomers 
 
2.1 Introduction 
Life as we know it would be impossible without enzymes, which are biocatalysts 
often containing metallic ions in their structure. Enzymes are used by nature to 
catalyze a wide range of reactions resulting in the formation of the desired product in 
high efficiency. Artificial catalysts have also been used for centuries and since the 
twentieth century this field has been rapidly growing in both industry and academia. 
In particular, homogeneous catalysis with transition metal complexes is nowadays a 
very important area in chemistry. A countless number of ligands has been prepared 
and screened in the search for catalysts achieving the selectivity and reactivity needed 
in many reactions. Despite all the effort and knowledge gained over the years, many 
reactions in industry still lack a proper catalytic system, forcing the use of 
stoichiometric amounts of reagents resulting in the accumulation of large quantities of 
chemical waste. To reduce the environmental damage caused by the chemical 
industry it is necessary to build catalysts which combine the selectivity of nature and 
the reactivity of transition metal moieties.
1-3
 In academia several research groups have 
combined the molecular recognition of proteins with transition metal catalysis
4-6,7
 and 
in more recent years the focus has also spread to the use of DNA combined with 
transition metal catalysis. Two methods have been used to attach the transition metal 
fragment to DNA: the covalent and the non covalent approaches. Roelfes et al
2, 8
 
developed the non covalent approach, which consists of the use of random DNA 
sequences (from commercial salmon testes or calf thymus DNA) together with a 
bipyridine intercalator and Cu(II) salts to catalyze asymmetric Diels-Alder and 
Michael addition reactions. The results are impressive with enantioselectivities 
reaching up to 99%. Those findings were pivotal to prove the concept of DNA as an 
efficient chiral inductor for highly selective transformations. A disadvantage of this 
non covalent approach is that the location of the intercalator in the DNA (and 
therefore of the catalytic centre) is not known and hence optimisation of the catalyst 
is difficult. For this reason the same group has more recently shifted to the covalent 
approach.
9
 Bipyridine Cu(II) complexes have been introduced into specific locations 
of a double stranded DNA via amide bond formation. This covalent approach has also 
been pursued by other groups. Ropartz et al
10
 introduced phosphine moieties onto a 
mononucleoside and short oligonucleotides and used them as ligands for Pd-catalyzed 
 42 
asymmetric allylic substitution reactions. An important contribution in this field has 
been made by Jäschke et al,
11
 who introduced bicyclo-[2.2.2]octadiene in the central 
position of a 19-mer as a ligand for asymmetric allylic alkylation with Ir (Scheme 1) 
The enantioselectivities were not high (up to 27% ee) although it was found that the 
catalytic results were sequence dependent. The same finding was observed by Roelfes 
et al in both covalent and non covalent approaches.
12
 
 
 
Scheme 1. Coupling of diene ligands to DNA strands. a is the coupling of a diamine to the 
modified monomer and b is the coupling of a diene carboxylic acid to the amine 
functionality. C is the coupling of a diene amine modified directly on the modified 
monomer.
11
 P. Fournier, R.Fiammengo and A. Jaeschke, Angewandte Chemie, International Edition, 2009, 48, 
4426-4429. Copyright Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission. 
 
This discovery shows a powerful advantage of DNA as ligand because simple 
changes in structure of the DNA such as the sequence of the complementary strands 
can give a completely new catalyst that can place the substrate of interest in a very 
different environment. Scheme 2 represents an example of how changing the 
complementary strand of a modified DNA strand can result in a very different 
environment. 
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Scheme 2. Coupling of a phosphine moiety to a DNA strand and introduction of 
complementary strands. Introduction of a complementary strand also containing a phosphine 
moiety results in a bidentate (a), mismatches in the complementary strand sequence can give 
rise to loops in the complementary strands (b) in the modified strand (c), or in a self 
complementary strand (d), addition of a fully complementary strand (e) produces yet another 
environment. 
 
Phosphine ligands are very powerful for asymmetric catalysis because they form 
stable complexes with catalytically interesting metals and their structure can be 
modulated with relative ease. Our aim is to functionalize DNA strands with phosphine 
units at specific positions, with the objective of applying them in homogeneous 
catalysis. A diphenylphosphine unit was previously introduced in our laboratory
10
 into 
monomers and trimers via Pd-catalyzed phosphine introduction to commercially 
available 5-iodo-2’-deoxyuridine. This method worked well for monomers and 
trimers and was also tested for longer strands such as nonamers although the 
phosphine coupling reactions were very low yielding, requiring high Pd loadings 
resulting in phosphine oxidation during purification by FPLC (Fast Protein Liquid 
Chromatography). Therefore, it was decided to change the method of phosphine 
introduction into the DNA strands. Sulfhydryl compounds are often used in 
biomolecules as linkers. Thiols are better nucleophiles than amines because of their 
high energy nonbonding lone pairs. Therefore, thiol groups allow fast couplings and 
are often used in molecules such as proteins which contain several amine 
functionalities. Several reagents have been used and a small selection is depicted in 
Scheme 3. 
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Scheme 3. Selected methods for coupling to a thiol functionality.
13, 14
 
 
Thiol functionalities are often introduced in DNA strands for a variety of 
applications. The sulfhydryl functionality can be placed at different locations of the 
DNA strand. Most commonly, thiol aliphatic chains are placed at the 5’ or 3’ termini 
of DNA strands
15, 16
 although they have been placed also at the 2’ position of a 
nucleoside,
17
 on the phosphate
18
 and on purines and pyrimidines.
19-22
 Thiol modified 
oligonucleotides have been grafted on gold nanoparticles,
23-26
 glass
27
 and 
polyethylene glycol surfaces.
28
 They can potentially be used in clinical diagnosis for 
the specific recognition of certain analytes such as proteins and specific nucleic acid 
sequences. They have also been used to form cross linkages between two DNA 
strands to study their properties such as structure, folding and dynamics.
29
 Thiol 
modifications have also been employed as a tool to form peptide-oligonucleotide 
conjugates;
15,30
 and they have found applications in the attachment of 
oligonucleotides to resins for the use in affinity chromatography.
31,32
 The two most 
common coupling methods used to modify oligonucleotides with thiol groups are via 
maleimides and disulfide bond formation. 
Oligonucleotide modifications are essential for the introduction of phosphine moieties 
into a DNA strand. Thiols readily react with different functional groups and in some 
cases such as thioesters and disulfides the linkage formation is reversible. In our 
laboratory, phosphines containing a carboxylic acid functionality have been coupled 
to a protein via thioester bond formation and cleaved under basic conditions to 
reproduce the free thiol functionality.
14
 This property could have high potential for the 
recycling of DNA ligands. Phosphine moieties are well known to be oxygen-sensitive 
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and once oxidized the DNA ligand looses its high affinity toward transition metals. 
We are aiming at the development of efficient DNA-based transition metal catalysts 
for selective conversions. We chose to couple phosphine moieties on thiol modified 
DNA strands as this is a well-developed selective and effective coupling reactions. 
Moreover, the expensive DNA ligand can potentially be recycled after its use by 
applying standard conditions for isolation and purification of synthetic DNA (Scheme 
4). This chapter focuses on the synthesis of three thiol modified monomers and their 
introduction into DNA.  
AGCTTAGCTCAGCCTAG AGCTTAGCTCAGCCTAG
PP
Transition
Metal
catalysis
AGCTTAGCTCAGCCTAG
P
basic conditions  
Scheme 4. Introduction of phosphine moieties (P) onto oligonucleotides and recycling of 
DNA strands.  
 
2.2 Results and Discussion 
2.2.1 Synthesis of cyanoethyl protected monomer 
For the introduction of phosphine moieties into DNA a central modification in the 
oligonucleotide strand is preferred. By placing the catalytic site in the central position 
it could benefit from the chiral environment produced by the surrounding nucleotides 
possibly exerting high enantioselectivity in the catalytic reactions. The first step 
toward the synthesis of a thiol modified nucleoside was the preparation of a terminal 
alkyne bearing a thiol functionality which can be attached to 5-iodo-2-deoxyuridine 
(IdU) via a Sonogashira coupling. Protection of the thiol functionality is necessary to 
prevent side reactions such as formation of disulfides. A cyanoethyl group was 
initially chosen as a suitable protecting group because it is compatible with DNA 
synthesis and is easily removed during DNA cleavage from solid support. The 
propargyl linker was synthesized over four steps as depicted in Scheme 5. 
Commercially available thiourea and 2-chloropropionitrile reacted to afford 
compound 1
33
 in 90% yield, which was oxidized to compound 2 with NaBO3 in 52% 
yield. The yield of this step was largely improved by ensuring a vigorous stirring of 
the reaction mixture. Reduction of the disulfide with Zn/HCl gave the free thiol
34
 (3) 
in 88% yield. This thiol is a very good nucleophile and was easily reacted with 
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propargyl bromide under basic conditions resulting in the desired product (4) (Scheme 
5).  
 
 
Scheme 5. Synthesis of protected thiol linker.
33, 34
  
 
Compound 4 was then coupled to 5-iodo-2-deoxyuridine by Sonagashira coupling 
resulting in 78% yield of the expected product 5 without any noticeable interference 
of the sulfur atom in this catalytic reaction. The next two steps to the target molecule 
were the standard protection of the primary hydroxyl group with 4,4'-Dimethoxytrityl 
chloride (DMT-Cl) giving compound 6  and phosphoramidite introduction to provide 
building block 7 (Scheme 6). The final product was found to be contaminated with 1 
eq of hydrolyzed chlorophosphoramidite reagent, which resonated at 14 ppm in the 
31
P{
1
H} NMR spectrum. This compound is known not to interfere with DNA 
synthesis
35
 and therefore compound 7 was used without any further purification.  
A crystal structure was also obtained for compound 5 which proved that the desired 
compound had been made (Figure 1). 
 
 
 
Scheme 6. Synthesis of thiol modified phosphoramidite. 
 47 
 
Figure 1. Ortep representation for 5. Thermal ellipsoids are drawn at 50% probability. 
 
2.2.2 Synthesis of tert-butyl protected monomer 
Monomers with tert-butyl disulfide as protecting group were synthesized
22
 in order to 
have a protecting group that would remain attached to the thiol functionality during 
cleavage from the solid support and purification of the oligonucleotide. C4 and C3 
propargyl linkers were chosen to be coupled to 5-iodo-2-deoxyuridine. The thiol 
functionality is introduced via the use of thiobenzoic acid. This protecting group is 
compatible with Sonagashira coupling although it does not survive DNA synthesis 
conditions therefore later in the synthesis it will be exchanged with a disulfide tert 
butyl group. The linkers were synthesized from commercially available 3-butyn-1-ol 
or propargyl alcohol and thiobenzoic acid using Mitsunobu conditions giving 66 and 
63% yield of the expected compounds 8 and 9 respectively. Although
 1
H NMR 
showed higher conversion to the product, the lower yield is explained by an 
unidentified orange impurity that could not be efficiently separated from compound 9 
because conventional column chromatography resulted in losses of product and 
vacuum distillation resulted in decomposition. In contrast, compound 8 could be 
purified by vacuum distillation although the yield was also only 66%. The remaining 
steps to reach the target compound are the same for both monomers and the resulting 
yields for each monomer are similar. Sonagashira coupling with 5-iodo-2- 
deoxyuridine afforded compound 11 in 61% yield. Protection of the primary alcohol 
with DMT-Cl resulted in compound 12 in 78% yield. Changing the thiol protecting 
group under basic conditions using di-tert-butyl(tert-buthylthio)-1,2-
hyrozinedicarboxylate produced compound 13 in 73% yield. Phosphoramidite 
introduction afforded compound 14 (Scheme 7) along with hydrolyzed 
chlorophosphoramidite. 
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Scheme 7. Synthesis of thiol modified phosphoramidite containing a tert-butyl disulfide as 
protecting group.
22
 
 
By crystallization from dichloromethane crystals suitable for X-ray diffraction were 
obtained for compound 11. The structure confirms the formation of the desired 
compound and the expected absolute configuration of the stereogenic carbon atoms of 
the ribose ring (Figure 2).  
 
 
Figure 2. Ortep representation for 11. Thermal ellipsoids are drawn at 50% 
probability. 
 
2.2.3 Introduction of monomers into DNA strands  
Modified base 7 was introduced into two DNA strands of 15 bases long (15-mers): 5’-
CGCCTACMACCGAAT-3’ and 5’-CTAGCTTMAAGCTAG-3’. A 15-mer is an 
adequate length to form double strands by strong enough Watson-Crick base pairing. 
In our experience longer strands might reduce the total yield of the synthesis to an 
unacceptably low level. Unexpectedly, purification of those two strands did not result 
in the desired product according to MALDI-TOF analysis and the chromatogram from 
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preparative HPLC showed several peaks suggesting that either the synthesis failed or 
DNA decomposition occurred before or during its purification. Thiols are known to 
dimerize in the presence of air. Therefore, during basic treatment and purification 
there is a risk that the DNA will form dimers or other side reactions could occur that 
might result in DNA degradation. 
The difficulties encountered in obtaining a DNA 15-mer containing compound 7 in 
the central position brought us to change the protecting group used for the protection 
of the thiol functionality. As explained before the difference in the two protecting 
groups is that the disulfide tert-butyl group is much more robust and is expected to 
withstand the cleavage and purification steps. This protecting group will be eliminated 
shortly before coupling to the phosphine moiety. Compound 14 was introduced into a 
15-mer using standard automated DNA synthesis and purified by HPLC. MALDI-
TOF analysis confirmed the preparation of the desired product (Figure 3). 
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Figure 3. 5’-CGCCTACMACCGAAT-3’, M = compound 14, MW = 4657.20. The two 
adjacent peaks (4678 and 4695) correspond to desired molecular weight plus Na and K.  
 
Once the desired DNA strand was obtained, deprotection of the thiol tert-butyl 
disulfide functionality was attempted with TCEP (tris(2-carboxyethyl)phosphine 
hydrochloride) or DTT (DL-Dithiothreitol). Deprotection was checked by a coupling 
of a maleimide containing a fluorescence probe. Maleimides are known to couple to 
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thiols efficiently13 and therefore this maleimide was used to test the coupling 
efficiency by fluorescence (Scheme 8).  
 
Scheme 8. Attempted coupling of a fluorescence probe to an oligonucleotide. 
 
No fluorescence could be detected after coupling and MALDI-TOF analysis gave the 
mass which corresponds to the DNA 15-mer containing the deprotected free thiol. 
The same coupling was repeated using different buffers at different pH values but the 
same results were obtained. In order to understand the problems encountered with the 
15-mer, the mononucleoside 11 was deprotected and purified by column 
chromatography. 
1
H NMR and mass spectroscopy confirmed that the desired 
compound was obtained. Compound 18 was then tested for coupling to phosphine 
moieties unsuccessfully despite many attempts under different conditions. The cause 
of the failure of all those couplings was finally exposed by the X-ray crystal structure 
of compound 18 (Figure 4), which revealed cyclization of the thiol linker after 
deprotection which led to compound 19 (Scheme 9).  
 
 
Scheme 9. Cyclization of compound 18.  
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Figure 4. Ortep representation of 19. Thermal ellipsoids are drawn at 50% probability. 
 
It was concluded that a free thiol functionality is very reactive toward the triple bond 
of the linker giving a stable 2,3-dihydrothiophene ring. To prevent this cyclization, 
two approaches were considered: hydrogenation of the triple bond in compound 10 
and the synthesis of a shorter linker, which is less likely to cyclise because of the 
formation of an unfavourable four-membered ring. Hydrogenation of the triple bond 
was tested with compound 6. NaBH4/NiCl2, H2/PtO2 (5 and 20%), H2/Pd/C, 
H2/[Rh(COD)(CNMe)2]BF4 and H2/[RhCl(PPh3)3] were used under different 
conditions but in all cases the hydrogenated product was not formed. Hydrogenation 
was also tested on compound 11 giving the same results. It seems that the protected 
sulfur atom in the linker deactivates the hydrogenation catalysts. Instead of 
hydrogenating the triple bond prior to sulfur introduction it was decided to synthesize 
a monomer similar to compound 11 with one carbon less in the thiol linker to prevent 
cyclization. Compound 10 was synthesized and deprotected. The molecular weight of 
the desired product is 298 but mass spectroscopy analysis showed molecular weights 
in the range of dimeric structures. 
 
2.3 Conclusion  
This chapter reports the synthesis of thiol modified nucleosides with three different 
protecting groups and attempts to introduce them into DNA strands. A monomer with 
a cyanoethyl protecting group on the thiol linker was introduced into a 15-mer 
although it was not possible to confirm the identity of the desired strand during and 
after purification. One of the monomers was successfully introduced in a 15-mer 
DNA strand although studies with the monobase showed cyclization of the reactive 
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thiol functionality with the triple bond of the linker forming a stable 2,3-
dihydrothiophene ring. To prevent this cyclization a similar monomer with a shorter 
carbon bridge was synthesized and deprotected, mass spectroscopy analysis suggests 
dimer formation. Another route to prevent the cyclization of the thiol linker is to 
hydrogenate the triple bond of the linker. This was attempted with the synthesized 
monomers although the thiol functionality deactivated the hydrogenation catalysts 
used. All the data obtained indicates that a triple bond and a free thiol functionality 
are not compatible in the systems studied here. Consequently, in future work 
monomers containing a fully hydrogenated thiol linker should be synthesized, a few 
examples of such monomers can be found in the work of Glick
36
 and Eritja.
37
 
The difficulties encountered during the synthesis of thiol modified DNA strands 
proved the task of introducing thiol functionalities into DNA to be more complex than 
expected and therefore, it was decided to change the strategy to amine modifications. 
Amine linkers have been widely applied in DNA chemistry by using terminal 
aliphatic linkers or amine modified monomers. The great advantage of using an amine 
group instead of a thiol functionality is that amines are less reactive and therefore are 
expected to give less unwanted reactions. On the other hand, the amide reaction is not 
reversible therefore this method will eliminate the possibility to recycle the DNA 
strand once used for catalytic reactions. Chapter 3 will focus on the synthesis of 
amine linkers into DNA strands.  
 
2.4 Experimental  
General procedures 
All reactions were performed under argon using standard Schlenk techniques. Chemicals 
were purchased from Aldrich Chemical Company, Acros, Fluka, Link Technologies and Glen 
Research. CH2Cl2 and acetonitrile were distilled from CaH2; ethanol and methanol were 
distilled from Mg/I2; toluene was distilled from Na, THF and Et2O were distilled from 
sodium /benzophenone and all the distillations were performed under nitrogen atmosphere. 
DMF was purchased “Extra dry” and stored over molecular sieves (4 Å) under argon. 
Aqueous solutions were degassed by three freeze/thaw cycles under vacuum and kept under 
argon. Thin Layer Chromatography (TLC) was performed on silica plates (Polygram 0.2 mm 
silica gel with fluorescent indicator UV254). Ninhydrin spray was used for the detection of 
primary and secondary amines on TLC silica plates. Silica gel 60 particle size 0.063-0.2 mm 
from Fluka was used for flash chromatography. NMR spectra were recorded at room 
temperature on Bruker Avance spectrometers (300, 400, and 500 MHz). Positive chemical 
shifts () are given (in ppm) for high-frequency shifts relative to a TMS reference (1H and 
13
C) or an 85% H3PO4 reference (
31
P). 
13
C, and 
31
P spectra were measured with 
1
H 
decoupling. The following abbreviations have been used in the description of the spectra: s, 
singlet; d, doublet; t, triplet; m, multiplet. IR spectra were recorded on a Perkin-Elmer 
Spectrum GX spectrometer in KBr pellets, with a window between 4000 and 400 cm
–1
. Mass 
spectrometry: MALDI-TOF mass spectra were recorded on a 4800 Plus MALDI TOF/TOF™ 
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Analyzer using a 9:1 3-hydroxypicolinic acid (HPA): ammonium citrate matrix. The matrix is 
made with 50 mg/ml of HPA in 50:50 MeCN:H2O and 50 mg/ml of ammonium citrate in 
H2O. The desalting column used for the preparation of MALDI-TOF samples was a GE 
Healthcare Illustra
® 
micron G-25 and the desalting tips were Millipore
®
 zip-tip C18, the 
Dowex used for desalting was a 50WX4 200-400 mash resin. Oligonucleotides prepared at 
our laboratories were synthesized by an Applied Biosystems 392 DNA/RNA synthesizer 
using protocols obtained from Applied Biosystems. The reagents used for the synthesis of 
oligonucleotides were bought from Glen research and were: oxidizing solution 0.10 M I2 in 
THF/pyridine/water; cap mix B (10% 1-methylimidazole in THF/pyridine); cap mix A 
(THF/pyridine/acetic anhydride); deblocking mix (3% trichloro acetic acid in DCM); 
activator (sublimed 1H-tetrazole in anhydrous acetonitrile); dA, dC, dG, dT 
phosphoramidites. Coupling yields for DNA synthesis are based on measurements of DMT 
release which is determined by conductivity measurements. Purification by ion exchange, 
size exclusion and desalting were carried out with a FPLC AktaBasic 100 (P-901), monitor 
UV-900. The column used for purification of the modified oligonucleotides was a HiLoad 
16/10 Q Sepharose HP with the following buffers: buffer A = 1 M NaCl, 10 mM NaOH and 
buffer B = 10 mM NaOH. The column for the desalting was a HiPrep 26/10 Desalting with a 
linear gradient of 0.15 M NH4HCO3 buffer. HPLC purification of oligonucleotides was 
carried out in a Waters machine equipped of a Waters 2700 sample manager, Waters 600 
controller and Waters 2487 dual absorption detector. The reverse phase column used was a 
Phenomenex, Clarity
®
 C18 5 μ oligo-RP, 250 x 21.20 mm. Syringe filter used for DNA were 
WHATMAN 0.2 μm PTFE.  
(2-Cyanoethyl)thiouronium hydrochloride (1)
33
 
Compound 1 was synthesized following literature 
procedure. The desired product resulted in a white solid. 
Yield: 10.8 g, 90%  
Characterization of the product fully agreed with data from 
literature. 
1
H NMR (400 MHz, CDCl3): δ = 5.92 (t, 2H, J = 6.7 Hz), 5.47 (t, 2H, J = 6.7 Hz) 
13
C NMR (100.6 MHz, CDCl3): δ = 172.2, 121.3, 28.7, 20.5 
Di(2-cyanoethyl) disulfide (2)
34
 
Compound 2 was synthesized following literature 
procedure. The remaining solid was crystallized from 
methanol to give a white solid. Yield: 13.7 g, 59%  
Characterization of the product fully agreed with data from literature. 
1
H NMR (400 MHz, CDCl3): δ = 2.88 (t, 4H, 7.1 Hz), 2.75 (t, 4H, 7.1 Hz) 
13
C NMR (100.6 MHz, CDCl3): δ = 116.8, 32.4, 16.9 
3-Mercaptopropionitrile (3)
34
 
Compound 3 was synthesized following literature procedure 
resulting in a colourless liquid. Yield: 3.5 g, 88% 
Characterization of the product fully agreed with data from 
literature. 
1
H NMR (400 Mz, CDCl3): δ = 2.81-2.72 (m, 2H), 2.71-2.68 (m, 2H), 1.81 (t, 1H, J = 
8.5 Hz)  
13
C NMR (100.6 MHz, CDCl3): δ = 118.0, 20.6, 20.8 
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3-(2-Propynylthio)propanenitrile (4) 
3-Mercaptopropionitrile (0.84 ml, 11 mmol, 1 eq) was 
dissolved in 15 ml of THF and triethylamine (3.2 ml, 23 mmol, 
2 eq) was added to it. After stirring for 5 minutes propargyl 
bromide (2.5 ml, 23 mmol, 2 eq) was slowly added at 0 ˚C to 
the reaction mixture and a white precipitate was formed. After stirring for 1 h at room 
temperature the mixture was filtered and the filtrate concentrated in vacuo. The 
resulting slightly yellow oil was purified by column chromatography (SiO2, ethyl 
acetate:petroleum ether, 30:70) resulting in a clear oil. Yield: 1.3 g, 90% 
1
H NMR (300 MHz, CDCl3): δ = 3.28 (d, 2H, J = 2.6 Hz), 2.92 (t, 2H, J = 7.2 Hz), 
2.67 (t, 2H, J = 7.2 Hz), 2.26 (t, 1H, J = 2.6 Hz) 
13
C NMR (75.4 MHz, CDCl3): δ = 118.2, 78.7, 72.2, 26.9, 19.3, 18.5  
IR (KBr), 

 (cm-1): 3584, 3288, 2963, 2250 
MS (ES+): 163.93 (M+Na
+
+O), 125.03 (M), HRMS calculated for C6H7NONaS; 
164.0146, found 164.0144  
5-(1-propynyl-3-thiopropanenitrile)-2’-deoxyuridine (5)  
5-Iodo-2-deoxyuridine (3.6 g, 10.2 mmol, 1 eq) was 
dissolved in 60 ml of DMF and the flask was covered 
with aluminium foil. CuI (0.38 g, 2.04 mmol, 0.2 eq) 
was added to the reaction and it was stirred for 30 
minutes. TEA (2.8 ml, 20.4 mmol, 2 eq), 3-(prop-2-
ynylthio)propanenitrile (3.2 g, 25.6 mmol, 2.5 eq) and 
[Pd(PPh3)4] (1.18 g, 1.02 mmol, 0.1 eq) were added to 
the mixture and it was stirred for 16 h in the dark. The 
mixture was concentrated in vacuo at 60 ˚C resulting 
in a dark orange oil. The oil was purified by column chromatography (SiO2, ethyl 
acetate:methanol (0-3%)) resulting in a yellow solid. The solid was heated in DCM at 
50 ˚C for 10 minutes and filtered to obtain a slightly orange coloured solid. Yield: 2.8 
g, 78%  
1
H NMR (400 MHz, MeOD): δ = 8.21 (s, 1H), 6.12 (t, 1H, J = 6.6 Hz), 4.31-4.28 (m, 
1H), 3.84-3.80 (m, 1H), 3.68 (ddd, 2H, J = 3.1 Hz, J = 12.2 Hz, J = 20.2 Hz), 3.51 (s, 
2H), 2.91 (t, 2H, J = 6.9 Hz), 2.78 (t, 2H, J = 6.9 Hz), 2.14-1.94 (m, 2H)  
13
C NMR (100.6 MHz, MeOD): δ = 164.5, 151.2, 145.1, 120.1, 100.2, 90.1, 89.2, 
87.0, 75.9, 71.9, 62.6, 41.7, 28.2, 20.6, 19.0 
Elemental analysis calculated for C15H17N3O5S: C 51.27, H 4.88, N 11.96: 
Found: C 51.10, H 4.57, N 11.74  
IR (KBr), 

 (cm-1): 3528, 3414, 3192, 2938, 2251, 1728, 1676, 1626  
MS (ES+): 374.00 (M+Na
+
), HRMS calculated for C15H17N3O5NaS, 374.0787; found 
374.0801 
Mp: 115-117 ˚C 
X-ray diffraction Crystals suitable for X-ray diffraction were grown by evaporation of 
dichloromethane solution at room temperature. 
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5’-O-Dimethoxytrityl-5-(1-propynyl-3-thiopropanenitrile)-2’-deoxyuridine (6) 
Compound 5 (2.0 g, 5.7 mmol, 1 eq) was 
coevaporated 3 times with dry pyridine and then 
dissolved in 20 ml of pyridine. 4,4'-Dimethoxytrityl 
chloride (2.7 g, 8 mmol, 1.4 eq) was dissolved in 20 
ml of pyridine was slowly added to the former 
solution. After 4 h 15 ml of methanol was added to 
the reaction mixture and it was evaporated in vacuo. 
The resulting red oil was purified by column 
chromatography (SiO2, dichloromethane:methanol 
98:2) resulting in a yellow powder. Yield: 3.30 g, 
48% 
1
H NMR (400 MHz, MeOD): δ = 8.04 (s, 1H), 7.37-7.35 (m, 2H, Ar), 7.27-7.22 (m, 
4H, Ar), 7.19-7.15 (m, 1H, Ar), 7.77-7.69 (m, 4H, Ar), 6.24 (t, 1H, J =6.8 Hz), 4.48-
4.45 (m, 1H), 4.00-3.98 (m, 1H), 3.70 (s, 6H), 3.31 (ddd, 2H, J = 2.9 Hz, J = 10.8 Hz, 
J = 46.4 Hz), 3.14 (d, 2H, J = 2.4 Hz), 2.62 (dt, 2H, J = 2.8 Hz, J = 7.2 Hz) 2.45-2.40 
(m, 1H) 2.38 (t, 2H, J = 6.8 Hz), 2.27-2.20 (m, 1H)  
13
C NMR (100.6 MHz, MeOD): δ = 161.3, 158.7, 149.0, 144.6, 142.4, 135.5, 135.4, 
130.0, 128.1, 127.9, 127.1, 118.5, 113.4, 99.9, 89.4, 87.0, 86.4, 85.6, 74.5, 72.1, 63.6, 
55.3, 41.6, 27.0, 20.1, 18.3 
MS (ES+): 675.78 (M+Na
+
), HRMS calculated for C36H35N3O7NaS, 676.2093; found 
676.2107 
IR (KBr), 

 (cm-1): 3447, 3065, 2930, 1701, 1507, 1459, 1282, 1250 
Mp: 83-90 ˚C 
5’-O-Dimethoxytrityl-3’-O-cyanoethyl-N,N-diisopropylphosphoramidite-5-(1-
propynyl-3-thiopropanenitrile)-2’-deoxyuridine (7)  
Compound 6 (1.3 g, 2 mmol, 1 eq) was dissolved in 25 
ml of DCM and diisopropylethylamine (0.95 ml, 6 
mmol, 3 eq) was added. The mixture was cooled to 70 
˚C and 2-cyanoethyl-N,N-
diisopropylchlorophosphoramidite (0.67 ml, 3 mmol, 
1.5 eq) dissolved in 20 ml of DCM was slowly added 
to the reaction mixture. After 3 h of stirring at room 
temperature the mixture was diluted with 40 ml of 
dichloromethane and washed with 5% aqueous 
solution of NaHCO3 (30 ml) and brine (30 ml). The 
organic layer was dried over Na2SO4 and concentrated 
in vacuo. The compound was purified using a 
chromatotron (SiO2, dichloromethane:methanol:TEA, 
97:2:1) resulting in an oil. Yield : 1.0 g, 58%  
1
H NMR (300 MHz, CDCl3): δ = 8.09, 8.05 (2s, 1H), 7.39-7.36 (m, 2H), 7.30-7.14 
(m, 7H), 7.80-7.76 (m, 4H), 6.26-6.20 (m, 1H), 7.57-4.51 (m, 1H), 4.13-4.07 (m, 1H), 
3.80-3.35 (m, 11H), 3.24-3.17 (m, 1H), 3.11-3.08 (m, 2H), 2.63-2.48 (m, 4H), 2.40-
2.20 (m, 4H), 1.11-1.08 (m, 9H), 1.00-0.95 (d, 3H, J = 7.2 Hz) 
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13
C NMR (101 MHz, CDCl3): δ = 161.8, 158.7, 149.3, 144.6, 142.4, 135.5, 130.1, 
130.0, 128.1, 128.0, 127.9, 127.0, 113.4, 99.8, 86.9, 85.7, 85.6, 63.1, 63.0, 58.4, 58.3, 
58.2, 58.1, 55.3, 43.4, 43.3, 43.2, 43.1, 40.7, 26.9, 24.6, 24.5, 20.2, 20.0, 18.3 
31
P NMR (121.5 MHz, CDCl3): δ = 149.2, 148. 8 
MS (ES+): 875.79 (M+Na
+
), HRMS calculated for C45H52N5O8NaPS, 876.3172; 
found 876.3145 
IR (KBr), 

 (cm-1): 3199, 3061, 2967, 2932, 2837, 2360, 2251, 1695, 1608, 1509, 
1561, 1281, 1180 
Mp: 66-70 ˚C 
2-propynyl benzothioate (8)
22
 n = 1  
Compound 8 was synthesized according to literature 
procedure and resulted in a yellow oil. Yield: 8.37 g, 66%  
1
H NMR (400 MHz, CDCl3): δ = 7.96-7.94 (m, 2H, Ar), 
7.61-7.57 (m, 1H, Ar), 7.48-7.44 (m, 2H, Ar), 3.83 (d, 2H, 
J = 2.7 Hz), 2.23 (t, 1H, J = 2.7 Hz)  
13
C NMR (100.6 MHz, CDCl3): δ = 190.1, 136.3, 133.8, 128.8, 127.4, 71.1, 17.5 
3-butynyl benzothioate (9)
22
 n = 2 
The same method as for 8 was employed using 3-butyn-1-ol. Yield: 3.40 g, 63% 
Characterization of the product fully agreed with data from literature. 
1
H NMR (400 MHz, CDCl3): δ = 7.89 (m, 2H, Ar), 7.50 (m, 1H), 7.37 (m, 2H, Ar), 
3.17 (t, 2H, J = 7.1 Hz), 2.50 (dt, 2H, J = 2.7 Hz, J = 7.1 Hz), 1.98 (t, 1H, J = 2.7 Hz)  
13
C NMR (100.6 MHz, CDCl3): δ = 191.4, 136.8, 135.5, 128.7, 127.3, 82.2, 69.7, 
28.0, 19.6  
5-(4-Benzoylthio-1- propynyl)-2’-deoxyuridine (10)22 n = 1 
Compound 10 was synthesized according to literature 
procedure resulting in a light yellow solid. The solid 
was precipitated in dichloromethane, filtered and 
concentrated in vacuo.Yield: 1.65 g, 56% 
Characterization of the product fully agreed with data 
from literature. 
1
H NMR (400 MHz, MeOD): δ = 8.18 (s, 1H), 7.87-
7.84 (m, 2H), 7.57-7.53 (m, 1H), 7.44-7.40 (m, 2H), 
6.13 (t, 1H, J = 6.7 Hz), 4.30-4.27 (m, 1H), 3.99 (s, 
2H), 3.83-3.80 (m, 1H), 3.67 (dd, 1H, J = 3.1 Hz, J = 12.1 Hz), 2.23-2.08 (m, 2H)  
13
C NMR (101 MHz, MeOD): δ = 191.6, 164.4, 151.4, 145.5, 137.8, 135.0, 130.0, 
128.2, 100.0, 89.4, 89.1, 87.0, 75.1, 72.0, 62.6, 41.7, 19.1 
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5-(4-Benzoylthio-1-butynyl)-2’-deoxyuridine (11)22 n = 2 
The same method as for 10 was employed. Yield: 1.6 g, 61% 
Characterization of the product fully agreed with data from literature.  
1
H NMR (400 MHz, acetone-d6): δ = 8.14 (s, 1H), 7.86-7.84 (m, 2H, Ar), 7.57-7.53 
(m, 1H), 7.45-7.41 (m, 2H, Ar), 6.25 (t, 1H, J = 6.8 Hz), 4.40-4.37 (m, 1H), 3.86-3.83 
(m, 1H), 3.72-3.64 (m, 2H), 3.14 (t, 2H,
 
J = 7.3 Hz), 2.61 (t, 2H, J = 7.3 Hz), 2.18-
2.14 (m, 2H)  
13
C NMR (100.6 Hz, acetone-d6): δ = 191.7, 162.1, 150.4, 144.2, 137.8, 134.6, 129.8, 
127.9, 100.1, 91.5, 88.9, 86.2, 74.7, 72.0, 62.6, 41.6, 28.7, 21.1  
5’-O-dimethoxytrityl-5-(4-Benzoylthio-1-butynyl)-2’-deoxyuridine (12)22 
Compound 12 was synthesized 
according to literature procedure and 
resulted as a pale yellow solid. Yield: 
1.26 g, 78% 
Characterization of the product fully 
agreed with data from literature. 
1
H NMR (400 MHz, CDCl3): δ = 8.00 
(s, 1H), 7.83-7.81 (m, 2H, Ar), 7.49-
7.45 (m, 1H, Ar), 7.36-7.18 (m, 10H, 
Ar), 7.14-7.11 (m, 1H, Ar), 6.76 (d, 
4H, Ar, J = 8.8 Hz), 6.25 (t, 1H, J = 
6.6 Hz), 4.47 (m, 1H), 4.03 (m, 1H), 3.68 (s, 6H) 3.27 (dt, 2H, J = 2.9 Hz, J = 10.8 
Hz, 22.3 Hz), 2.75(t, 2H,
 
J = 7.4 Hz), 2.46-2.34 (m, 3H), 2.25-2.18 (m, 1H) 
13
C NMR (101 MHz, CDCl3): δ = 190.3, 160.7, 157.6, 148.3, 143.5, 141.2, 135.8, 
134.5, 132.4, 128.9, 127.5, 127.0, 126.9, 126.2, 125.9, 112.3, 99.6, 91.7, 86.0, 85.6, 
84.6, 71.3, 70.9, 62.5, 54.2, 40.5, 29.9, 26.5, 19.6 
5’-O-dimethoxytrityl-5-(1-butynyl)-2’-deoxyuridine-tert-butyl disulfide (13)22 
Compound 13 was synthesized 
according to literature procedure. The 
desired product was obtained as a yellow 
solid. Yield: 0.72 g, 73%  
Characterization of the product fully 
agreed with data from literature. 
1
H NMR (300 MHz, CDCl3): δ = 8.63 
(bs, 1H), 8.00 (s, 1H), 7.37-7.13 (m, 
9H), 6.79 (d, 4H, J = 8.8 Hz), 6.26 (t, 
1H, J = 6.6 Hz), 4.48-4.45 (m, 1H), 
4.01-3.96 (m, 1H), 3.72 (s, 6H), 3.30 
(ddd, 2H, J = 4.3 Hz, J = 8.7 Hz, J = 25.8 Hz), 2.45-2.17 (m, 6H), 1.98 (bd, 1H, J = 
3.7 Hz) 1.18 (s, 9H) 
13
C NMR (75 MHz, CDCl3): δ = 161.4, 158.7, 149.0, 144.5, 142.1, 135.5, 130.0, 
128.1, 127.9, 127.0, 133.4, 100.6, 92.9, 87.1, 86.4, 85.5, 72.4, 71.6, 63.4, 55.3, 41.5, 
37.8, 29.8, 20.4 
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5’-O-dimethoxytrityl-3’-O-cyanoethyl-N,N-diisopropylphosphoramidite-5-(1-
butynyl)-2’-deoxyuridine-tert-butyl disulfide (14)22 
Compound 14 was synthesized 
according to literature procedure 
resulting in a yellow solid. Desired 
product contains hydrolyzed starting 
material. Yield: 0.56 g, 75%  
Characterization of the product fully 
agreed with data from literature. 
1
H NMR (300 MHz, C6D6): δ = 8.13, 
8.11 (2s, 1H), 7.69 (d, 2H, J = 8.0 Hz), 
7.56 (d, 4H, J = 8.6 Hz), 7.33 (t, 2H, J 
= 7.7 Hz), 7.20-7.15 (m, 1H), 6.92 (d, 
4H, J = 8.9 Hz), 6.41 (t, 1H, J = 6.4 Hz), 4.73-4.63 (m, 1H), 4.30, 4.24 (2m, 1H), 
3.61-3.07 (m, 13H), 2.56-2.35 (m, 3H), 2.29-2.11 (m, 1H), 1.81-1.68 (m, 3H), 1.20, 
1.19 (2s, 9H), 1.16-1.04 (m, 12H) 
31
P NMR (121.5 Hz, C6D6): δ = 149.0, 148.2  
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Chapter 3: Amine Modified Oligonucleotides 
 
3.1 Introduction 
As previously explained in chapter 2 our aim is to functionalize DNA strands with 
phosphine units at specific locations, with the objective of applying them in 
asymmetric homogeneous catalysis. After the failed attempts to introduce a thiol 
functionality in an oligonucleotide the coupling method was changed to amide bond 
formation. This method is compatible with water and results in high conversion. This 
method was also successfully used by Jäschke
1
 and other groups
2-4
 to introduce 
phosphine moieties into oligonucleotides. This chapter focuses on the introduction of 
amine linkers into nucleosides and nucleotides, the subsequent coupling of phosphine 
moieties on amino groups via amide bond formation and the use of new chiral 
phosphine modified nucleosides in asymmetric catalytic reactions. Several amine 
linkers of different length can be introduced at different locations of the DNA. Our 
focus is on the introduction of aliphatic linkers at the terminal and central positions of 
oligonucleotides (Figure 1). 
AGCTCAMTGCGTA AGCTCAMTGCGTA
P
P
AGCTCMAMTGCGT
AGCTCMAMTGCGT
P P
AGCTCATGCGTAM
MAGCTCATGCGTA
AGCTCATGCGTAM MAGCTCATGCGTA
P P
AGCTCATGCGTAM
TCGAGTACGCATM
AGCTCATGCGTAM
P
TCGAGTACGCATM
P
P
M= modified monomer,  P= phosphine moiety, A=adenine, G= guanine, T= thymidine, C= cytosine
TCGAGTACGCAPTTTTTCGAGTACGCAT
 
Figure 1. Introduction of phosphine moieties into DNA. 
 
Figure 2 shows the aliphatic linkers that have been synthesized to introduce in DNA 
strands. 
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Figure 2. Amino linkers and modified nucleosides. 
 
3.2 Results and Discussion 
3.2.1 Aliphatic linker modifiers 
Aliphatic amine linkers can be synthesized in less than three steps and are compatible 
with standard DNA synthesis. Four linkers have been synthesized for the introduction 
into DNA strands. To introduce a linker into DNA it is necessary to have a 
phosphoramidite unit and the amino and hydroxyl functionalities have to be protected 
to prevent unwanted side reactions during DNA synthesis. C2, C3 and C5 linkers were 
synthesized (1, 2, 3 Figure 3) for the 5’ terminal position and a chiral amino diol 
linker (4) was synthesized as a nucleotide replacement for modification at a central 
position (Figure 3). 
 
 
 
Figure 3. Protected aliphatic amine linkers.
5, 6
 
 
3.2.1.1 Central linker 
The central aliphatic modifier
6
 was initially preferred over a modified nucleoside 
because of its easy and fast synthesis and because the amine functionality is 
embedded in the oligonucleotide therefore placing the phosphine moiety closer to the 
 63 
chiral centres. The central linker was synthesized from the commercially available 
(R)-3-amino-1,2-propandiol. TFA (trifluoroacetic acid) was chosen as a more suitable 
protecting group (5, Scheme 1). It is a stable group during the linker synthesis and 
can withstand the conditions of DNA synthesis. Protection of the amino group with a 
trifluoro acetyl group was accomplished with neat trifluoroacetic acid ethylester at 60 
˚C, which gave high yields (92 %) and easy work up. DMT protection of the primary 
hydroxyl group gave relatively low yields (47%) (6). Phosphoramidite introduction to 
the secondary hydroxyl group was initially carried out with pyridine as the base 
needed to quench the equivalent of HCl produced. However, the pyridinium salt 
formed during the reaction is too acidic and cleaves off the diisopropylamino 
fragment of the phosphoramidite. When the base was changed to 
diisopropylethylamine (Hünig’s base) the desired product (4) was obtained as 
confirmed by NMR analysis (
1
H-
13
C HMBC experiments) (Scheme 1).
6
 
 
 
Scheme 1. Synthesis of central protected linker (6).
6
 
 
3.2.1.2 5’ Terminal linkers 
The C2 (1) and C3 (2) 5’ terminal modifiers were also first protected with Fmoc (9-
Fluorenylmethyloxycarbonyl)
7
 and then the protecting group was changed to TFA for 
1 and finally to MMT-Cl (monomethoxytrityl chloride).
5
 An advantage of the latter is 
that during DNA synthesis the coupling efficiency can be calculated 
spectrophotometrically by measuring the trityl release. For the same reason DMT is 
used as the protecting group for the secondary hydroxyl group in the central modifier. 
The synthesis of amine linkers 1, 2 and 3 is depicted in Scheme 2 and 3.
5
 
Surprisingly, the phosphoramidite coupling reaction with 3-aminopropanol resulted in 
two compounds. Analysis performed by mono and multinuclear two-dimensional 
NMR analysis (
1
H-
1
H, 
1
H-
13
C, 
1
H-
31
P correlations) showed that the isopropylamino 
group of the phosphoramidite is substituted by the amino group of the 3-
aminopropanol resulting in a more stable cyclic product (compound 12) (Scheme 3). 
This cyclization can also be caused by the use of pyridine during the reaction. It is 
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possible that the pyridinium salt formed cleaves the isopropylamino group facilitating 
the attack by the terminal amine as also seen for compound 4. Therefore, a two 
carbon bridge (ethanolamine) and a five carbon bridge (pentanolamine) were used for 
the synthesis of the terminal modifier assuming that this would reduce the chance of 
cyclisation.  
 
 
Scheme 2. Synthesis of C2 and C5 linkers.
5
 
 
 
Scheme 3. Synthesis of C3 amine linker resulting in desired product and cyclized compound.  
 
3.2.2 Synthesis of monomers 
As explained later in this chapter the central aliphatic linker resulted in DNA 
degradation and therefore, a nucleoside was modified with an amine functionality. 
Several of such modified nucleotides have been described in the literature, in 
particular, several groups have reported the synthesis of thymidine containing a 
propargylamino group.
8-14
 This base modification was chosen because of its 
straightforward synthesis. The amine functionality was introduced by a 
propargylamine precursor (13). Linkers with longer bridges can be used for this 
purpose,
15, 16
 although this specific linker was considered ideal for two main reasons. 
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Firstly, it can be synthesized in one step from the commercially available 
propargylamine and trifluoroacetic anhydride (Scheme 4), and secondly, linkers with 
longer chains would place the phosphine moiety further away from the DNA 
probably reducing the chance of efficient chiral induction. Compound 13 was first 
synthesized using ethyl trifluoroacetate in methanol resulting in a low yield of crude 
product (42%). Trifluoroacetic anhydride gave better conversion with a 60% yield of 
pure product after vacuum distillation.
17
 
Pd-catalyzed Sonogashira coupling of 13 to 5’-iodo-2-9deoxyuridine (IdU) affords 
the modified nucleobase 14 (58% yield).
12
 During this reaction triethylamine (TEA) 
neutralizes the hydrogen iodide formed giving the Et3N·HI. This salt co-elutes along 
with the desired product during purification with column chromatography. Although, 
it could be easily eliminated by stirring the purified product with K2CO3 in 
tetrahydrofuran to neutralize the ammonium salt back to triethylamine. Higher yields 
were obtained by lowering the quantities of the Pd catalyst and CuI. 
 
 
Scheme 4. Synthesis of propargyl amine modified thymidine.
12
 
 
Modified thymidine can be deprotected by using concentrated aqueous ammonia. The 
deprotected base contains trifluoroacetate salt according to 
19
F NMR. This salt could 
be removed in the case of compound 15 by column chromatography yielding crystals 
of the pure product, whose X-ray structure is depicted in Figure 4. The crystal 
structure shows that the amine functionality points away from the chiral centre and 
that the absolute configuration is retained. The purification of compound 15 however 
was not routinely carried out because it was found that the presence of TFA salt did 
not affect the coupling with phosphinocarboxylic acids. 
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Figure 4. Ortep representation for 15. Thermal ellipsoids drawn at 50% probability. 
 
For introduction of the monobase into the DNA it is necessary that the amine function 
remains protected. Continuing from compound 14 the next two steps are protection of 
the primary hydroxyl group with 4,4'-dimethoxytrityl chloride (DMT-Cl) to give 
compound 16 (80% yield)
12
 and phosphoramidite introduction to yield compound 
17,
12
 which was contaminated with 40% of hydrolyzed phosphoramidite reagent (18) 
after purification by column chromatography (Scheme 5). This contamination was 
also reported in literature.
12
 
 
 
Scheme 5. Synthesis of amine modified thymidine phosphoramidite.
12
 
 
The triple bond of monobase 14 was hydrogenated to increase the flexibility and 
reactivity of the amino group (compound 19). Both NaBH4/NiCl2 and 5% PtO2
8
 gave 
mixtures of saturated and unsaturated products along with starting material. 20% PtO2 
and 10% Pd/C instead both afforded the hydrogenated product with less than 4% 
impurities. As Pd/C is considerably less expensive than PtO2, the former was chosen 
as the preferred catalyst. Filtration of the reaction mixture resulted in the pure desired 
product without any further purification. Protection of the primary hydroxyl group 
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with DMT-Cl gave the tritylated nucleoside (20) in 75% yield. The protected 
nucleoside (16) was also hydrogenated with Pd/C and afforded the desired product in 
95% yield. Phosphoramidite introduction produced the expected product without any 
hydrolysis in 56% yield (21) (Scheme 6). 
 
 
 
Scheme 6. Synthesis of propylamino modified thymidine phosphoramidite.
11
 
 
3.2.3 Synthesis of trimer 
A DNA trimer is a good model for the study of longer oligonucleotides, with the 
advantage that they can be prepared in solution in much larger quantities. De Koning 
et al
18
 reported an efficient and fast synthesis of short DNA strands in solution. 
Following their procedure a trimer was prepared with an amine modified monomer in 
the central position. For the synthesis of DNA in solution the first base requires a 
protecting group for the secondary alcohol at the 3’ position compatible with DNA 
synthesis conditions while amenable to be deprotected during ammonia treatment at 
the end of the synthesis. The protecting group reported is the adamantylacetyl ester 
and the chosen nucleoside for the 3’ position was thymidine. The primary hydroxyl 
group was protected with DMT affording compound 22 in 85% yield, then the 
secondary hydroxyl group could be protected with adamantane acetic acid (AdaOH) 
leading to compound 23 in 85% yield. The amino group present in thymidine was 
then protected with chloromethylpivalate (Pom) to increase the solubility in organic 
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solvents producing compound 24 in 81% yield. The last step was DMT removal 
under acidic conditions to afford 25. The yield of this last step was 69% (Scheme 7).  
 
 
 
Scheme 7. Synthesis of protected thymidine.
18
 
 
The trimer is synthesized starting from compound 25, by coupling with modified 
nucleoside phosphoramidite (21) and guanine phosphoramidite respectively 
(dTdXdG) (Scheme 8). Aqueous ammonia at 55 ˚C for 3 days is used for the 
deprotection and as explained in chapter 2 purification is performed with FPLC using 
different concentrations of TEAA (triethylamine acetic acid) buffer as eluent. 
MALDI-TOF analysis shows the molecular weight peak corresponding to the desired 
product.  
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Scheme 8. Synthesis of trimers in solution with the amine modified base at the central 
position.
18
 
 
3.2.4 Synthesis of 15-mers 
3.2.4.1 Introduction of aliphatic linkers into DNA 
A complete turn of a double stranded DNA requires at least 10 base pairs. 15-mers 
were considered to have the optimal length for a modified oligonucleotide because 
they can form a duplex with a complementary strand and in optimal conditions its 
synthesis gives relatively high yields (20-40%). Longer strands in our findings would 
inevitably be obtained in considerably lower yields and shorter strands might not be 
able to give duplex formation due to structural distortions caused by the modification. 
DNA modifications can be introduced at different locations of the strand at will. 
Phosphine moieties in a central position of a DNA strand are more likely to be 
influenced by the chiral environment especially when a double helix is formed by 
introducing a complementary strand. On the other hand, phosphine modification at 
the terminal positions together with a complementary strand allows the templated 
formation of a bidentate. (Figure 1) 
Compound 4 (Figure 5) was introduced into several 15-mers.  
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Figure 5. Terminal aliphatic linkers and central aliphatic linker.
5, 6
 
 
The purification of DNA was initially performed with an FPLC ion exchange column 
followed by a desalting step. HPLC purification is most commonly used for the 
purification of DNA strands so it was decided to change our method of purification to 
preparative HPLC with a C18 clarity column. There are two major advantages of 
HPLC purification. Firstly, it uses a volatile buffer, therefore the desalting step is no 
longer required and additionally it drastically reduces the amount of sodium salts 
present in the DNA. Secondly, DNA strands of several lengths can be purified. The 
only drawback of HPLC is that only small amounts of DNA can be purified in each 
run. The maximum column load for a C18 Clarity column is 5 μmol while in contrast, 
for an HP 16/10 QXL Sepharose FPLC column the maximum load can be up to 70 
μmol depending on the sample purity and the length of the strand.  
When the 15-mers were purified by preparative HPLC several peaks appeared and the 
main peak did not give the expected molecular weight in MALDI-TOF analysis. This 
suggests that the DNA decomposes into smaller fragments. The deprotection 
procedure was then changed from 1:1 concentrated aqueous ammonia/40% 
methylamine, to concentrated aqueous ammonia 80 ˚C for 8 h and finally to aqueous 
concentrated ammonia at 50˚C for 17 h but no major change in chromatograms were 
observed. Despite numerous attempts, only on a few occasions fractions containing 
the desired product (according to MALDI-TOF analysis) could be collected. The 
quantity of the 15-mer collected was much less than 1 nmol. Therefore, the use of 
linker was abandoned because of its instability and difficulty of purification.  
It is important to emphasize that sample preparation is important for MALDI-TOF 
analysis. Salts are known to disrupt the analysis of DNA therefore several methods 
were tested to reduce the amount of salts present in the samples. The best results were 
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obtained with a combination of two different desalting methods. The DNA samples 
are first desalted using a desalting column, followed by Dowex 50X, which is an ion 
exchange resin and finally prior to analysis desalting tips are used.  
Linkers 1 and 3 were also introduced into a DNA 15-mer although the desired strand 
could not be synthesized. The final coupling during the automated synthesis of the 
15mer with C2 (1) as terminal linker gave 78% yield although MALDI-TOF analysis 
after FPLC purification resulted in 73 mass units less than the expected molecular 
weight. When the C5 linker 3 was introduced into the terminal position of the 15mer, 
again by standard DNA synthesis, the coupling efficiency was 0% indicating that the 
coupling had failed. To analyze the coupling efficiency of compound 3 a test was 
employed with methanol and tetrazole in solution. After the addition of tetrazole the 
phosphoramidite peak in 
31
P NMR successfully moved from 146.8 ppm to 139.5 ppm 
showing that coupling to methanol was successful. Coupling of compound 3 to a 
DNA strand was attempted several times but the same results were obtained. Because 
of those unsuccessful results it was decided to buy a commercial 15mer with a C3 
linker at the 3’ position.  
 
3.2.5.2 Introduction of amino modified thymidine into 15-mers 
Compound 16 was introduced in the central and terminal position of DNA strands of 
15 bases long (15-mers). These syntheses are typically performed automatically in a 
DNA synthesizer and the steps have been explained in the previous chapter. Modified 
base 16 was successfully introduced in the central position and 5’ position of several 
15-mers (Table 1). 
 
Strand # Strands Synthesized Molecular 
Weight 
Mass Found 
S1 5’-TAAGCCAMCATCCGC-3’ 4535.9 4534.3 
S2 5’-ATTCGGTMGTAGGCG-3’ 4678.0 4676.4 
S3 5’-GCGGATGMTGGCTTA-3’ 4678.0 4676.9 
S4 5’-MATTCGGTAGTAGGCG-3’ 4991.3 4989.4 
 
Table 1. Mass spec analysis (MALDI-TOF) of the synthesized 15-mers M= amine modified 
base 16.  
 
Once the desired DNA strand had been synthesized it was cleaved off from the solid 
support and all the protecting groups were deprotected simultaneously using basic 
conditions. The first method of deprotection used was the most commonly 
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encountered in the literature: concentrated aqueous ammonia at 80 ˚C for 8 h or at 55 
˚C overnight. After purification using a preparative HPLC column, MALDI-TOF 
analysis for 15-mers S2 and S3 showed an extra peak next to the desired peak at 53 
mass units higher (Figure 6). A likely explanation for this peak is that the acrylonitrile 
released from the phosphate is attacked by the free amine of the linker before being 
quenched by the ammonia (Scheme 9). 
 
 
 
Figure 6. MALDI-TOF analysis of 15-mer S2 showing the peak of the expected compound 
plus a peak of 53 units higher. ˚ 
 
Scheme 9. Attack of the amine linker by the acrylonitrile during oligonucleotide cleavage 
from solid support with ammonia. 
 
Studies with the nucleoside (14) and acrylonitrile in ammonia showed that the amine 
linker is very reactive towards acrylonitrile. Reaction of one equivalent of the 
protected nucleoside in ammonia with 14 equivalents of acrylonitrile resulted in 
complete addition of the amino group to acrylonitrile, whereas around 25% of the 
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modified base is found to be coupled to acrylonitrile when the ratio is one to one. 
Surprisingly, this is not observed in the trimer and not in all the 15-mers, indicating 
that the exact sequence of the strand has a large influence on its reactivity. 
Hydrogenated amine-modified monomer (20) was introduced into three DNA strands 
(table 2). 
 
Strand # Strands Synthesized Molecular 
Weight 
Mass Found 
5H 5’-ATTCGGTHGTAGGCG-3’ 4682 4683 
6H 5’-CGCCTACHACCGAAT-3’ 4540 4540 
7H 5’-HTTCGGTAGTAGGCG-3’ 4682 4680 
 
Table 2. Mass spec analysis (MALDI-TOF) of the synthesized 15-mers H= amine modified 
base 20. 
 
Strand 5H was used to test two different methods of deprotection: a 1:1 mixture 
solution of ammonia/aqueous 40% methylamine for 17 h at 55 ˚C, and concentrated 
aqueous methyl amine (40%) for 8 h at 55 ˚C. The strand was cleaved off with both 
methods as shown by two main overlapping peaks in the HPLC chromatograms. 
MALDI-TOF analysis of those two peaks showed the desired product although the 
last peak contained a signal about 53 units higher indicating that a small amount of 
oligonucleotide is still attacked by acrylonitrile. This indicates that a small amount of 
DNA still reacts with acrylonitrile even when a strongly nucleophilic base such as 
methylamine is used for the deprotection.  
 
3.2.5 Coupling of phosphine moieties to monomers, trimers and 15-mers 
3.2.5.1 Coupling of phosphines to monomers  
Before coupling phosphine moieties to DNA, phosphine modified monomers were 
synthesized to serve as models for longer DNA chains. Ortho-, meta- and para-
diphenylphosphinobenzoic acids and 4-(bis(2-diphenylphosphino)ethyl)amino)-4-
oxobutanoic acid (Whitesides carboxylic acid) were successfully coupled to the 
amine modified thymidine. Ortho- and para-diphenylphosphinobenzoic acids are 
commercially available, whereas meta-diphenylphosphinobenzoic acid and the 
Whitesides carboxylic acid were synthesized following literature procedures.
19
 
Compound 30 was synthesized from bis(2-chloroethyl) amine hydrochloride and 
diphenylphosphine in 67% yield. This compound is commonly referred to as 
“Whitesides ligand” after George M. Whitesides.20 Methyl-4-chloro-4-oxobutyrate 
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was added to compound 30 to give the protected compound 31
19
 in 72% yield. 
(Scheme 10). Purification of this compound proved to be troublesome because part of 
the desired product co-eluted with an unidentified brown impurity during column 
chromatography purification. Later it was found in the group that by replacing 
methanol by acetone as eluent the desired product could be obtained in pure form in 
81% yield. Deprotection with LiOH afforded the desired product 32 in 70 % yield. 
 
 
Scheme 10. Synthesis of 4-(bis(2-diphenylphosphino)ethyl)amino)-4-oxobutanoic acid. 
 
The coupling of phosphine moieties to the nucleosides was performed under the same 
conditions as those to be employed with DNA strands (Scheme 11). The 
phosphinocarboxylic acids were activated with EDC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide)/NHS (N-Hydroxysuccinimide) in dry DMF and 
added to the modified bases in a 0.1 M aqueous solution of NaHCO3. The amine 
functionality of the modified thymidine is deprotected prior to the coupling by using 
concentrated aqueous ammonia. Purification by column chromatography gave pure 
product with less than 5% oxidation in good yields up to 82%. Preparation of 
monomer 40 modified with compound 32 gave yields lower than 10% and its 
synthesis was not further pursued. The three phosphinocarboxylic acids mentioned 
before were coupled to both propargyl and propylamino modified monomers. The 
coupling reaches about 80% conversion as monitored by 
31
P-NMR spectroscopy 
when the propylamino base is used. In order to improve the yields, other coupling 
reagents were tested such as DCC (Dicyclohexylcarbodiimide)/HOBT 
(Hydroxybenzotriazole)/TEA,
21
 CDI (1,1'-Carbonyldiimidazole), NHS/EDC/TEA
22
 
and pentafluorophenol/DCC/IPEA
23
 (Figure 7) but none of the reactions provided the 
desired product. 
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Figure 7. Common reagents used for amide bond formation. 
 
 
Scheme 11. Synthesis of phosphine modified monomers with ortho-, meta-, para-
diphenylphopshinobenzoic acids and 4-(bis(2-diphenylphosphino)ethyl)amino)-4-
oxobutanoic acid.  
 
Crystals suitable for X-ray crystallography of compounds 37 (Figure 8) and 38 
(Figure 9) were obtained by slow evaporation of acetonitrile solutions at room 
temperature.  
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Figure 8. Ortep representation for 37. Thermal ellipsoids are drawn at 50% probability. 
 
 
Figure 9. Ortep representation for 38. Thermal ellipsoids are drawn at 50% probability. 
 
The crystal structures proved the identity of compounds 37 and 38 and confirmed the 
expected absolute configurations of the stereogenic carbons of the the ribose ring. 
Bonding distances and angles are similar to those found in other compounds.
24
 In 
spite of that, both structures look very different. 38 presents an open structure with 
the diphenylphosphino unit far away from the ribose ring and the electron pair of the 
phosphorus atom pointing outwards of the molecule. This conformation is probably 
forced by an intramolecular hydrogen bond between O(13)H and the O(2) of the 
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carbonyl of the amido group. In contrast, 37 has a much more closed structure, with 
the PPh2 group pointing inwards, in the direction of the 5’-OH of the ribose ring and 
without the hydrogen bond found for 38. 
 
3.2.5.2 Coupling of phosphine moieties to DNA strands 
Similar coupling conditions
1
 were used to introduce the phosphine moiety onto the 
trimer and several 15-mers. The differences between the coupling of the phosphine 
moiety to the monomer and the oligonucleotides were the quantities of DNA 
employed and the equivalents of phosphinocarboxylic acid used. The amounts of 
oligonucleotides used for those syntheses are in the micro and nanomolar range and 
therefore, the purification and analysis of those compounds can not be achieved with 
the standard organic synthesis methods. For the trimer, 4 equivalents of activated 
phosphinobenzoic acid were used while for the 15-mers 250-500 equivalents were 
employed. Trimer modified with ortho-diphenylphosphinobenzoic acid (Scheme 11), 
was purified by FPLC using an ion exchange column. 
31
P{
1
H} NMR before 
purification showed the phosphate peaks at around 0 ppm, a peak at −6.94 ppm which 
is the expected region for the coupled phosphine, a peak at −8.58 ppm which 
corresponds to the phosphine starting material and some other minor peaks. After 
purification, 
31
P{
1
H} NMR shows the phosphate peaks at 0 ppm and a peak at 36 
ppm which is most likely the oxidized coupled phosphine with an integral ratio of 2 
to 1. The coupling reaction was repeated and the crude product was split in two 
fractions which were purified by HPLC and FPLC, in parallel. For both methods, the 
contact with air of the reaction mixture was minimized and all solvents were 
degassed. 
31
P{
1
H} NMR of product after FPLC showed the phosphate peak and the 
peak of the phosphine oxide. HPLC purification gave no peaks corresponding to the 
trimer. It is most likely that the trimer is not soluble in the eluting medium and it 
precipitates on the column. Because of the sensitivity of the phosphine to oxygen it 
was decided that it was necessary to protect the phosphorus atom before the 
purification step. BH3 was chosen as protective group because the DNA is compatible 
with its deprotection conditions. However, previous experience in the group on the 
deprotection of phosphine compounds showed that BH3 removal could be 
troublesome. For the trimer it is necessary to find a deprotection method that does not 
require any further purification. Van Overschelde et al
25
 successfully deprotected 
phosphine-boranes by simply stirring them in refluxing methanol or ethanol. This 
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method was tested for the deboronation of the trimer. After coupling of ortho-
diphenylphosphinobenzoic acid to the trimer the crude mixture was treated with 
BH3·SMe2 to protect the phosphine ligand and perform purification under air. 
Purification by HPLC was repeated and MALDI-TOF analysis of the purified trimer 
showed a peak corresponding to the expected mass of 1221.6. The sample was then 
deboronated by refluxing in methanol for 1 h. After being concentrated in vacuo a 
31
P{
1H} NMR spectrum was taken which showed the phosphates signal, a peak at −6 
ppm, which corresponds to the deprotected phosphine coupled to the DNA and 
several other peaks around the +36 ppm region which probably correspond to the 
oxidized phosphine. Metal complexation with [Rh(acac)(CO)2] was attempted and the 
reaction was followed by MALDI-TOF but no peak corresponding to the metal 
complex formation could be observed. However, MALDI-TOF may not be an 
adequate technique of the analysis of DNA-metal complexes.  
 
 
 
 
Scheme 12. Coupling of ortho-diphenylphosphinobenzoic acid to the trimer.
1
 
 
15-mers with central and terminal modifiers were also functionalized with phosphine 
moieties using the same coupling conditions as with the trimers and monomers. 
Because of the higher molecular weight 15-mers can be purified using other methods. 
They were initially purified by using a membrane filter with a cut-off of molecular 
weight at 3000 daltons. The filter consists of a cellulose membrane that separates 
molecules by their molecular weight using centrifugal force (Figure 10).  
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Figure 10. Illustration of a membrane filter from Millipore. 
 
After DCM or CHCl3 washing the aqueous layer contains a white precipitate which 
was removed by centrifugation. The clear aqueous layer was placed in the membrane 
filter and it was centrifuged several times with degassed water to separate all the low 
molecular weight compounds from the desired strand. The contact with air was 
minimized as much as possible. 
31
P{
1
H} NMR spectrum of the water phase solution 
remaining in the membrane filter still showed the peak corresponding to the excess of 
phosphine. MALDI-TOF analysis showed the molecular weight of the phosphine 
oxide coupled to DNA. To exclude a DNA catalyzed oxidation of the phosphine with 
water, 
31
P{
1
H} NMR spectrum of a DNA strand in presence of 240 equivalents of p-
diphenylphosphinobenzoic acid was recorded. 50 measurements were taken every 30 
minutes (64 scans) to monitor the appearance of oxidized phosphine. After 25 h no 
oxidation was observed suggesting that the DNA does not favour the oxidation of the 
phosphine moiety. Another result indicating that the phosphine unit is not oxidized by 
the DNA or during purification was mass spectrometric analysis with electrospray 
ionisation. In this case, the molecular weight corresponds to the non oxidized 
phosphine (15-mer S4 with o-dppba).  
It has to be mentioned that many attempts were also carried out to couple strands S1, 
S3 and S4 to o-, p-diphenylphosphinobenzoic acid (dppba) and 5 but unfortunately, 
the coupling reactions with the propargylic amines exhibited bad reproducibility. The 
only reproducible coupling was obtained with a commercial strand (7CS) of sequence 
5’-GCTGATGACTATCGAM-3’ which has a C3 3’ flexible terminal linker. The 
Propargylic amines are considerably less basic and nucleophilic than those bearing 
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saturated groups. Moreover, the rigidity of the carbon bridge might render the 
coupling more difficult. For these reasons we discontinued our efforts with 
propargylic amine modified strands S1, S2, S3 and S4 and the triple bond of 
monobase 14 was hydrogenated to increase both the flexibility of the bridge and the 
nucleophilicity of the nitrogen atom, potentially improving the coupling efficiency. In 
addition, to simplify the method and to obtain purer strands, the purification of the 
coupled DNA 15-mers was changed to ethanol precipitation. Precipitation of 217 
nmol crude product resulted in 155 nmol of DNA, therefore about 30% of the DNA is 
lost during this procedure. Due to the unreliability of MALDI-TOF analysis, a more 
robust and complementary analytical technique was required. Therefore, 
31
P-NMR 
analysis was attempted although it was anticipated to be problematic due to the 
extremely small amounts of phosphine modified DNA available. Strand 5H was 
coupled to p-(diphenylphosphino) benzoic acid and after washing and ethanol 
precipitation a 
31
P{
1
H} NMR sample was prepared under inert atmosphere. The 
31
P{
1
H} NMR spectrum (Figure 11) showed the peaks of the phosphates at 0 ppm a 
small peak at −5.5 ppm corresponding to the coupled phosphine moiety, small peaks 
at 35 ppm corresponding to partial oxidation of the coupled phosphine and an 
unidentified extra peak at 24 ppm. No excess of free phosphine was present. The 
integration of the two phosphorus peaks does not correspond to 1 to 14. The different 
relaxation times of the phosphine and the phosphates makes integration unreliable. In 
spite of that, the NMR strongly suggests the success of the coupling and to the best of 
our knowledge constitutes the first NMR evidence of a phosphine moiety coupled to a 
relatively long DNA strand. Figure 14 shows a model of the strand with the phosphine 
moiety in yellow drawn with the modelling program pymol. MALDI-TOF analysis of 
the same strand used for NMR analysis gave the molecular weight expected for the 
oxidized coupled compound (Figure 12), indicating that the oxidation takes place 
during the MALDI-TOF measurements. No peak corresponding to the uncoupled 15-
mer could be observed. Analysis by MALDI-TOF of a mixture of phosphorylated and 
uncoupled 15-mer was attempted to obtain a better indication of the coupling 
efficiency but no signal above the mass of 1200 could be observed. Due to the large 
amount of salts present with the DNA, the 15mer was filtered through a desalting 
NAP-10 column. This procedure was performed under inert conditions. 
31
P{
1
H}NMR 
after desalting showed complete oxidation of the phosphine moiety as indicated by 
peaks at 35 ppm. The coupling was repeated with strand 6H and in this case 
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31
P{
1
H}NMR showed about 50% oxidation of the coupled phosphine moiety and 
again a small peak at 24 ppm. This strand was complexed with dimer [PdCl(η3-
allyl)]2. 
31
P{
1
H}NMR of the Pd allyl chloride complexed 15-mer shows the 
appearance of a broad peak at 27 ppm and the disappearance of the peak at −5.5 ppm 
suggesting the successful formation of the Pd complex with the phosphine moiety 
coupled to the DNA 15-mer (Figure 13). MALDI-TOF analysis was attempted but the 
peak corresponding to the expected molecular weight was not detected. Strand 7H was 
coupled to the Whitesides carboxylic acid, MALDI-TOF analysis shows the molecular 
weight of the coupled oxidized phosphine ligand proving a successful coupling 
although 
31
P{
1
H}NMR shows complete oxidation of the coupled phosphine ligand. 
The Whitesides ligand is more oxygen sensitive compared to diphenylphosphino 
benzoic acid because the third electron withdrawing phenyl ring is replaced by an 
aliphatic chain therefore increasing the electron density on the phosphorous atom 
making it more prone to oxidation.  
The oxidized phosphine strands were analyzed by HPLC to identify the coupling 
efficiency although only two overlapping peaks were visible with a retention time of 6 
minutes. Using the same gradient for purification of the modified DNA the 15-mer 
was eluted after 26 minutes. This suggests that the phosphine moiety drastically 
changes the interaction between the 15-mer and the C18 reversed phase material of the 
column.  
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Figure 11. 
31
P{
1
H}NMR spectrum after 16 h of acquisition time with a 500 MHz NMR 
machine. The peak at −1.2 ppm is the phosphate peak and the peak at −6.7 ppm is the peak of 
the phosphine coupled to the 15-mer. 
4880.0 4962.2 5044.4 5126.6 5208.8 5291.0
Mass (m/z )
12.7
0
10
20
30
40
50
60
70
80
90
100
%
 I
n
t
e
n
s
it
y
4700 Reflector Spec #1 MC[BP = 5032.8, 13]
5
0
3
1
.9
1
0
6
5
0
0
9
.8
7
8
9
5
0
7
6
.8
6
0
4
5
0
5
3
.8
4
6
2
4
9
8
7
.9
0
7
7
 
Figure 12. MALDI-TOF analysis of the phosphine modified 15-mer. Calculated mass is of 
4970, mass found is 4987 which represents the coupled oxidized compound, peaks at 5009.9, 
5031.9, 5053.6, and 5076.8 are the coupled compound plus Na.   
 
 
 83 
 
 
Figure 13. Overlapping 
31
P NMR spectra of phosphine modified 15-mer. Red spectrum 
shows a peak at −5.5 ppm representing the coupled phosphine. Blue spectrum shows the Pd 
complexed phosphine with a peak at 27 ppm. 
 
 
 
Figure 14. Stick and sphere representation of phosphine (in yellow) modified 15-mer using 
Pymol.   
 
3.2.6 Catalysis with modified bases  
As explained in the introduction, phosphine modified monobases have been used as 
ligands for Pd-catalyzed allylic substitution resulting in enantoselectivities up to 
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80%.
24
 Pd-catalyzed allylic substitution is a model reaction for Pd catalyzed C-C 
bond formation and it is a very well established reaction.
26, 27
 For those reasons allylic 
substitution of 1,3-diphenylallyl acetate with dimethyl malonate as nucleophile was 
chosen to study the catalytic properties of the six phosphine modified bases (Scheme 
13). The reactions were performed in CH2Cl2 and THF. 
 
 
 
Scheme 13. Allylic alkylation (a) BSA (N,O-Bis(trimethylsilyl)acetamide), [Pd(allyl)Cl]2, 
KOAc) and allylic amination (b) [Pd(allyl)Cl]2) reactions using the modified nucleobases as 
ligands.  
 
Allylic alkylation in CH2Cl2 resulted in 100% conversion for compounds 35, 36, 38, 
39 and less than 10% conversion for compounds 37 and 34 (Table 3). 
Enantioselectivities were lower than 4%. The same reaction repeated in THF resulted 
in much lower conversion and ee lower than 5%. The much stronger coordination 
properties of THF probably slow down the reaction. 
Compounds 34, 35, 36 were also tested in allylic alkylation at 0 ˚C to observe any 
change in enantioselectivity. No change in ee was observed although the conversions 
dropped to lower than 20% (Table 3). 
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Ligand Solvent Conv. % 
34 DCM 1.6, 0* 
34 THF 0 
35 DCM 100, 15* 
35 
 
THF 14.5 
36 DCM 100, 19* 
36 THF 3.4 
37 DCM 9.2 
37 THF 3.4 
38 DCM 100 
38 THF 9.8 
39 DCM 100 
39 THF 4.4 
 
Table 3. 0.5 μmol of [Pd(η3-C3H5)Cl]2, 1,3-diphenylallyl acetate:dimethyl malonate: BSA:Pd 
= 50:150:150:1, 400 μl of solvent at 25 ˚C, for 24 h. * reactions performed at 0 ˚C for 24 h. 
 
Allylic amination was performed with the same substrate and benzylamine acting 
both as base and nucleophile. Allylic amination was more problematic, in CH2Cl2 the 
conversions for compounds 35, 36, 38, 39 were 99-100%. Conversion for compound 
37 was lower than 10% and for 34 the results were not consistent (Table 4). In THF 
the results were non reproducible and the reactions were not tried again.  
 
Ligand Solvent Conv. % 
35 
 
DCM 100 
36 DCM 100 
37 DCM 8.2 
38 DCM 99.5 
 39 DCM 100 
 
Table 4. 0.5 μmol of [Pd(η3-C3H5)Cl]2, 1,3-diphenylallyl acetate:benzylamine:Pd = 
50:150:1 400 μl of solvent at 25 ˚C, for 24 h.  
 
The Pd complex of the 15-mer described above was tested as ligand for Pd-catalyzed 
allylic alkylation of the benchmark substrate 1,3-diphenylallyl acetate with dimethyl 
malonate but unfortunately no conversion was observed. 
The same 15-mer was synthesized again and analyzed by 
31
P{
1
H}NMR spectroscopy, 
which showed the unoxidized phosphine peak at −5.5 ppm. The strand was 
complexed in situ with [Rh(acac)(CO)2] and used directly for hydroformylation of 
styrene, which did not give any conversion either. 
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3.3 Conclusion 
This chapter details the successful synthesis of two modified thymidines with amino 
groups and central and terminal aliphatic linkers. Those modifications were 
successfully introduced into oligonucleotides using standard solid phase synthesis and 
amine modified thymidine was also introduced in the central position of a trimer 
using solution phase synthesis. Ortho-, meta-, and para-diphenylphosphinobenzoic 
acids were coupled to amine modified thymidine and used in Pd-catalysed allylic 
substitution reactions. Although the reactions were not selective towards any specific 
enantiomer, four ligands gave complete conversions in allylic alkylation. A trimer 
was successfully synthesized in solution phase containing thymidine modified with an 
alkene amine linker in the central position. Ortho- diphenylphosphinobenzoic acid 
was coupled to it resulting in 50% oxidation after purification by preparative HPLC 
and BH3 deprotection in refluxing methanol. 15-mers were modified with thymidine 
containing an alkyne amine linker, thymidine containing an alkane modified linker, a 
central aliphatic amine linker, a 3’ C3 linker and a 5’ C3, C5 terminal aliphatic amine 
linkers. Some of those amine modified oligonucleotides could be coupled to 
phosphine moieties. Oxidation of the phosphine moiety was prevented after several 
attempts and after the use of several different purification methods. Methods were 
developed for the purification of oligonucleotides prior and after phosphine 
modification and an appropriate method was found for the MALDI-TOF analysis of 
oligonucleotides. A Pd metal complex was obtained as indicated by NMR analysis 
and a few attempts were made in using the phosphine modified 15-mer ligands in 
catalysis. 
Having optimized the coupling and purification procedures, future work should be 
focused on the use of DNA phosphine modified oligonucleotides as ligands for 
asymmetric catalytic reactions. A bidentate system could be generated from single 
stranded oligonucleotides with phosphine modification at the 5’ and 3’ position and 
different complementary strands could be used to change the local environment of the 
substrate. Moreover, several different phosphines could be synthesized bearing 
carboxylic acid moieties and then introduced on the DNA increasing the variety of 
ligands that could be synthesized in a relatively short period of time.  
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Part of the work shown in this chapter was done in collaboration with Dr. Arnald 
Grabulosa. Part of this work was also published with cover in the European Journal 
of Organic Chemistry 
 
3.4 Experimental 
General Procedures 
All reactions were performed under argon using standard Schlenk techniques. 
Chemicals were purchased from Aldrich Chemical Company, Acros, Fluka, Link 
Technologies and Glen Research. CH2Cl2 and acetonitrile were distilled from CaH2; 
ethanol and methanol were distilled from Mg/I2; toluene was distilled from Na, THF 
and Et2O were distilled from sodium /benzophenone and all the distillations were 
performed under nitrogen atmosphere. DMF was purchased “Extra dry” and stored 
over molecular sieves (4 Å) under argon. Aqueous solutions were degassed by three 
freeze/thaw cycles under vacuum and kept under argon. Thin Layer Chromatography 
(TLC) was performed on silica plates (Polygram 0.2 mm silica gel with fluorescent 
indicator UV254). Ninhydrin spray was used for the detection of primary and 
secondary amines on TLC silica plates. Silica gel 60 particle size 0.063-0.2 mm from 
Fluka was used for flash chromatography. NMR spectra were recorded at room 
temperature on Bruker Avance spectrometers (300, 400, and 500 MHz). Positive 
chemical shifts () are given (in ppm) for high-frequency shifts relative to a TMS 
reference (
1
H and 
13
C) or an 85% H3PO4 reference (
31
P). 
13
C, 
31
P, and 
19
F spectra 
were measured with 
1
H decoupling. The following abbreviations have been used in 
the description of the spectra: s, singlet; d, doublet; t, triplet; m, multiplet. IR spectra 
were recorded on a Perkin-Elmer Spectrum GX spectrometer in KBr pellets, with a 
window between 4000 and 400 cm
–1
. Mass spectrometry: MALDI-TOF mass spectra 
were recorded on a 4800 Plus MALDI TOF/TOF™ Analyzer using a 9:1 3-
hydroxypicolinic acid (HPA): ammonium citrate matrix. The matrix is made with 50 
mg/ml of HPA in 50:50 MeCN:H2O and 50 mg/ml of ammonium citrate in H2O. The 
desalting column used for the preparation of MALDI-TOF samples was a GE 
Healthcare Illustra
® 
micron G-25 and the desalting tips were Millipore
®
 zip-tip C18, 
the Dowex used for desalting was a 50WX4 200-400 mash resin. Oligonucleotides 
prepared at our laboratories were synthesized by an Applied Biosystems 392 
DNA/RNA synthesizer using protocols obtained from Applied Biosystems. The 
reagents used for the synthesis of oligonucleotides were bought from Glen research 
and were: oxidizing solution 0.10 M I2 in THF/pyridine/water; cap mix B (10% 1-
methylimidazole in THF/pyridine); cap mix A (THF/pyridine/acetic anhydride); 
deblocking mix (3% trichloro acetic acid in DCM); activator (sublimed 1H-tetrazole 
in anhydrous acetonitrile); dA, dC, dG, dT phosphoramidites. Coupling yields for 
DNA synthesis are based on measurements of DMT release which is determined by 
conductivity measurements. Purification by ion exchange, size exclusion and 
desalting were carried out with a FPLC AktaBasic 100 (P-901), monitor UV-900. The 
column used for purification of the modified oligonucleotides was a HiLoad 16/10 Q 
Sepharose HP with the following buffers: buffer A = 1 M NaCl, 10 mM NaOH and 
buffer B = 10 mM NaOH. The column for the desalting was a HiPrep 26/10 Desalting 
with a linear gradient of 0.15 M NH4HCO3 buffer. HPLC purification of 
oligonucleotides was carried out in a Waters machine equipped of a Waters 2700 
sample manager, Waters 600 controller and Waters 2487 dual absorption detector. 
The reverse phase column used was a Phenomenex, Clarity
®
 C18 5 μ oligo-RP, 250 x 
21.20 mm. Oligonucleotides synthesis at the University of Leiden was performed 
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with a AKTA-oligopilot DNA synthesizer. Chiral HPLC analyses were carried out in 
an Agilent Technologies 1200 Series apparatus equipped with a UV-Vis photodiode 
array detector. The measurements were performed at 254 nm, with an injection 
volume of 1 µl.  
N-(2,3-dihydroxypropyl)trifluoroacetamide (5)
6
 
Compound 5 was synthesized according to literature procedure. 
The desired compound is a white solid. Yield: 1.29 g, 92%  
Characterization of the product fully agreed with data from 
literature.  
1
H NMR (300 MHz, CD3OD): δ = 3.80-3.72 (m, 1H, H-4), 3.52-3.41 (m, 3H, CH, 
CH2), 3.33-3.26 (m, 1H, CH) 
19
F NMR (300 MHz, CD3OD): δ = −73.86 
N-(2,3-dihydroxy-3-O-
dimethoxytritylpropyl)trifluoroacetamide (6)
6
 
Compound 6 was synthesized according to literature 
procedure. The desired compound is a white foam. 
Yield: 3.0 g, 47% 
Characterization of the product fully agreed with data 
from literature.  
1
H NMR (300 MHz, CDCl3): δ = 7.34-7.31 (m, 2H, Ar), 7.21-7.17 (m, 7H, Ar), 6.78-
6.75 (m, 4H, Ar), 6.60 (bs, 1H), 3.87-3.81 (m, 1H), 3.71 (s, 6H), 3.57-3.48 (m, 1H), 
3.27-3.18 (m, 2H), 3.09-3.04 (m, 1H), 3.36 (d, 1H, J = 4.6 Hz) 
13
C NMR (300 MHz, CD3OD): δ = 160.1, 159.2 (q), 146.4 (Ar), 137.3 (Ar), 131.3 
(Ar), 129.3 (Ar), 129.8 (Ar), 127.8 (Ar), 117.5 (q), 114.1, 87.52, 70.1, 66.8, 55.7, 
44.5  
19
F NMR (300 MHz, CDCl3): δ = −76.30 
N-(2,3-dihydroxypropyl-2-O-cyanoethyl-N,N-diisopropylphosphoramidite-3-O-
dimethoxytritylpropyl)trifluoroacetamide (4)
6
 
Compound 4 was synthesized according to literature 
procedure. The desired compound was obtained as a 
white powder. Yield: 420 mg, 64%  
Characterization of the product fully agreed with data 
from literature.  
1
H NMR (300 MHz, CD3OD): δ = 7.32-7.10 (m, 9H, 
Ar), 6.7 (m, 4H, Ar), 6.68 (br. s, 1H), 3.98 (m, 2H), 
3.84 (m, 1H), 3.72 (s, 6H), 3.58 (m, 2H) 3.30 (m, 1 H), 3.19 (d, 1H), 3.14 (dd, 1H), 
3.05 (dd, 1H), 2.57, 2.38 (t, 2H), 1.10 (m, 12H) 
31
P NMR (300 MHz, CD3OD): 150.6 (s) 
MS: 712.22 (M+Na
+
) 
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N-[(methoxyphenyl)diphenylmethyl]-2-aminoethanol (9)
28
  
Compound 9 was synthesized according to literature 
procedure. The desired product was obtained as a white solid. 
Yield: 1.6 g, 73%  
Characterization of the product fully agreed with data from 
literature.  
1
H NMR (300 MHz, CDCl3): δ = 7.41-7.08 (m, 12H, Ar), 7.76-7.73 (m, 2H Ar), 3.71 
(s, 3H), 3.61 (t, 2H, J = 5.2 Hz), 2.28 (t, 2H, J = 5.3 Hz), 1.88 (bs, 2H)   
N-[(methoxyphenyl)diphenylmethyl]-3-aminopropanol (11)
5
 
Compound 11 was synthesized according to literature procedure. The desired product 
was obtained as a white solid. Yield: 2.0 g, 87% 
1
H NMR (400 MHz, CDCl3): δ = 7.46-7.42 (m, 4H, Ar), 7.36-7.27 (m, 6H, Ar), 7.23-
7.18 (m, 2H, Ar), 6.84-6.80 (m, 2H, Ar), 3.89 (t, 2H, J = 5.4 Hz), 3.79 (s, 3H), 2.41 (t, 
2H, J = 5.9 Hz), 1.71 (q, 2H, J = 5.8 Hz) 
13
C NMR (75.4 MHz, CDCl3): δ = 156.9, 144.6, 136.4, 128.7, 127.4, 126.90, 125.4, 
112.2, 69.9, 62.6, 54.2, 42.3, 31.3 
N-[(methoxyphenyl)diphenylmethyl]-5-aminopentanol (10)
5
 
The name method as for 11 was employed. Yiled 3.9 g, 79%  
Characterization of the product fully agreed with data from literature.  
1
H NMR (300 MHz, CDCl3): δ = 7.40-7.37 (m, 4H, Ar), 7.30-7.27 (m, 2H, Ar), 7.20-
7.16 (m, 4H, Ar), 7.11-7.07 (m, 2H, Ar), 6.74-6.70 (m, 2H, Ar), 4.70 (s, 3H), 3.52 (t, 
2H, J = 6.6 Hz), 2.05 (t, 2H, J = 6.6 Hz), 1.47-1.39 (m, 6H), 1.33-1.37 (m, 2H)  
13
C NMR (75.4 MHz, CDCl3): δ = 156.7, 145.5, 137.4, 128.7, 127.5, 126.7, 125.1, 
112.0, 69.3, 61.7, 54.1, 42.5, 31.6, 29.6, 22.5  
N-[(methoxyphenyl)diphenylmethyl]-2-aminoethanol-O-cyanoethyl-N,N-
diisopropylphosphoramidite (1) 
Compound 9 (1.6 g, 4.8 mmol, 1eq), was 
dissolved in 15 ml of THF, and cooled to −70˚C. 
Diisopropylethyl amine (1.5 ml, 9.6 mmol, 3 eq) 
and 2-cyanoethyl diisopropylphosphoramidite (7 
ml of a 1M solution in ACN, 7 mmol, 1.5 eq) 
were added to the reaction mixture and stirred at 
room temperature for 1.5 h. The reaction mixture 
was concentrated to driness and the resulting oil 
was purified by column chromatography (SiO2, petroleoum ether: acetone 
80:20→70:30) The desired product resulted as a solid. Yield: 1.2 g, 47% 
Characterization of the product fully agreed with data from literature.  
1
H NMR (400 MHz, CDCl3): δ = 7.41-7.07 (m, 12H, Ar), 6.75-6.71 (m, 2H, Ar), 
3.76-3.64 (m, 7H), 3.56-3.44 (m, 2H), 2.49 (t, 2H, J = 6.7 Hz), 2.30-2.28 (m, 2H), 1.9 
(bs, 1H), 1.09 (t, 12H, J = 6.7 Hz) 
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N-[(methoxyphenyl)diphenylmethyl]-5-aminopentanol-O-Cyanoethyl-N,N-
diisopropylphosphoramidite (3) 
The same method as for 1 was employed. Yield: 1.0 g, 63%  
Characterization of the product fully agreed with data from literature.  
1
H NMR (400 MHz, CDCl3): δ = 7.73-7.70 (m, 4H, Ar), 7.59-7.56 (m, 2H, Ar), 7.30-
7.10 (6H, Ar), 6.87-6.84 (m, 2H, Ar), 3.80-3.59 (m, 4H), 3.51-3.37 (m, 5H), 2.34 (t, 
2H, J = 6.4 Hz), 1.85-1.79 (m, 2H), 1.66-1.41 (m, 7H), 1.26-1.22 (m, 12H) 
31
P NMR (101 MHz, CDCl3): δ = 147.8  
N-(2-propynyl)trifluoroacetamide (13)
17
 
Compound 13 was synthesized according to literature procedure resulting in a clear 
oil. Yield: 7.9 g, 57%  
Characterization of the product fully agreed with data from 
literature.  
1
H NMR(400 MHz, CDCl3): δ = 6.72 (bs, 1H), 4.15 (ddd, 2H, J 
= 2.60 Hz, J = 5.4 Hz, J = 0.5 Hz), 2.33(1H, J = 2.6 Hz) 
19
F NMR (376.3 MHz, CDCl3): δ = −76.45 
13
C NMR (75.4 MHz, CDCl3): δ = 157.1 (q, COCF3, J = 37.9 Hz), 115.5 (q, CF3, J = 
287.7 Hz), 73.0, 29.6  
5-[1-(N-trifluoroacetyl-3-amino-1-propynyl)]deoxyuridine (14)
12
 
This compound was prepared with a slightly modified 
procedure than those previously published. 
5-Iodo-2’-deoxyuridine (2.00 g, 5.65 mmol, 1 eq) and CuI 
(108.6 mg, 0.57 mmol, 0.1 eq) were suspended in 30 ml of 
anhydrous DMF. The mixture was stirred for 30 minutes 
protected from light. To this mixture triethylamine (1.60 
ml, 11.50 mmol, 2 eq), N-propynyltrifluoroacetamide (2.60 
g, 17.20 mmol, 3 eq) and 
tetrakis(triphenylphosphine)palladium(0) (330 mg, 0.28 mmol, 0.05 eq) were added 
in this order. The yellow clear solution was stirred for 18 h protected from light 
giving an orange solution. The solvents were then removed in vacuo and the residue 
was dissolved in 70 ml of THF. Solid potassium carbonate (approximately 4 g) was 
added and the suspension was stirred in an open flask for 2 hours. The salts were 
filteringed and the liquid was concentrated to dryness. The gummy residue was 
treated with 30 ml of methanol causing the precipitation of a yellow solid. This solid 
was filtered and discarded. The remaining liquid was concentrated to dryness and the 
methanol treatment was repeated until no solid precipitates (usually two or three 
times). The filtrate was concentrated in vacuum again and the residue was 
recrystallized from 30 ml of acetonitrile. After several hours in the freezer, the 
desired product was obtained as a yellow powder. Yield: 1.6 g, 58% 
Characterization of the product fully agreed with data from literature.  
1
H NMR (400 MHz, MeOD): δ = 8.22 (s, 1H), 6.13 (t, 1H, J = 6.6 Hz), 4.30-4.27 (m, 
1H), 4.17 (s, 2H), 3.85-3.82 (m, 1H), 3.66 (ddd, 2H, J = 3.0 Hz, J = 12.1 Hz, J = 16.1 
Hz), 2.24-2.04 (m, 2H)  
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13
C NMR (100.6 MHz, MeOD): δ = 163.8, 157.7 (q, COCF3, J = 37.3 Hz), 150.3, 
144.9, 116.6 (q, CF3, J = 286.7 Hz), 98.7, 88.3, 87.53, 86.2, 75.3, 71.1, 61.7, 40.9, 
29.9 
5-[1-(N-trifluoroacetyl-3-amino-1-propynyl)]-5’-O-dimethoxytrityldeoxyuridine 
(16)
12
 
Compound 14 (800 mg, 2.1 mmol, 1 eq), was 
azeotropically dried 3 times with 2 ml of toluene and 
then dissolved in 10 ml of pyridine. DMT-Cl (862 mg, 
2.54 mmol, 1.2 eq), dissolved in 10 ml of pyridine, was 
slowly added to the solution of compound 4. After 4h, 4 
ml of MeOH was added and the reaction mixture was 
concentrated to dryness. The resulting oil was purified 
by column chromatography (SiO2, MeOH:CH2Cl2, 
2:98→3:97). The desired product was obtained as a 
white powder. Yield: 1.3 g, 80%  
Characterization of the product fully agreed with data from literature.  
1
H NMR(400 MHz, CDCl3): δ = 8.23 (s, 1H), 7.43-7.40(m, 2H, Ar), 7.33-7.20 (m, 
7H, Ar), 6.94 (bs, 1H, NH), 6.86-6.82 (m, 4H, Ar), 6.36-6.33 (m, 1H), 4.61-4.58 (m, 
1H), 4.13-4.10 (m, 1H), 3.98-3.86 (m, 2H), 3.78 (s, 6H), 3.42-3.32 (m, 2H), 2.56-2.50 
(m, 1H), 2.36-2.29 (m, 1H) 
 
13
C NMR (100.6 MHz, CDCl3): δ = 161.6, 157.6 (Ar), 157.7 (Ar), 155.5 (q, COCF3, J 
= 37.6 Hz ) 148.7, 143.5 (Ar), 142.5, 134.4 (Ar), 129.0 (Ar), 128.9 (Ar), 127.0 (Ar), 
126.8 (Ar), 126.0 (Ar), 114.5 (q, CF3, J = 289.4 Hz), 112.3 (Ar), 98.0, 86.4, 86.1, 
86.0, 84.0, 74.2, 71.4, 62.5, 54.2, 40.6, 29.4  
5-[1-(N-trifluoroacetyl-3-amino-1-propynyl)]-3’-O-cyanoethyl-N,N-
diisopropylphosphoramidite-5’-O-dimethoxytrityldeoxyuridine (17)12 
Compound 16 (1.1 g, 1.6 mmol, 1eq) was 
azeotropically dried 3 times with 2 ml of 
toluene. It was dissolved in 20 ml of CH2Cl2 
and cooled to 0 ˚C. Diisopropylethylamine 
(0.68 ml, 4.8 mmol, 3 eq) was added 
followed by slow addition of 2-cyanoethyl 
diisopropylphosphoramidite (2.8 ml of a 1 
M solution in acetonitrile, 1.3 eq). After 3 h 
the reaction mixture was diluted with 100 ml 
of ethyl acetate and washed with 100 ml of 
5% aqueous NaHCO3. The organic layer 
was dried over Na2SO4 and concentrated under vacuum at 35 ˚C. The resulting yellow 
oil was purified by column chromatography (SiO2, DCM:MeOH:TEA, 96:3:1). The 
desired product resulted in a transparent solid, containing 40% of hydrolyzed 2-
cyanoethyl diisopropylphosphoramidite was present with the product. Yield: 880 mg, 
63%  
Characterization of the product fully agreed with data from literature.  
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1
H NMR(400 MHz, CDCl3): δ = 8.17, 8.13 (2s, 1H), 7.39-7.36 (m ,2H), 7.28-7.13 
(m, 7H), 6.80-7.76 (m, 4H), 6.29-6.24 (m, 1H), 4.59-5.53 (m, 1H), 4.14-4.08 (m, 1H), 
3.86-3.32 (m, 13H), 3.27-3.22 (m, 1H), 2.56-2.46 (m, 2H), 2.35 (t, 1H, J = 6.3 Hz), 
2.31-2.24 (m, 1H), 1.22-1.19 (m, 12H) 
31
P NMR (162 Hz, CDCl3): δ = 148.9, 148.6 
 
5-[1-(N-trifluoroacetyl-3-aminopropyl)]deoxyuridine 
(19) 
The mononucleoside 14 (2.0 g, 5.3 mmol) and 10% Pd/C 
(564 mg, 0.53 mmol of Pd) were suspended in 30 ml of 
dry methanol and hydrogenated under 10 bar of H2 for 26 
hours. The resulting suspension was filtered through a 
pad of celite and concentrated in vacuo. The crude was 
purified via a short column (SiO2, EtOAc:MeOH, 90:10) 
to yield, after removal of the solvent, the title product as a 
pale yellow solid. Yield: 1.78 g, 90% 
Characterization of the product fully agreed with data from literature. 
1
H NMR (400 MHz, DMSO-d6): δ = 11.28 (bs, NH), 9.40 (bs, NH), 7.67 (s, 1H), 6.15 
(t, 1H, J = 6.9 Hz), 5.24 (bs, OH), 5.02 (bs, OH) 4.24-4.21 (m, 1H), 3.76-3.74 (m, 
1H), 3.60-3.50 (m, 2H), 3.16 (t, J = 6.8 Hz), 2.25-2.02 (m, 4H), 1.67-1.60 (m, 2H) 
13
C NMR (100.6 MHz, MeOD): δ = 165.7, 158.7 (q, COCF3, J = 39.7 Hz) 151.4, 
137.93, 116.0 (q, CF3, J = 285.57 Hz), 113.9, 86.5, 85.1, 70.3, 60.9, 38.7, 38.6, 26.2, 
23.6  
5-[1-(N-trifluoroacetyl-3-
aminopropyl)]-5’-O-
dimethoxytrityldeoxyuridine (20)
12
 
The mononucleoside 16 (2.0 g, 2.94 
mmol) and 10% Pd/C (313 mg, 0.294 
mmol of Pd) were suspended in 30 ml 
of dry methanol and hydrogenated 
under 10 bar of H2 for 24 hours. The 
resulting suspension was filtered 
through a pad of celite and concentrated in vacuo. The crude product was purified via 
a short column (SiO2, CH2Cl2:MeOH:NEt3, 89:10:1) to yield, after removal of the 
solvent, the title product as a pale yellow solid. Yield: 1.91 g, 95% 
Characterization of the product fully agreed with data from literature.  
1
H NMR (300 MHz, CDCl3): δ = 7.67 (s, 1H), 7.56 (bt, 1H), 7.38-7.35 (m, 2H, Ar), 
7.32-7.23 (m, 7H, Ar), 6.84-6.81 (m, 4H, Ar), 6.49-6.44 (m, 1H), 4.63-4.59 (m, 1H), 
4.11-4.08 (m, 1H), 3.78 (s, 6H), 3.37 (ddd, 2H, J = 3.0 Hz, 10.8 Hz, J = 38.8 Hz), 
3.12-2.98 (m, 2H), 2.48-2.41 (m, 1H), 2.38-2.29 (m, 1H) 1.87-1.79 (m, 1H), 1.69-
1.59 (m, 1H) 1.38-1.29 (m, 2H) 
13
C NMR (75.4 MHz, CDCl3): δ = 165.1, 159.2 (Ar), 157.6 (q), 150.9, 144.5 (Ar), 
137.9, 135.6 (Ar), 130.6 (Ar), 130.6 (Ar), 128.7 (Ar), 128.4 (Ar), 127.7 (Ar), 116.5 
(q), 114.3, 113.7 (Ar), 87.3, 86.9, 85.3, 72.8, 63.9, 55.7, 41.5, 38.8, 28.6, 23.5  
19
F NMR (282 MHz, CDCl3): δ = −77.78 
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5-[1-(N-trifluoroacetyl-3-aminopropyl)]-3’-O-cyanoethyl-N,N-
diisopropylphosphoramidite-5’-O-dimethoxytrityldeoxyuridine (21)12 
Compound 20 (900 mg, 1.32 mmol, 1 eq) 
was azeotropically dried once with 
acetonitrile and 3 times with toluene. It was 
dissolved in 20 ml of DCM and 
diisopropylethylamine (0.9 ml, 5.3 mmol, 4 
eq) was added. After cooling to 0 ˚C 2-
cyanoethyl diisopropylphosphoramidite (2.6 
ml of a 1 M solution in acetonitrile, 2 eq) 
was added dropwise. After this addition the 
reaction was slowly warmed to room 
temperature and stirred for 3 h. The reaction 
mixture was then diluted with 100 ml of ethyl acetate and washed with 50 ml of 5% 
NaHCO3 and 50 ml of brine. The organic layer was dried over Na2SO4 and 
concentrated in vacuo at 35 ˚C. The resulting yellow oil was purified by silica column 
chromatography using DCM:EtOAc:TEA 60:39:1 mixture. Yield: 600 mg, 67%  
Characterization of the product fully agreed with data from literature.  
1
H NMR: (400 HMz, CDCl3): δ = 7.62, 7.58 (2s, 1H), 7.31-7.17 (m, 9H), 6.79-6.75 
(m, 4H), 6.38-6.33 (m, 1H), 4.64-4.60 (m, 1H), 4.12-4.05 (2m, 1H), 3.80-3.45 (m, 
12H), 3.25 (dt, 1H, J = 10.1 Hz, 2.5 Hz), 3.06-2.89 (m, 2H), 2.56 (t, 1H, J = 6.0 Hz), 
2.53-2.41 (m, 1H), 2.34 (t, 1H, J = 6.0 Hz), 2.33-2.56 (m, 1H), 1.83-1.76 (m, 1H), 
1.65-1.56 (m, 1H), 1.26-1.20 (m, 2H), 1.11-1.08 (m, 10H), 0.97 (d, 2H, J = 6.6 Hz) 
13
C NMR (100.6 MHz, CDCl3): δ = 162.6, 156.9, 155.2, 148.3, 148.2, 142.2, 135.6, 
135.5, 133.3, 128.4, 126.5, 126.4, 126.1, 125.5, 125.4, 115.8, 115.5, 115.5, 112.6, 
112.1, 113.0, 111.1, 85.0, 83.9, 83.5, 82.9, 82.7, 71.8, 71.7, 71.5, 71.4, 61.0, 61.0, 
56.4, 56.3, 56.2, 56.1, 53.4, 41.5, 41.4, 41.4, 41.3, 38.2, 38.1, 36.4, 26.4, 22.7, 21.0, 
18.5, 18.3  
31
P NMR (161.9 MHz, CDCl3): δ = 140.9, 148.7 
19
F NMR (376.3 MHz, CDCl3): δ = −76.50 
5’-O-dimethoxytrityl-deoxythymidine (22)18 
Compound 22 was synthesized according to literature 
procedure. The desired product was isolated as a slightly 
yellow powder. Yield: 13.8 g, 85% 
Characterization of the product fully agreed with data 
from literature.  
1
H NMR (400 MHz, CDCl3): δ = 7.53 (s,1H), 7.33-7.31 
(m, 2H, Ar), 7.23-7.13 (m, 7H, Ar), 6.72 (d, 4H, Ar, J = 
8.9 Hz), 6.36 (t, 1H, J = 6.9 Hz), 4.53-4.50 (m, 1H), 4.02-
4.00 (m, 1H), 3.65 (s, 6H), 3.36-3.24 (ddd, 2H, J = 3.1 
Hz, J = 10.5 Hz, J = 20.8 Hz), 2.38-2.34 (m, 1H), 2.23-2.20 (m, 1H), 1.33 (s, 3H) 
13
C NMR (100.6 MHz, CDCl3): δ = 163.3, 157.6, 149.8, 143.4, 134.9, 134.4, 134.4, 
129.1, 127.1, 126.9, 126.0, 112.2, 110.2, 85.8, 85.4, 83.8, 71.4, 62.7, 54.2, 44.7, 39.9, 
10.8 
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3’-O-Adamantaneacetyl-5’-O-dimethoxytrityl-
deoxythymidine (23)
18
 
Compound 23 was synthesized according to literature 
procedure.  The desired compound was obtained as white 
foam. Yield: 12.8 g, 88% 
1
H NMR (400 MHz, CDCl3): δ = 9.47 (bs, 1H), 7.53 (s, 
1H), 7.33-7.31 (m, 2H), 7.23-7.13 (m, 7H), 6.75 (d, 4H, J 
= 8.7 Hz), 6.37 (t, 1H, J = 7.1 Hz), 5.38-5.37 (m, 1H), 
4.06-4.04 (m, 1H), 3.70 (s, 6H), 3.40 (m, 1H), 2.40-2.34 
(m, 2H), 2.01 (bs, 2H), 1.88 (bs, 3H), 1.63-1.52 (m, 12H), 
1.30 (s, 3H)  
13
C NMR (100.6 MHz, CDCl3): δ = 170.2, 162.9, 157.7, 149.7, 143.2, 134.8, 134.7, 
134.2, 129.1, 129.1, 127.1, 127.0, 126.2, 112.3 , 110.6, 86.1, 83.4, 83.2, 73.7, 62.7, 
54.2, 47.6, 41.4, 37.0, 35.6, 32.0, 27.5, 10.6  
3’-O-Adamantaneacetyl-5’-O-dimethoxytrityl-N-
pivaloyloxymethyl-deoxythymidine (24)
18
  
Compound 24 was synthesized according to 
literature procedure. The desired compound was 
obtained as a white foam. Yield: 12.0 g, 81%  
Characterization of the product fully agreed with 
data from literature.  
1
H NMR (400 MHz, CDCl3): δ = 7.56 (s, 1H), 7.33-
7.30 (m, 2H), 7.22-7.19 (m, 6H), 7.16-7.12 (m,1H), 
7.76-6.74 (d, 4H, J = 8.9 Hz), 6.38 (t, 1H, J = 7.1 
Hz), 5.89-5.84 (m, 2H), 5.40-5.37 (m, 1H), 4.07-4.05 (m, 1H), 3.68 (s, 6H), 3.40 (m, 
2H), 2.40-2.37 (m, 2H), 1.99 (s, 2H), 1.87 (bs, 3H), 1.62-1.50 (m, 12H), 1.33 (s, 3H), 
1.10(s, 9H)  
13
C NMR (100.6 MHz, CDCl3): δ = 175.7, 165.4, 160.7, 157.0, 148.6, 142.5, 133.5, 
133.4, 132.7, 128.3, 126.4, 125.4, 111.5, 108.9, 85.4, 83.3, 72.8, 63.4, 61.8, 53.4, 
46.8, 40.7, 37.0, 36.3, 34.9, 31.2, 26.7, 25.3, 10.5 
3’-O-Adamantaneacetyl-N-pivaloyloxymethyl-
deoxythymidine (25)
18
 
Compound 25 was synthesized according to literature 
procedure. The desired compound is a white foam. Yield: 
2.0 g, 69%  
Characterization of the product fully agreed with data 
from literature.  
1
H NMR (400 MHz, CDCl3): δ = 7.61 (s, 1H), 6.25 (t, 1H, 
J = 7.3 Hz), 5.91-5.85 (m, 2H), 5.30-5.26 (m, 1H), 4.05-
4.03 (m, 1H), 3.87 (m, 2H), 2.35-2.31 (m, 2H), 2.03 (s, 
2H), 1.90 (bs, 3H), 1.66-1.53 (m, 12H), 1.11 (s, 9H) 
13
C NMR (100.6 MHz, CDCl3): δ = 177.7, 171.6, 162.6, 150.4, 135.3, 110.5, 86.2, 
85.3, 74.2, 65.1, 62.5, 48.6, 42.4, 38.8, 37.5, 36.6, 33.0, 28.5, 27.0, 13.2  
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General procedure for one synthesis cycle toward trimer (29) synthesis
18
  
Compound 25 (266 mg, 0.5 mmol, 1 eq) and compound 21 (663 mg, 0.75 mmol, 1.5 
eq) were coevaporated with acetonitrile three times and dissolved in 3.3 ml of 
acetonitrile. DCI (266 mg, 2.25 mmol, 4.5 eq) was added and the reaction mixture 
was stirred for 1 h. 200 μl of water was added and the reaction mixture was stirred for 
2 minutes, 7.2 ml of 0.2 M I2 in THF:pyridine 4:1 was added and the reaction mixture 
was stirred for 5 minutes. The reaction mixture was diluted with 25 ml of ethyl 
acetate and 5 ml of THF and washed with a saturated solution of Na2S2O3 (20 ml), 
10% aqueous KHSO4 (2 x 20 ml), 10% aqueous NaHCO3 (20 ml), and 1:1 
brine:water (20 ml). The organic layer was dried over MgSO4, filtered and 
concentrated to dryness.  
The protected nucleoside was dissolved in 14 ml of 0.1 M HCl solution made from 
AcCl in MeCN:MeOH 1:6. After 30 min, 6 ml of 0.23 M TEAA was added and the 
reaction changed colour from red to clear. It was diluted with 10 ml of acetonitrile 
and washed with heptane:diethylether 2:1 (4 x 30 ml). Ethyl acetate:THF, 5:2 was 
added to the water layer and it was washed with water (2 x 20 ml), a saturated 
solution of NaHCO3 (2 x 20 ml), brine:water 1:1 (20 ml). The final organic layer was 
dried over MgSO4, filtered and concentrated to dryness. 
General procedure for deprotection and purification of trimer 
Oligonucleotides were deprotected in a solution of 40% methylamine in ammonia for 
3 days at 55 ˚C. The reaction mixture was concentrated to dryness at 60 ˚C, dissolved 
in 6 ml of water and centrifuged. The supernatant was purified using an ion exchange 
sepharose column with buffer A: 20 mM TEAA, buffer B: 2 M TEAA. 
N,N-Bis(2-(diphenylphosphino)ethyl)ammonium chloride (30)
29
 
Compound 30 was synthesized according to literature 
procedure. The desired product resulted as white crystals. 
Yield: 27.0 g, 67% 
Characterization of the product fully agreed with data from 
literature.  
1
H NMR: (400 HMz, CDCl3): δ = 7.40-7.37 (m, 8H), 7.32-7.30 
(m, 12H), 2.95-2.94 (m, 4H), 2.58-2.53 (m, 4H) 
13
C NMR (100.6 MHz, CDCl3): δ = 136.1 (d, JCP = 12.1 Hz), 
132.7 (d, JCP = 19.1 Hz), 129.2, 128.8 (d, JCP = 6.6 Hz), 44.2 (d, JCP = 24.1 Hz), 23.8 
(d, JCP = 16.3 Hz)  
31
P NMR (161.9 MHz, CDCl3): δ = −21.0 
Methyl-4-(N,N-bis(2-(diphenylphosphino)ethyl)amino)-4-oxobutanoate (31)
29
 
Compound 31 was synthesized according to literature 
procedure resulting in a slight yellow solid. Yield: 1.8 
g, 72% 
Characterization of the product fully agreed with data 
from literature.  
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1
H NMR (400 MHz, CDCl3): δ = 7.34-7.22 (m, 20H, Ar), 3.60 (s, 3H), 3.36-3.30 
(m, 2H), 3.22-3.16 (m, 2H, CH2), 2.47 (t, J = 6.6 Hz, 2H), 2.23-2.14 (m,6H)  
31
P NMR (162 MHz, CDCl3): δ = −20.9, −22.1 
4-(N,N-bis(2-(diphenylphosphino)ethyl)amino)-4-oxobutanoic acid (32)
29
 
Compound 32 was prepared according to literature 
procedure resulting in a white powder. Yield: 1.0 g, 
70% 
Characterization of the product fully agreed with data 
from literature.  
1
H NMR (300 MHz, CDCl3): δ = 7.24-7.14 (m, 20H), 
3.21-3.19 (m, 2H), 3.0 (m, 2H), 2.23-1.98 (m, 8H) 
13
C NMR (100.6 MHz, CDCl3): δ = 178.4, 171.9, 136.9 
(d, JCP = 13.0 Hz), 136.2 (d, JCP = 12.4 Hz), 131.6 (d, JCP = 19.0 Hz), 128.0, 127.7, 
127.6, 127.5, 127.4 (d, JCP = 6.6 Hz), 44.2 (d, JCP = 26.2 Hz), 43.6 (d, JCP = 24.0 Hz), 
30.9, 28.1, 26.4 (d, JCP = 15.5 Hz), 25.1 (d, JCP = 14.7 Hz)  
31
P NMR (121.47 MHz, CDCl3): δ = −20.4, −21.6 
5-(3-amino-1-propynyl)-2’-deoxyuridine (15)11 
The protected base 14 (100 mg, 0.27 mmol) was dissolved in 
10 ml of concentrated ammonia and stirred for 12 h. 
Removal of the liquid furnished the desired deprotected base 
15 in quantitative yield as a yellowish oil. This product was 
used without any purification for the couplings with the 
phosphinocarboxylic acids. However 
19
F NMR spectroscopy 
showed the presence of the trifluoroacetate anion at –75 ppm. 
This impurity was removed by column chromatography 
(SiO2, CH2Cl2/MeOH, 70:30), to quantitatively yield the pure product as a yellow 
solid. 
Characterization of the product fully agreed with data from literature. 
1
H NMR(400 MHz, MeOD): δ 7.88 (s, 1H, H-6), 5.90 (t, 1H, J = 6.4 Hz, H-1’), 4.13-
4.09 (m, 1H, H-3’), 3.74-3.71 (m, 1H, H-4’), 3.68 (s, 2H, H-c), 3.54-3.41 (m, 2H, H-
5’), 2.15-2.09 (m, 1H, H-2’), 2.05-1.98 (m, 1H, H-2’) 
X-ray diffraction Crystals suitable for X-ray diffraction were grown from evaporation 
of dichloromethane/methanol solution at room temperature. 
5-(3-aminopropyl)-2’-deoxyuridine (33)11 
The protected base 19 (114.6 mg, 0.3 mmol) was dissolved in 6 
ml of concentrated ammonia and stirred for 12 hours. Removal 
of the liquid furnished the desired deprotected base 33 in 
quantitative yield as a yellowish oil. This product was used 
without any purification for the couplings with the 
phosphinocarboxylic acids.  
Characterization of the product fully agreed with data from 
literature.  
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1
H NMR (300 MHz, D2O): δ = 7.57 (s, 1H, H-6), 6.12 (dd, 1H, J = 6.8, H-1’), 4.33-
4.29 (m, 1H, H-3’), 3.89-3.86 (m, 1H, H-4’), 3.71-3.67 (m, 1H, H5’), 3.63- 3.59 (m, 
1H, H-5’), 2.87-2.83 (m, 2H, H-c), 2.28-2.18 (m, 4H, H-2’, H-a), 1.70 (tt, 2H, J = 7.8 
Hz, 7.5 Hz, H-b). 
(ortho) (34) 
o-Diphenylphosphinobenzoic acid (306 mg, 1.2 mmol, 
1.2 eq), EDC·HCl (230 mg, 1.2 mmol, 1.2 eq) and NHS 
(173 mg, 1.5 mmol, 1.5 eq) were dissolved in 20 ml of 
dry degassed DMF and stirred for 2 h. 
The nucleoside 15 (281 mg, 1.0 mmol, 1 eq) was 
dissolved in 10 ml of previously degassed 0.1 M 
NaHCO3 aqueous solution and the activated phosphine 
was added by syringe. A white precipitate formed but 
redissolved after a few minutes, giving a clear orange 
mixture, which was stirred for 12 h. Water (50 ml), CHCl3 (50 ml) and brine (10 ml) 
were added to the reaction mixture giving a biphasic system. The organic phase was 
separated and the aqueous layer extracted twice with CHCl3 (50 ml). The combined 
organic layers were washed with water (100 ml) and dried over Na2SO4. After 
filtration, the solvent was removed under vacuum (heating to 60 ºC was necessary to 
remove the last traces of DMF) giving a gummy white residue. This crude was 
purified by column chromatography (SiO2, CHCl3:MeOH, 90:10) to give the title 
product as a white foam after solvent removal. Yield: 171 mg, 30% 
IR (KBr), 

 (cm-1): 3411, 3054, 1700 ν(C=O), 1653 ν(C=O), 1584, 1465, 1434, 1282, 
1093, 747, 697 
1
H NMR (500 MHz, CD3OD): δ = 8.34 (s, 1H, H-6), 7.60 (ddd, 1H, J = 7.6 Hz, 3.6 
Hz, 1.0 Hz, Ar), 7.43 (td, 1H, J = 7.5 Hz, 1.1 Hz, Ar), 7.27-7.37 (m, 11 H, Ar), 
7.01(ddd, 1H, J = 7.6 Hz, 4.1 Hz, 0.7 Hz), 6.27 (t, 1H, H-1’, J = 6.6 Hz), 4.43-4.41 
(m, 1H, H-3’), 4.13 (s, 2H, H-c), 3.97 (dd, 1H, H-4’, J = 6.5 Hz, 3.2 Hz), 3.83 (dd, 
1H, H-5’, J = 12.0 Hz, 3.1 Hz), 3.75 (dd, 1H, H-5’, J = 12.0 Hz, 3.5 Hz), 2.36-2.31 
(m, 1H, H-2’), 2.26-2.21 (m, 1H, H-2’) 
13
C NMR (126 MHz, CD3OD): δ = 171.4 (e), 164.8 (4), 151.2 (2), 145.5 (6), 142.0 
(d, C, JCP = 24.5 Hz); 138.9 (d, JCP = 8.6 Hz), 138.8 (d, JCP = 13.6 Hz), 135.2-128.6 
(Ar), 100.0 (5), 89.8 (a); 89.2 (4’), 87.1 (1’), 75.6 (b), 72.1 (3’), 62.7 (5’), 41.8 (2’), 
31.0 (c) 
31
P NMR (162 MHz, CD3OD): δ = –9.5 
MS (ES+): 592.24 (M+Na
+
), HRMS calculated for C31H28N3NaO6P, 592.1613, found 
592.1615 
MP: Decomposes over 135 ºC 
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(meta) (35) 
The same method as for 34 was employed using 
m-diphenylphosphinobenzoic acid. Yield: 107 
mg, 63% 
IR (KBr), 

 (cm-1): 3423, 1686 (C=O), 1542, 
1459, 1434, 1283, 1093, 746, 696 
1
H NMR (400 MHz, CD3OD): δ = 8.31 (s, 1H, H-
6), 7.90 (s, 1H), 7.86 (dt, 1H, J = 8.1 Hz, 1.5 Hz), 
7.82 (dt, 1H, J = 7.7 Hz, 1.3 Hz), 7.45 (tdd, 1H, J 
= 7.7 Hz, 1.3 Hz, 0.6 Hz), 7.39-7.26 (m, 10 H), 
6.23 (t, 1H, H1’, J = 6.6 Hz), 4.39-4.37 (m, 1H, H3’), 4.31 (s, 2H, H-c), 3.93 (dd, 1H, 
H-4’, J = 6.6 Hz, 3.3 Hz), 3.80 (dd, 1H, H-5’, J = 12.0 Hz, 3.1 Hz), 3.72 (dd, 1H, H-
5’, J = 12.0 Hz, 3.5 Hz), 2.33-2.27 (m, 1H, H-2’), 2.24-2.219 (m, 1H, H-2’) 
13
C NMR (101 MHz, CD3OD): δ = 169.3 (C, e), 164.7 (4), 151.1 (2), 145.5 (6), 140.0 
(d, JCP = 13.5 Hz), 138.0 (d, JCP = 10.9 Hz), 137.7 (d, JCP = 15.5 Hz), 135.4 (d, JCP = 
7.5 Hz), 134.9-128.7 (Ar), 99.9 (5), 90.0 (a), 89.1 (4’), 87.0 (1’), 75.2 (b), 72.0 (3’), 
62.6 (5’), 41.7 (2’), 31.0 (c) 
31
P NMR (162 MHz, CD3OD): δ = –5.5 
MS (ES+): 592.03 (M+Na
+
), HRMS calculated for C31H28N3NaO6P, 592.1613, found 
592.1605 
MP: Decomposes over 140 ºC 
(para) (36) 
The same method as for 34 was employed using p-
diphenylphosphinobenzoic acid. 171 mg, 30% 
IR (KBr), 

 (cm-1): 3394; 3054; 2963; 1691 
(C=O), 1535, 1465, 1434, 1263, 1094, 802, 746, 
696 
1
H NMR (300 MHz, CD3OD): δ = 8.32 (s, 1H, H-
6), 7.81-7.78 (m, 2H), 7.39-7.26 (m, 12 H), 6.23 (t, 
1H, H-1’, J = 6.6 Hz), 4.40-4.35 (m, 3H, H-3’, Hc), 3.93 (dd, 1H, H-4’, J = 6.6 Hz, 
3.3 Hz), 3.80 (dd, 1H, H-5’, J = 12.0 Hz, 3.1 Hz), 3.72 (dd, 1H, H-5’, J = 12.0 Hz, 3.5 
Hz), 2.34-2.20 (m, 2H, H-2’) 
13
C NMR (75 MHz, CD3OD): δ = 169.3 (e), 164.7 (4), 151.1 (2), 145.5 (6), 144.0 (d, 
JCP = 8.9 Hz), 137.8 (d, JCP = 6.0 Hz), 135.2-128.3 (Ar), 99.9 (5), 90.0 (a), 89.2 (4’), 
87.0 (1’), 75.2 (b); 72.0 (3’), 62.6 (5’), 41.7 (2’), 31.0 (c) 
31
P NMR (121 MHz, CD3OD): δ = –5.5 
MS (ES+): 592.02 (M+Na
+
), HRMS calculated for C31H28N3NaO6P, 592.1613, found 
592.1617 
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(ortho) (37) 
The same method as for 34 was employed starting 
from 0.3 mmol (85.84 mg) of mononucleoside 33. 
Yield: 80 mg, 46% 
IR (KBr), 

 (cm-1): 3403, 3053, 2930, 1671 ν(C=O), 
1475, 1434, 1275, 1055, 746, 698 
1
H NMR (300 MHz, CD3OD): δ = 7.85 (s, 1H, H-
6), 7.52 (ddd, 1H, J = 7.6 Hz, 3.6 Hz, 1.3 Hz), 7.42 
(dt, 1H, J = 7.8 Hz, 13 Hz), 7.36-7.23 (m, 11 H), 
6.96 (ddd, 1H, J = 4.1 Hz, 3.6 Hz, 0.9 Hz), 6.27 (t, 
1H, H-1’, J = 6.8 Hz), 4.41-4.36 (m, 1H, H-3’), 3.90 (dd, 1H, H-4’, J = 6.9 Hz, 3.5 
Hz), 3.77 (dd, 1H, H-5’, J = 12.0 Hz, 3.1 Hz), 3.68 (dd, 1H, H-5’, J = 12.0 Hz, 3.8 
Hz), 3.18 (t, 2H, H-c, J = 6.7 Hz), 2.28-2.21 (m, 4H, H-2’, Ha), 1.63-1.55 (m, 2H, H-
b) 
13
C NMR (75 MHz, CD3OD): δ = 172.2 (e), 166.0 (4), 152.3 (2), 138.9 (6), 138.6-
128.4, 114.8 (5), 88.9 (4’), 86.4 (1’), 72.2 (3’), 62.9 (5’), 41.2 (2’), 39.7 (c), 28.9 (b), 
25.0 (a) 
31
P NMR (121 MHz, CD3OD): δ = –10.1 
MS (ES+): 572.19 (M–H), 573.20 (M), HRMS calculated for C31H31N3O6P, 
573.1950; found 572.1942 
X-ray diffraction Crystals suitable for X-ray diffraction were grown from evaporation 
of an acetonitrile solution at room temperature. 
(meta) (38) 
The same method as for 34 was employed 
starting from 0.3 mmol (85.84 mg) of 
mononucleoside 33. Yield: 142 mg, 82% 
IR (KBr), 

 (cm-1): 3421, 3054, 2926, 1675 
ν(C=O), 1539, 1465, 1434, 1275, 1093, 744, 
696 
1
H NMR (300 MHz, CD3OD): δ = 7.87 (s, 1H, 
H-6), 7.85-7.77 (m, 2H), 7. 44 (td, 1H, J = 7.6 
Hz, 0.7 Hz), 7.37-7.26 (m, 11 H), 6.27 (t, 1H, H-1’, J = 6.7 Hz), 4.41-4.37 (m, 1H, H-
3’), 3.90 (dd, 1H, H-4’, J = 6.7 Hz, 3.4 Hz), 3.78 (dd, 1H, H-5’, J = 12.1 Hz, 3.1 Hz), 
3.69 (dd, 1H, H-5’, J = 12.1 Hz, 3.7 Hz), 3.35 (t, 2H, H-c, J = 6.8 Hz), 2.37 (t, 2H, H-
a, J = 7.2 Hz), 2.25-2.21 (m, 2H, H-2’), 1.83-1.74 (m, 2H, H-b) 
13
C NMR (75 MHz, CD3OD): δ = 169.9 (e), 166.1 (4), 152.2 (2), 138.8 (6), 139.9-
128.6, 114.8 (5), 88.9 (4’), 86.4 (1’), 72.2 (3’), 62.8 (5’), 41.3 (2’), 49.1 (c), 29.2 (b), 
25.1 (a) 
31
P NMR (121 MHz, CD3OD): δ = –5.4 
MS (ES+): 596.11 (M+Na
+
), 612.11 (M+O+Na
+
), HRMS calculated for 
C31H32N3NaO6P, 596.1926; found 596.1908 
X-ray diffraction Crystals suitable for X-ray diffraction were grown by evaporation of 
an acetonitrile solution at room temperature 
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(para) (39) 
The same method as for 34 was employed 
using p-diphenylphosphinobenzoic acid. 
Yield: 103 mg, 60% 
IR (KBr), 

 (cm-1): 3423, 3054, 2927, 1686 
ν(C=O), 1475, 1434, 1276, 1093, 746, 697 
1
H NMR (300 MHz, CD3OD): δ = 7.89 (s, 1H, 
H-6), 7.79 (d, 1H, J = 1.4 Hz), 7.76 (d, 1H, J = 
1.4 Hz), 7.39-7.26 (m, 12 H), 6.27 (t, 1H, H-1’, J = 6.8 Hz), 4.42-4.38 (m, 1H, H-3’), 
3.90 (dd, 1H, H-4’, J = 6.7 Hz, 3.4 Hz), 3.80 (dd, 1H, H-5’, J = 12.1 Hz, 3.1 Hz), 3.71 
(dd, 1H, H-5’, J = 12.1 Hz, 3.7 Hz), 3.40 (t, 2H, H-c, J = 6.7 Hz), 2.39 (t, 2H, H-a, J = 
7.2 Hz), 2.25-2.22 (m, 2H, H-2’), 1.82 (quint, 1H, H-b, J = 6.9 Hz) 
13
C NMR (75 MHz, CD3OD): δ = 170.0 (e), 166.1 (4), 152.2 (2), 138.8 (6), 135.1-
128.2, 114.8 (5), 88.9 (4’), 86.3 (1’), 72.1 (3’), 62.8 (5’), 41.3 (2’), 40.0 (c), 29.2 (b), 
25.2 (a) 
31
P NMR (121 MHz, CD3OD): δ = –5.6 
MS (ES+): 596.02 (M+Na
+
), HRMS calculated for C31H32N3NaO6P, 596.1926; found 
596.1915 
(Whitesides) (40) 
 The same method as for 34 was employed 
using Whitesides. Yields 10-20% 
IR (KBr), 

 (cm-1): 3423, 3054, 2923; 1671 
(C=O); ν1475; 1434; 1276; 1096; 742; 698 
1
H NMR (500 MHz, CD3OD): δ = 7.85 (s, 
1H, H-6), 7.39-7.29 (m, 20 H), 6.25 (t, 1H, 
H-1’, J = 6.8 Hz), 4.39-4.37 (m, 1H, H-3’), 
3.89 (dd, 1H, H-4’, J = 6.3 Hz, 3.2 Hz), 3.79 
(dd, 1H, H-5’, J = 12.1 Hz, 3.0 Hz), 3.69 
(dd, 1H, H-5’, J = 12.1 Hz, 3.5 Hz) 3.39-3.31 (m, 4H, H-j, H-j’), 3.20-3.12 (t, 2H, H-
c), 2.37 (bs, 4H, H-f, H-g), 2.30 (m, 4H), 2.25 (t, 2H, H-k or k’ J = 7.8 Hz), 2.19-2.16 
(m, 2H, H-2’), 1.71-1.564 (m, 2H, H-b) 
13
C NMR (125 MHz, CD3OD): δ = 174.8 (e), 173.6 (h), 165.9 (4), 152.2 (2), 139.4 
(d, JCP = 12.6 Hz), 139.0 (d, JCP = 12.2 Hz), 138.8 (6), 133.9-133.6, 130.3-129.6, 
114.8 (5), 88.9 (4’), 86.4 (1’), 72.2 (3’), 62.9 (5’), 46.6 (d, j or j’, JCP = 24.7 Hz), 45.0 
(d, j or j’, JCP = 24.1 Hz), 41.4 (C-2’), 39.2 (c), 31.8 (f), 29.5 (g), 29.2 (b), 28.5 (d, k 
or k’, JCP = 14.6 Hz), 27.3 (d, j or j’, JCP = 13.8 Hz), 24.9 (a) 
31
P NMR (121 MHz, CD3OD): δ = –21.0; –21.7 
MS (ES+): 831.02 (M+Na
+
), 847.02 (M+O+Na
+
), HRMS calculated for 
C44H50N4NaO7P2, 831.3052; found 831.3040 
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General procedure for DNA phosphorylation
1
 
A DNA 15-mer (15 nmol) was dissolved in a 300 μl solution of 0.1 M aqueous 
NaHCO3. Diphenylphosphinobenzoic acid (2.3 mg, 7.5 μmol, 500 eq), EDC·HCl (1 
mg, 9 μmol, 600 eq), and NHS (1.4 mg, 7.5 μmol, 500 eq) were dissolved in 600 μl of 
DMF and stirred for 2 h. The activated phosphine was added to the DNA solution and 
stirred for 12 h. 600 μl of water was added to the reaction mixture and the reaction 
mixture was washed with dichloromethane (3 x 2 ml). The water layer was 
concentrated in vacuo and redissolved in 1 ml of water. 200 μl of this solution was 
placed in an eppendorf. 20 μl of a 3 M NaAc aqueous solution and 700 μl of cold 
EtOH were added to the DNA solution and placed at 0 ˚C for 1 h. It was centrifuged 
for 30 minutes at 4 ˚C at 13000 rpm. The supernatant was removed and a cold 70% 
aqueous EtOH solution was added and the sample was centrifuged for another 30 
minutes. 
General procedure for allylic alkylation of 1,3-diphenylallyl acetate with 
dimethyl malonate  
A mixture of [Pd(η3-C3H5)Cl]2 (0.5 μmol) and ligand (2 μmol) were dissolved in THF 
or DCM, and they were stirred for 30 minutes. A trace of KOAc, 1,3-diphenylallyl 
acetate (100 μmol), diphenyl ether (100 μmol), dimethyl malonate (300 μmol ) and 
BSA (300 μmol) were added to the metal complex solution in this order. The reaction 
mixture was stirred for 24 h. Each solution was filtered through SiO2 and left to 
evaporate overnight. A CHIRACEL OD-H chiral column (Daicel Chemical Industry 
Ltd.) was employed using a 99:1 (hexane:iPrOH) isochratic mixture with a flow of 1 
ml/min. tR (S) 23.6 min, tR (R) 24.3 min. 
General procedure for allylic amination of 1,3-diphenylallyl acetate with 
benzylamine 
A mixture of [Pd(η3-C3H5)Cl]2 (0.5 μmol) and ligand (2 μmol) were dissolved in THF 
or DCM, and they were stirred for 30 minutes. 1,3-diphenylallyl acetate (100 μmol), 
diphenyl ether (100 μmol) and benzylamine (300 μmol) were added to the metal 
complex solution in this order. The reaction mixture was stirred for 24 h. Each 
solution was filtered through SiO2 and left to evaporate overnight. A CHIRACEL 
OD-H chiral column (Daicel Chemical Industry Ltd.) was employed using a 99.5:0.5 
((hexane:iPrOH) isochratic mixture with a flow of 0.5 ml/min. tR (R) 28.4 min, tR (S) 
30.3 min. 
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Chapter 4: Modified PNA in Catalysis 
 
4.1 Introduction 
Peptide nucleic acids (PNA), a mimic of DNA, were first synthesized by Nielsen and 
coworkers in 1991.
1
 The PNA backbone is based on N-(2-aminoethyl)glycine units, 
which contain purine and pyrimidine bases, linked through amide bonds as in peptide 
chains (Figure 1).  
 
 
 
Figure 1. Example of a PNA DNA duplex.
2
 Reprinted from L. Bialy et al. Tetrahedron 2005, 61,  
8295-8305. Copyright 2005, with permission from Elsevier. 
 
PNA forms duplexes with single stranded DNA and triplexes with double stranded 
DNA. In both cases the interstrand interactions are stronger than in natural DNA-
DNA double strands. This is explained by the neutral backbone of PNA which 
replaces the anionic phosphate backbone of DNA, thereby avoiding electrostatic 
repulsion.
3
 DNA has been replaced by PNA in many occasions because of its 
increased stability and compatibility with organic synthesis. PNA has been used for 
biosensors such as microarrays,
4,5
 in diagnostic devices
6
 and as antisense 
oligonucleotides.
7
 
Transition metal complexes have been introduced in PNA for several reasons. The 
most common ligands used contain nitrogen atoms for metal coordination. 6-(2-
pyridyl)-4-pyrimidine (A), 5-(2-pyridyl)-1H-3-pyrazole (B) and bis(2-picolyl)-amine 
(C) complexes with Zn
II
, Cu
II
 and Ni
II
 have been studied as tools for suppression of 
 105 
gene expression.
8
 A hybrid between a metallosalen and a metallopeptide where the 
metal is Ni
(II)
 (D) has been used for selective modification of DNA with an aldehyde 
functionality that can be used for further functionalization such as labelling and 
binding to proteins.
9
 A ferrocene and a tris(bipyridine)ruthenium
II
 complex served as 
markers for binding between PNA and DNA for future use in genetic diagnostics.
10
 
Bipyridines have also replaced nucleic bases in specific locations of PNA for the 
introduction of Ni
II
, Co
II
, and Cu
II
 in the double helix
11
 (Figure 2). The majority of 
those ligands have been introduced on the PNA through amide bond formation at the 
terminal position of a PNA strand or as a replacement of a base.  
 
 
 
Figure 2. A selection of ligands coupled to PNA strands.
8-11
 
 
As previously explained in chapters 2 and 3, DNA’s high selectivity and specificity 
towards small molecules makes it a good candidate as a ligand for catalytic 
asymmetric reactions. Despite its appealing qualities DNA is only soluble in water 
and only minute quantities can be produced per synthesis. In contrast, PNA is soluble 
in organic solvents and can be synthesized at larger scale. Even though PNA is not a 
chiral molecule, the use of chiral amino acids
12
 or duplex formation with DNA 
strands
13,14
 can result in strand chirality.  
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Our objective is to synthesize a PNA strand containing a bidentate ligand which could 
be complexed to transition metals and used in asymmetric catalysis (Scheme 1). Two 
different strategies were employed; the first strategy is based on the introduction of 
phosphines on PNA strands. The backbone of PNA is resistant to the conditions of 
phosphine deprotection therefore a phosphine functionality can be protected and 
introduced directly on the PNA monomer prior to strand synthesis. This method 
facilitates the purification of the phosphine modified strand and guarantees complete 
coupling of the phosphine moiety to the PNA strand. As explained in chapter 3, 
phosphines are very sensitive towards oxidation. Therefore the second strategy 
presented in this chapter is exploiting the synthesis of a bipyridine monomer, which 
can also be introduced on the PNA during strand synthesis and it is not air sensitive. 
Bipyridine ligands are known to be compatible with DNA and have been used for 
Diels-Alder catalyzed reactions.
15
 Our aim is to build chiral ligands to use with 
transition metals as catalysts in asymmetric synthesis. Our method is to use these 
novel PNA-based ligands in combination with DNA and to test them in transition 
metal catalyzed asymmetric reactions (Scheme 1). This chapter details the synthesis 
of a diphosphine modified and bipyridine modified PNA monomer and the successful 
synthesis of a short modified PNA strand. 
 
L L
M
PNA  
synthesis
L L
Catalysis
Transition
Metal
GTACTTAMCAGTATA
CATGAATCMGTCATAT
L L
GTACTTAMCAGTATADNA
 
 
Scheme 1. Introduction of modified monomer into a PNA strand and its use in catalysis. 
 
4.2 Results and Discussion  
4.2.1 Synthesis of phosphine modified PNA monomer 
The Whitesides ligand described in chapter 3 (1) was used for the synthesis of the 
PNA monomer. This ligand was protected with sulfur to give (2) in 94% yield. 
Reaction with methyl-4-chloro-4-oxobutyrate and subsequent deprotection gave 
compound (4) in 71% yield. The PNA backbone is commercially available as the HCl 
salt and, therefore, coupling of this compound to the PNA backbone was preceded by 
preliminary neutralization by washing with a saturated solution of NaHCO3.
16
 This 
method afforded the desired product (5) in 47% yield. Partial deprotection of the 
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Fmoc group during basic washing accounts for the low yields. 
1
H NMR of the PNA 
backbone after washing with NaHCO3 showed partial cleavage of the Fmoc group. 
For this reason neutralization of HCl was attempted with the addition of TEA but this 
procedure was not successful and the previous method was used to synthesize the 
desired product. The 
1
H NMR of the desired compound was very complex. Mass 
spectroscopy analysis showed the desired product and the integrations in the 
1
H NMR 
spectra corresponded to the expected number of protons. High temperature 
31
P{
1
H} 
NMR studies were performed to test if the desired compound exists as different 
conformers. At high temperature the peaks become sharper and merged into one peak 
at 393 °K which suggests that the desired product is a conformer. Deprotection of the 
Boc group with trifluoroacetic acid gave the desired product after filtration without 
the need of any further purification (6) (79% yield) (Scheme 2). 
 
 
 
Scheme 2. Synthesis of phosphine modified PNA monomer. 
 
4.2.2 Synthesis of bipyridine modified PNA monomer 
A second monomer with a bipyridine ligand was also synthesized. 2,2-Bipyridine-5-
carboxylic acid 8 was prepared from trimethyl-(2-pyridyl)tin and methyl-6-
chloropyridine-3-carboxylate to give compound 7 in 64% yield. Deprotection under 
basic conditions gave the desired product 8 in 84% yield.
17
 Compound 8 was coupled 
to the Fmoc protected PNA backbone using the same procedure as for compound 6 
(84% yield) (Scheme 3). The 
1
H NMR spectrum of this compound after purification 
was very complex as in compound 5. High temperature 
1
H NMR studies were 
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performed to test if the compound exists as different conformers. As shown in the 
1
H 
NMR spectra taken from 313 to 393 K (Figure 3) the peaks become sharper and 
merge into one peak belonging to the desired product. This behaviour at high 
temperatures suggests that compound (9) indeed exists as different conformers. This 
behaviour has also been reported for a similar compound by Williams et al.
18
 
Deprotection with trifluoroacetic acid gave compound (10) in 77% yield.  
 
 
Scheme 3. Synthesis of bipyridine modified PNA monomer.
17
 
 
 
Figure 3. Overlap of six 300 MHz 
1
H NMR spectra taken at different temperatures. The 
spectra coloured in blue represents compound (9) taken at 313 K, the spectra above it were 
taken at an increase interval of temperature of 16 K. 
 
4.2.3 Synthesis of PNA strands 
Introduction of 10 into a PNA strand was attempted following the protocol of Bradley 
et al using PyBop (benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate) and NEM (N-ethylmorpholine).
19
 A linker was placed on a 
393 K 
313 K 
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polystyrene (PS) solid support. This linker contained an amine group protected by 
Fmoc which was deprotected by using 20% piperidine in DMF. PNA monomers are 
most commonly synthesized with Fmoc (9-Fluorenylmethyloxycarbonyl)/Bhoc 
(benzhydryloxycarbonyl)
20
 or Boc (tert-Butyloxycarbonyl)/Cbz (Carbobenzyloxy)
21
 
protecting groups. Monomers A, C, G and T are commercially available containing 
Fmoc as protecting group. Coupling and deblocking steps are repeated until the 
desired length is synthesized. Each step is analyzed using the Kaiser test.
22
 The Kaiser 
test can give an indication of the coupling success although at a certain strand length 
the test loses its validity.  
TFA/TIS(triisopropylsilane)/DCM is used to cleave the strand from the solid support 
(Scheme 4). Reverse phase HPLC is the common method of purification. 
 
 
Scheme 4. Synthesis of PNA strands on solid support.  
 
During the synthesis of the 15 mer, a small sample, after the introduction of the 8
th
 
monomer, was taken for HPLC analysis to monitor the process of the synthesis. This 
chromatrogram showed several peaks and MALDI-TOF analysis also showed several 
peaks; none of them corresponding to the desired product. Therefore, the synthesis 
was not further continued.  
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Scheme 5. Cyclization of deprotected PNA monomer.
23
 
 
As shown in Scheme 4 during PNA synthesis basic conditions were applied to 
deprotect the primary amine from the Fmoc group. It is possible that during this 
deprotection step a small percentage of product cyclizes. When terminal amines are 
not protected two undesirable side reactions can take place under basic conditions 
(Scheme 5). The free amine can attack the acetyl group of the heterocyclic base 
transferring it from the central secondary amine to the terminal primary amine.
24
 The 
other possible side reaction is the attack of the acetyl group of the PNA backbone by 
the primary terminal amine.
25,23
 Both side reactions result in termination of strand 
synthesis. 
Another point in the synthesis where this reaction can occur is during the coupling 
step because it is performed under basic conditions (NMM as base). Some of the 
couplings were left overnight therefore increasing the possibility of Fmoc 
deprotection by NMM. This can not only lead to cyclization but also to multiple 
coupling. The synthesis failure can be related to partial product cyclization preventing 
the continuation of the strand and multiple coupling therefore giving a various range 
of different strands as seen by HPLC analysis. 
The second strategy used was to synthesize phosphine modified compound (6) and 
introduce it into PNA. The synthesis of the PNA strands was performed with A, T, 
and C monomers containing Dde (1-(4,4-dimethyl-2,6-dioxacyclohexylidene)ethyl) 
protecting groups kindly provided by Professor Bradley’s group. The same group2 has 
developed the synthesis of PNA nucleosides with Dde/MMT protecting groups. This 
method was initially developed for the synthesis of PNA-peptide conjugates although 
it also gives a more robust protection to the terminal amine functionality than the 
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more common Fmoc method. The Dde protecting group is more resistant to basic 
conditions then Fmoc therefore it is less affected by the basic conditions used during 
the coupling step. A 5-mer, 9-mer and 15-mer were the target strands (Table 1). The 
5-mer was the only successful synthesis (Figure 4) because in the syntheses of the 9-
mer and 15-mers mixtures of shorter strands were obtained.  
 
Strand # Strands Synthesized Molecular 
Weight 
Mass Found 
S1 5’-TAMCA-3’ 1773 1793 
S2 5’-ACTTMAATC-3’ 2832 2603, 2336 
S3 5’-TCAACCAMCATCCTC-3’ 4360 3314, 
3049,2799 
 
Table 1. Molecular weight of PNA strands synthesized containing compound 6 (M) and their 
mass found by MALDI-TOF analysis. 
 
 
 
Figure 4. PNA 5-mer (TAMCA, M = compound 6) synthesized using Dde as the protecting  
group for the PNA monomers. 
 
Because PNA is a lipophilic compound, it can aggregate on the solid support during 
the synthesis, decreasing the coupling efficiency as the strand grows longer.
26
 The 
synthesis of Dde protected PNA monomers consists of several steps and therefore 
those monomers were not readily available to test the synthesis of bipyridine modified 
PNA.  
 
4.2.4 Phosphine deprotection  
Gilbertson et al have been introducing sulfur protected phosphine moieties into 
peptide chains for their use in catalytic reactions.
27
 The two methods used for 
phosphine deprotection have been Raney-Ni after purification of the peptide strands 
and MeOTf / HMPT on solid supported peptides. The 15-mer strand which resulted in 
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a shorter strand was tested for sulfur deprotection using Raney-Ni. MALDI-TOF 
analysis showed the same pattern of peaks for the strand before deprotection 
suggesting that the deprotection was not successful. The presence of modified 
phosphine monomer in the failed 15-mer strand was confirmed by calculating the 
possible combinations in the sequence of the monomers in the 15-mer. The molecular 
weights present in the MALDI-TOF can only correspond to shorter strands (9-mer, 
10-mer 11-mer) containing the phosphine moiety. Phosphine deprotection tests were 
made with sulfur protected Whitesides ligand as a model for PNA strands. Following 
the procedure of Gilbertson et al
28
 for the deprotection of phosphine modified 
peptides, Raney nickel was employed. The main advantage of using this deprotection 
method is that Raney nickel can be removed from the desired compound by filtration 
with no need of any further purification. The deprotection was attempted several 
times with different batches of Raney nickel but was unsuccessful. The HMPT 
method resulted in successful deprotection but gave rise to unidentified phosphorus 
impurities. A clean method of deprotection is necessary to avoid any further 
purification and possible oxidation of the phosphine ligand. The HMPT method was 
tested with compound (6) coupled on solid support and 
31
P{
1
H} NMR showed 
complete deprotection. The disadvantage of this method is that after phosphine 
deprotection with HMPT on solid support the PNA can not be purified because that 
would probably result in oxidation of the phosphine during HPLC purification.  
 
4.3 Conclusion 
In this chapter PNA monomers containing a diphosphine sulfide and a 2,2’-bipyridine 
moiety were synthesized. The phosphine modified monomer was successfully 
introduced into a 5-mer but the sulfide deprotection was troublesome. Synthesis 
failure of PNA strands could be prevented by using Dde instead of Fmoc protecting 
group. Also, the synthesis of shorter strands would give higher yields and reduce the 
risk of cyclization. Two short strands with terminal monodentates could be combined 
with a DNA complementary strand to receive chirality and place the ligands in the 
central position of a helix. 
 
 
 
 
 
 113 
4.4 Experimental 
General procedure 
All reactions were performed under argon using standard Schlenk techniques. 
Chemicals were purchased from Aldrich Chemical Company, Acros, Fluka, Link 
Technologies and Glen Research. CH2Cl2 and acetonitrile were distilled over CaH2; 
ethanol and methanol were distilled over Mg/I2; toluene was distilled over Na, THF 
and Et2O were distilled over sodium /benzophenone and all the distillations were 
performed under nitrogen atmosphere. DMF was purchased “Extra dry” and stored 
over molecular sieves (4 Å) under argon. Aqueous solutions were degassed by three 
freeze/thaw cycles under vacuum and kept under argon. Thin Layer Chromatography 
(TLC) was performed on silica plates (Polygram 0.2 mm silica gel with fluorescent 
indicator UV254). Ninhydrin spray was used for the detection of primary and 
secondary amines on TLC silica plates. Silica gel 60 particle size 0.063-0.2 mm from 
Fluka was used for flash chromatography. NMR spectra were recorded at room 
temperature with Bruker Avance spectrometers (300, 400, and 500 MHz). Positive 
chemical shifts () are given (in ppm) for high-frequency shifts relative to a TMS 
reference (
1
H and 
13
C) or an 85% H3PO4 reference (
31
P). 
13
C, 
31
P, and 
19
F spectra were 
measured with 
1
H decoupling. The following abbreviations have been used in the 
description of the spectra: s, singlet; d, doublet; t, triplet; m, multiplet. IR spectra were 
recorded in a Perkin-Elmer Spectrum GX spectrometer in KBr pellets, with a window 
between 4000 and 400 cm
–1
. Mass spectrometry: electrospray mass spectra were 
recorded on waters, micromass LCT time of flight mass spectrometer coupled to a 
Waters 2975 HPLC. MALDI spectra were acquired on a Voyager-De™ STR 
MALDI-TOF MS(Applied Biosystems). The matrix was sinapinic acid (10 mg/ mL) 
in 50 % MeCN in water with 0.1 % TFA. HPLC used for the purification of PNA was 
an HPLC/Prep Agilent 1100 series. The column used was a Phenomenex Prodigy 5 μ 
ODS (3) 100 A size 250 x 10 mm. The eluents used were ACN with 0.1 % TFA and 
H2O with 0.1 % TFA. 
Bis(2-(diphenylphosphorothioyl)ethyl)amine (2) 
Compound 1 (1 g, 2.1 mmol, 1 eq) was added to a solution of 
sulfur (0.80 g, 2.5 mmol, 1.2 eq) in 20 ml of dichloromethane. 
After a few minutes a white precipitate was formed which was 
filtered and recrystallized with dichloromethane. Yield: 900 
mg, 90%  
1
H NMR (400 MHz, CDCl3):
 δ = 10.20 (bs, 2H), 7.79-7.73 (m, 
8H), 7.46-7.36 (m, 12H), 3.18 (m, 4H), 3.08 (m, 4H)  
31
P NMR: 38.7 (s, 2P)  
13
C NMR (100.6 MHz, DMSO-d6): δ = 132.3, 131.1, 131.04, 131.0, 130.2, 129.2, 
129.0, 42.9, 28.7, 28.2 
MS (ES+): 505.78 (M+Na
+
), HRMS calculated for C28H30NNaP2S2, 506.1295 found 
506.1299 
Elemental analysis calculated for C28H30ClNP2S2: C 62.04, H 5.58, N 2.58: 
Found: C 62.12, H 5.43, N 2.46  
IR: 3437, 2910, 2702, 2436, 1587, 1436, 1104 
mp: 232-234 ˚C 
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Methyl 4-(bis(2-(diphenylphosphorothioyl)ethyl)amino)-4-oxobutanoate (3)
29
 
This compound was prepared using the same method as 
for compound 26 of chapter 3. Yield: 1.0, 84% 
1
H NMR (300 MHz, CDCl3): δ = 7.87-7.72 (m, 8H, Ar), 
7.50-7.34 (m, 12H, Ar), 3.64 (s, 3H, CH3), 3.62-6.56 
(m, 2H), 3.49-3.42 (m, 2H), 2.78-2.66 (m, 4H), 2.53-
2.49 (m, 2H), 2.38-2.34 (m, 2H)  
13
C NMR (75.5 MHz, CDCl3): δ = 173.4, 171.8, 132.9, 
132.3, 131.9, 131.7, 131.1, 131.0, 130.8, 129.0, 128.9, 128.8, 128.6, 51.8, 43.3, 41.5, 
32.2, 31.5, 31.0, 30.3, 28.8, 28.0 
P NMR (121.5 MHz, CDCl3): δ = 40.3, 38.4 
MS (ES+): 641.73 (M+Na
+
), HRMS calculated for C33H35NNaO3P2S2, 642.1431 
found 642.1429 
Elemental analysis calculated for C33H35NO3P2S2: C 63.96, H 5.69, N 2.26: 
Found: C 63.89, H 5.79, N 2.15  
IR: 3447, 3057, 2943, 1735, 1646, 1480, 1437, 1366, 1161, 1104 
mp: 133-135 ˚C 
4-(bis(2-(diphenylphosphorothioyl)ethyl)amino)-4-
oxobutanoic acid (4)
29
 
This compound was synthesized using the same method 
as for compound 27 of chapter 3 Yield: 1.65 g, 88% 
1
H NMR (300 MHz, CDCl3): δ = 7.90-7.78 (m, 8H), 
7.55-7.40 (m, 12H), 3.67 (m, 2H), 3.52 (m, 2H), 2.80 (m, 
4H), 2.58 (m, 2H), 2.43 (m, 2H) 
13
C NMR (100.6 MHz, CDCl3): δ = 179.2, 173.8, 132.7, 
132.2, 131.9, 131.8, 131.6, 131.4, 131.1, 131.0, 130.9, 129.0, 128.8, 128.7, 128.6, 
43.0, 32.3, 31.7, 31.2, 30.5, 29.9, 29.6 
31
P NMR (121.4 MHz, CDCl3):δ = 40.0, 38.3  
MS (ES+): 627.76 (M+Na
+
), HRMS calculated for C32H33NNaO3P2S2, 628.1275 
found 628.1274 
IR: 3431, 3047, 2928, 2364, 1701, 1644, 1437, 1169, 1104 
mp: 189-190 ˚C 
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N-[2-(Fmoc-amino)-ethyl]-gly-O-tert-Butyl-N-(bis(2-
(diphenylphosphorothioyl)ethyl)amino)-4-yl (5) 
N-[2-(Fmoc-amino)-ethyl]-gly-O-tBu·HCl (0.6 g, 
1.4 mmol, 1 eq) was dissolved in 40 ml of 
chloroform and washed with a saturated solution 
of NaHCO3 (2 x 20 ml). The organic layer was 
dried over Na2SO4 and concentrated to dryness. 
The resulting oil was dissolved in 12 ml of DMF 
and compound 3 (0.95 g, 1.6 mmol, 1.1 eq) was 
added. When all the compounds were completely 
dissolved EDC HCl (0.3 g, 1.6 mmol, 1.1 eq) was 
added and the reaction mixture was left stirring 
overnight. The reaction mixture was concentrated 
to dryness, redissolved in DCM and washed with 5 ml of water. The organic layer 
was dried over Na2SO4 and purified by column chromatography (SiO2, MeOH:DCM, 
1:99). The desired product resulted as a white powder. Yield: 650 mg, 47%. 
1
H NMR (300 MHz, DMSO-d6, 393 K): δ = 7.89-7.78 (m, 12H), 7.54-7.46 (m, 12H), 
7.41 (t, 2H, J = 7.3 Hz), 7.34 (t, 2H, J = 7.3 Hz), 3.98 (s, 2H), 3.56-3.48 (m, 5H), 3.37 
(t, 2H, J = 6.5 Hz), 2.90-2.75 (m, 10H), 2.39 (t, 2H, 6.5 Hz), 1.43 (s, 9H)  
13
C NMR (75.5 MHz, CDCl3): δ = 172.5, 172.3, 156.8, 156.6, 141.3, 132.9, 132.4, 
131.8, 131.5, 131.3, 131.2, 131.1, 130.8, 129.0, 128.8, 128.7, 128.6, 127.8, 127.7, 
127.1, 125.2, 120.0, 82.1, 66.8, 49.7, 49.5, 47.2, 43.3, 41.6, 39.7, 28.1, 27.4 
31
P NMR (121.4 MHz, CDCl3): δ = 40.0, 39.9, 38.2, 38.1 
IR: 3421, 3054, 2925, 2847, 2357, 1966, 1912, 1720, 1645, 1517, 1478, 1450, 1436, 
1309, 1242, 1155, 1103 
Elemental Analysis Calculated for C55H59N3O6P2S2: 67.12, H 6.04, N 4.27, found: C 
67.24, H 5.69, N 4.10 
MS (ES+): 1005.72 (M+Na
+
) 
mp: 90-92 ˚C 
N-[2-(Fmoc-amino)-ethyl]-gly-N-(bis(2-(diphenylphosphorothioyl)ethyl)amino)-
4-yl(6)  
Compound 5 (0.6 g, 0.6 mmol, 1 eq) was 
dissolved in 3 ml of DCM and 4 ml of TFA (5 
mmol, 8 eq) were added at 0 ˚C. The reaction 
mixture was stirred for 2 h and concentrated to 
dryness. The resulting dry yellow powder was 
dissolved and washed with a saturated solution of 
NaHCO3 (2 x 20 ml). The organic layer was dried 
over Na2SO4 and concentrated to dryness resulting 
in a slightly yellow powder, with no further 
purification required. Yield: 440 mg, 79% 
1
H NMR (300 MHz, DMSO-d6, 363 K): δ = 7.88-7.75 (m, 12H, Ar), 7.50-7.42 (m, 
12H, Ar), 7.36 (dt, 2H, J = 7.3 Hz, 1.2 Hz), 7.30 (dt, 2H, J = 7.4 Hz, 1.4 Hz), 3.70 (s, 
1H), 3.61-3.59 (m, 1H), 3.54-3.42 (m, 5H), 3.14-2.85 (m, 6H), 2.52-2.40 (m, 2H), 
2.31 (m, 2H) 
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13
C NMR (75.5 MHz, CDCl3): δ = 175.2, 174.6, 172.3, 172.0, 156.2, 155.8, 142.9, 
140.1, 131.8, 131.3, 131.2, 130.7, 130.5, 130.2, 130.1, 129.8, 127.9, 127.8, 127.7, 
127.6, 127.5, 126.6, 126.1, 124.3, 124.0, 120.0, 118.8, 65.7, 46.0, 42.1, 40.0, 38.8, 
38.5, 38.2, 35.4, 30.5, 29.8, 29.4, 28.7, 27.1, 26.6 
31
P NMR (121.4 MHz, CDCl3): δ = 40.2, 40.1, 38.5 
IR: 3421, 3055, 2944, 1969, 1912, 1912, 1715, 1636, 1521, 1437, 1478, 1451, 1369, 
1311, 1246, 1168, 1104  
MS (ES+): 949.79 (M+Na
+
) 
mp: 125-130 ˚C 
Methyl 2,2'-bipyridine-5-carboxylate (7)
17
 
This compound was prepared following literature procedure. 
Yield: 1.45 g, 64%  
Characterization of the product fully agreed with data from 
literature.  
1
H NMR (400 MHz, CDCl3): δ = 9.20-9.19 (m, 1H), 8.65-8.63 
(m, 1H), 8.45-8.39 (m, 2H), 8.35-8.32 (m, 1H), 7.78 (t, 1H, J = 7.8 Hz, 1.7 Hz), 7.29 
(m, 1H), 3.91 (s, 3H)  
2,2'-bipyridine-5-carboxylic acid (8)
17
 
This compound was prepared following literature procedure. 
Yield: 590 mg, 84%  
Characterization of the product fully agreed with data from 
literature.  
1
H NMR (400 MHz, MeOD): δ = 9.15-9.14 (m, 1H), 8.73-7.72 
(m, 1H), 8.51-8.38 (m, 3H), 7.98 (dt, 1H, J = 7.9 Hz, 1.54 Hz), 7.52-7.49 (m, 1H) 
13
C NMR (100.6 MHz, DMSO-d6): δ = 166.1, 158.3, 154.1, 150.1, 149.5, 138.2, 
137.5, 126.5, 124.9, 121.3, 120.2 
N-[2-(Fmoc-amino)-ethyl]-gly-O-tert-butyl-N-2,2'-bipyridine-5-
carboxamido)acetate (9) 
N-[2-(Fmoc-amino)-ethyl]-gly-O-tBu·HCl (350 
mg, 0.81 mmol, 1 eq) was dissolved in 20 ml of 
chloroform and washed with 2 x 40 ml of an 
aqueous saturated solution of NaHCO3 The water 
layer was extracted with 40 ml of chloroform and 
the combined organic layers were dried over 
Na2SO4 and concentrated to dryness. The resulting 
oil was coevaporated with toluene and compound 8 
(194 mg, 0.97 mmol, 1.2 eq), EDC·HCl (217 mg, 1.13 mmol, 1.4 eq) and 20 ml of 
DCM were added. The reaction was stirred for 12 h and washed with 10 ml of water. 
The water layer was back extracted with 20 ml of DCM and the combined organic 
layers were dried over Na2SO4, filtered and concentrated to dryness. The residue 
product was purified by column chromatography (SiO2, DCM:MeOH, 96:4, SiO2). 
The desired compound resulted as a white powder. Yield: 390 mg, 84%  
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1
H NMR (300 MHz, DMSO-d6 at 393 K): δ = 8.70-8.63 (m, 2H), 8.41-8.34 (m, 2H), 
7.94-7.82 (m, 4H), 7.62 (d, 2H, J = 7.5 Hz), 7.46-7.37 (m, 3H), 7.30 (t, 3H, J = 7.5 
Hz, 1.1 Hz), 6.80 (bs, 1H), 4.31 (d, 2H, J = 6.7 Hz), 4.21 (t, 1H, J = 6.4 Hz), 4.06 (s, 
2H), 3.50 (t, 2H, J = 6.4 Hz), 3.23 (q, 2H, J = 5.8 Hz, 6.2 Hz), 1.44 (s, 9H) 
13
C NMR (100.6 MHz, CDCl3): δ = 170.1, 169.0, 168.7, 156.8, 156.2, 155.1, 149.4, 
147.3, 143.9, 141.3, 137.1, 135.7, 135.4, 131.1, 127.7, 127.1, 125.2, 124.3, 124.2, 
121.6, 120.6, 112.0, 83.2, 82.7, 67.0, 66.9, 52.7, 50.7, 49.2, 47.7, 47.2, 39.2, 28.1, 
28.0 
IR: 3357, 2978, 2361, 1720, 1589, 1518, 1434, 1369, 1246, 1152, 1091, 1018 
MS (ES+): 601.02 (M+Na
+
), HRMS calculated for C34H34N4NaO5, 601.2427; found, 
601.2427 
mp: 75-76 ˚C  
N-[2-(Fmoc-amino)-ethyl]-gly-N-2,2'-bipyridine-5-carboxamido)acetate (10) 
Compound 9 (50 mg, 0.865 mmol) was dissolved in 
TFA:water (5:1 mixture) and stirred for 2 h. Cold 
Et2O was added and a precipitate was formed. The 
solution was filtered and the solid washed with 
Et2O. The slightly yellow solid was dried in vacuo. 
Yield: 35 mg, 77% 
1
H NMR (300 MHz, DMSO-d6 at 363 K): δ = 8.68-
8.63 (m, 2H), 8.37 (d, 2H, J = 8.1 Hz), 7.98 (t, 1H, J = 7.6 Hz), 7.89 (dd, 1H, J = 8.2 
Hz, 2.1 Hz), 7.80 (d, 2H, J = 7.5 Hz), 7.60 (bd, 2H, J = 7.4 Hz), 7.51-7.47 (m, 1H), 
7.35 (t, 2H, J = 7.4 Hz), 7.26 (dt, 2H, J = 7.5 Hz, 1.2 Hz), 6.95 (bs, 1H), 4.27-4.15 (m, 
3H), 4.08 (bs, 2H), 3.46 (bs, 2H), 3.20 (bs, 2H) 
13
C NMR (75.5 MHz, CDCl3): δ = 171.1, 170.9, 169.7, 169.4, 159.5 (q, CF3, J = 
38.46 Hz), 157.7, 157.4, 157.1, 148.6, 148.5, 147.7, 147.4, 145.9, 145.6, 145.3, 143.8, 
143.7, 143.5, 143.4, 142.7, 141.1, 140.6, 137.2, 136.6, 134.5, 134.3, 133.9, 127.6, 
127.4, 126.9, 126.86, 126.78, 124.8, 124.79, 124.5, 124.0, 123.6, 122.0, 121.9, 121.8, 
119.6, 119.5, 116.8, 114.8 (q, CF3, 283.26 Hz), 114.6, 67.2, 66.5, 66.4, 51.2, 50.4, 
49.6, 46.8, 46.4, 38.5, 37.9 
IR: 3369, 3065, 1719, 1638, 1531, 1452, 1192, 1020 
MS (ES+): 522.94 (M+Na
+
), HRMS calculated for C30H27N4O5, 523.1981; found, 
523.1972 
mp: 105-109 ˚C 
General procedure for PNA synthesis
19
 
A PEGA resin with a rink amide linker (10 µm, 1 eq) was placed in a SP extractor and 
shaken with DMF for 30 min. The resin was washed with DCM, MeOH, and DMF 3 
times. 20% piperidine in DMF was added and it was shaken for 10 min. This 
procedure was repeated twice. The resin was washed again and the monomer A (41 
mg, 56.1 µmol, 5.5 eq) and PyBOP (25.5 mg, 49 µmol, 4.8 eq), in N-ethylmorpholine 
(11.7 mg, 102 µmol, 10 eq) and 550 µl of DMF were added. The mixture was placed 
in a microwave for 20 min at 60˚C. The resin was washed and the deprotection mix in 
DMF (700 µl:140 µl, 5:1) was added and shacked for 1 hour (deprotection mix: 
NH2OH·HCl (2.5 g, 3.6 mmol), imidazole (1.836 g, 2.7 mmol) in 10 ml of 1-methyl-
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2-pyrrolidone). The resin was washed again with DCM, MeOH, and DMF 3 times and 
another monomer was added to it. This procedure was repeated until the desired PNA 
length was obtained. Cleavage of PNA strand from resin was done by using 
TFA:TIS:DCM, 90:5:5 and shaking for one hour. The resulting mixture was collected 
in an eppendorf and the resin was washed with 0.6 ml of DCM and it was placed 
together with the other fraction. The mixture was dried by a flow of N2 and a yellow 
solid was formed. Diethylether was added and a white precipitate was formed. It was 
sonicated and centrifuged for 5 min. Diethylether was removed and this procedure 
was repeated a second time. The white solid was dried by a flow of N2 and purified by 
preparative HPLC. 
When monomers containing Fmoc protecting group were used for PNA synthesis the 
coupling was performed by shaking for 2 h at room temperature and a PS resin was 
used. 
 119 
4.5 References 
1. P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, Science (Washington, 
DC, United States), 1991, 254, 1497-1500. 
2. L. Bialy, J. J. Diaz-Mochon, E. Specker, L. Keinicke and M. Bradley, 
Tetrahedron 2005, 61, 8295-8305. 
3. S. Shakeel, S. Karim and A. Ali, Journal of Chemical Technology & 
Biotechnology, 2006, 81, 892-899. 
4. O. Brandt and J. D. Hoheisel, Trends Biotechnol. , 2004, 22, 617-622. 
5. J. L. Harris and N. Winssinger, Chemistry--A European Journal, 2005, 11, 
6792-6801. 
6. F. Pellestor, P. Paulasova and S. Hamamah, Curr. Pharm. Des. , 2008, 14, 
2439-2444. 
7. L. Good, S. K. Awasthi, R. Dryselius, O. Larsson and P. E. Nielsen, Nat. 
Biotechnol. , 2001, 19, 360-364. 
8. A. Mokhir, R. Stiebing and R. Kraemer, Bioorganic & Medicinal Chemistry 
Letters, 2003, 13, 1399-1401. 
9. O. Kornyushyna, A. J. Stemmler, D. M. Graybosch, I. Bergenthal and C. J. 
Burrows, Bioconjugate Chemistry, 2005, 16, 178-183. 
10. J. C. Verheijen, G. A. van der Marel, J. H. van Boom and N. Metzler-Nolte, 
Bioconjugate Chemistry, 2000, 11, 741-743. 
11. R. M. Franzini, R. M. Watson, G. K. Patra, R. M. Breece, D. L. Tierney, M. P. 
Hendrich and C. Achim, Inorg. Chem. , 2006, 45, 9798-9811. 
12. R. Corradini, S. Sforza, T. Tedeschi and R. Marchelli, Chim. Oggi 2007, 25, 
4-6, 8. 
13. M. Egholm, O. Buchardt, L. Christensen, C. Behrens, S. M. Freier, D. A. 
Driver, R. H. Berg, S. K. Kim, B. Norden and P. E. Nielsen, Nature (London, 
United Kingdom), 1993, 365, 566-568. 
14. P. Wittung, P. E. Nielsen, O. Buchardt, M. Egholm and B. Norden, Nature 
(London, United Kingdom), 1994, 368, 561-563. 
15. G. Roelfes, Mol. BioSyst. , 2007, 3, 126-135. 
16. B. P. Gilmartin, K. Ohr, R. L. McLaughlin, R. Koerner and M. E. Williams, 
Journal of the American Chemical Society, 2005, 127, 9546-9555. 
17. C. A. Panetta, H. J. Kumpaty, N. E. Heimer, M. C. Leavy and C. L. Hussey, J. 
Org. Chem. , 1999, 64, 1015-1021. 
18. K. Ohr, R. L. McLaughlin and M. E. Williams, Inorg. Chem. , 2007, 46, 965-
974. 
19. D. Pouchain, J. J. Diaz-Mochon, L. Bialy and M. Bradley, ACS Chemical 
Biology, 2007, 2, 810-818. 
20. The compounds are commercially available from Link Technologies 
21. K. L. Dueholm, M. Egholm, C. Behrens, L. Christensen, H. F. Hansen, T. 
Vulpius, K. H. Petersen, R. H. Berg, P. E. Nielsen and O. Buchardt, J. Org. 
Chem. , 1994, 59, 5767-5773. 
22. E. Kaiser, R. L. Colescott, C. D. Bossinger and P. I. Cook, Anal. Biochem. , 
1970, 34, 595-598. 
23. S. I. Antsypovitch, Russian Chemical Reviews, 2002, 71, 71-83. 
24. M. Eriksson, L. Christensen, J. Schmidt, G. Haaima, L. Orgel and P. E. 
Nielsen, New J. Chem. , 1998, 22, 1055-1059. 
25. P. E. Nielsen, Peptide Nucleic Acids. Protocols and Applications Second 
Edition Peter E. Nielsen edn., Horizon Bioscience, Norfolk, 2004. 
26. A. Porcheddu and G. Giacomelli, Curr. Med. Chem. , 2005, 12, 2561-2599. 
 120 
27. A. Agarkov, S. Greenfield, D. Xie, R. Pawlick, G. Starkey and S. R. 
Gilbertson, Biopolymers 2006, 84, 48-73. 
28. S. R. Gilbertson, G. Chen and M. McLoughlin, Journal of the American 
Chemical Society, 1994, 116, 4481-4482. 
29. R. den Heeten, Universiteit van Amsterdam, 2009. 
 
 
 
 121 
 
Chapter 5: Preliminary Studies of the Use of Aptamers in 
Catalysis 
 
5.1 Introduction 
Aptamers are RNA and DNA strands which are capable of selectively binding small 
molecules.
1-4 They are selected for a specific compound using systematic evolution of 
ligands by exponential enrichment (SELEX).
5
 A library of oligonucleotides is synthesized 
and multiplied by the Polymerase Chain Reaction (PCR). This library is then used for 
screening binding affinity towards target substrates. Two main screening methods are used; 
the first screening method consists of incubating the random polynucleotide mixture and the 
target molecule in a buffer. The aptamers that bind to the target are filtered by using a 
nitrocellulose filter partitioning. The aptamers that are not selective to the target elute first, 
the aptamers bound to the target elute last. The second method involves immobilization of the 
target molecule on a solid support. All the sequences that do not bind to the target are washed 
away. This selection is repeated several times until the desired strongest binding aptamer is 
found.
4,5,7-10
 This method has been applied to discover aptamers for several molecules.
2,4,11,12
 
The use of chiral molecules that non-covalently bind to transition metal coordinating ligands 
has been increasing over the past 30 years. After the pioneering work of Whitesides
13
 other 
groups have used proteins
14-16
 and DNA
17,18
 as a tool to transfer chirality to asymmetric 
catalytic reactions.  
Aptamers are chiral molecules that could potentially transfer their chirality to asymmetric 
reactions. Both DNA and RNA aptamers have been produced for selective binding of 
arginine as target substrate.
19,20-22
 This molecule is a commercially available amino acid 
containing an amine moiety that can be functionalized through amide bond formation. Our 
project aim is to use the high selectivity of DNA aptamers and their chirality to produce 
ligands for asymmetric reactions. Arginine will act as a non-covalent binding target, which 
will be modified with a bipyridine ligand via amide bond formation and its aptamer will be 
used to transfer its chirality to the Cu bipyridine catalyst for Diels-Alder reactions (Figure 1).  
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Figure 1. Example of a Diels-Alder reaction using the high recognition of aptamers towards a 
bipyridine ligand. Target molecule in purple represents arginine and the aptamer is represented in 
blue. 
 
Bipyridines are compatible with DNA as ligands for Diels-Alder reactions resulting in 
enantioselectivities up to 99% for reaction 1 represented in scheme 1.
17,23,24
 Moreover, 
biomolecules such as ribozymes (RNA capabe to catalyze reactions) have also been known to 
catalyze Diels-Alder reactions.
25,26
 Jäschke et al
27,28
 were the first to synthesize a Diels-
Alderase ribozyme which enantioselectively catalyzed a carbon-carbon bond formation 
between anthracene and a maleimide achieving over 95% ee for (reaction 2 represented in 
scheme 1). This catalytic reaction was chosen as a model because it is well known and is 
compatible with biomolecules. This chapter ldescribes the synthesis of a bipyridine modified 
arginine. 
 
Scheme 1. Diels-Alder reactions using a DNA catalyst (1)
17,23,24
 and a ribozyme catalyst (2)
27,28
 
 
5.2 Results and Discussion 
target 
molecule
target 
molecule
target 
molecule
target 
molecule
Aptamer
Aptamer
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5.2.1 Synthesis of modified arginine 
Bipyridine modified arginine was synthesized in three steps. The preparation of bipyridine 
carboxylic acid was previously represented in chapter 4 1. To couple the bipyridine moiety to 
arginine, bipyridine carboxylic acid 1 was activated with N-hydroxysuccinimide (NHS) to 
afford 2 in 70% yield. Coupling of 2 to L-arginine ethyl ester resulted in 98% conversion 
according to 
1
H NMR. Purification of this compound proved troublesome. Because of its 
high polarity it could not be purified by silica or alumina column chromatography and 
precipitation with a variety of solvent mixtures was unsuccessful. Finally, compound 3 was 
purified by using reverse phase HPLC on a C18 phenomenex column, although the final 
yields were poor (11%). The buffer used for the purification of this compound was 
triethylamine and acetic acid which proved difficult to remove from the desired compound 
after purification. By co-evaporation with acetonitrile and heating to 80 ˚C in vacuo most of 
the buffer was removed although one equivalent of acetic acid was still present possibly 
because of hydrogen bonding with the guanidinium group of the arginine. 
 
 
 
Scheme 2. Synthesis of bipyridine modified arginine.
29
 
 
During the addition of bipyridine carboxylic acid racemization of the desired compound is 
conceivable. Therefore, a racemic version of compound 3 was synthesized. Racemic 
ethylester arginine is not commercially available so it was synthesized from the commercial 
racemic arginine using HCl gas in ethanol to yield 77% of compound 4.
30
 The same steps as 
in scheme 1 were performed to achieve the desired racemic bipyridine ligand 5, again in poor 
yield.  
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Scheme 3. Synthesis of racemic arginine bipyridine ligand.30
Analysis of compound 5 by chiral reverse phase chromatography showed two peaks of
similar ratio (57:43), (A in Figure 2). The same analysis performed with compound 3 results
in one single peak (B in Figure 2) with very similar retention times as the second peak shown
in Figure 1. This proves that compound 3 does not racemize during its synthesis.
Figure 2. Compound 5 (A) and 3 (B) analyzed using a CHIRACEL OD-H column using
hexane:ipropanol 90:10 plus 1% TFA.
Frankel and Harada19 have identified an aptamer (5’-
GATCGAAACGTAGCGCCTTCGATC-3’) which binds to Arginine and specifically
908580757065605550454035302520151050
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
-10 ADD start peak at RT=16.075
SP
W

0.
20
ST
H

10
.
00
TI

O
FF
RT [min]
mAU mn309-15micl1.DATA [Prostar 325 Absorbance Channel 1 169.254.125.6]
908580757065605550454035302520151050
400
380
360
340
320
300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
-20
-40
-60 ADD start peak at RT=18.187
SP
W

0.
20
ST
H

10
.
00
TI

O
FF
RT [min]
mAU mn3031.DATA [Prostar 325 Absorbance Channel 1 169.254.125.6]
A
B
 125 
to the guanidinium part of the molecule. They have also shown that the negative 
charge of the carboxylate present in arginine reduces the binding affinity for the 
aptamer. For this reason it was decided to use protected arginine bipyridine ligands 3 
for preliminary catalytic studies. Preliminary studies were performed for copper 
catalyzed Diels-Alder reaction of azachalcone with cyclopentadiene using 
Cu(NO3)2·3H2O as precursor (Scheme 4).  
 
 
 
Scheme4. Diels-Alder of azachalcone with cyclopentadiene using compound 3 and/or 
aptamer. 
 
The copper complex of the aptamer adduct with compound 3 was used as catalyst for 
the Diels Alder reaction between azachalcone and cyclopentadiene resulting in 13% 
ee of the product. Under the same reaction conditions the copper catalyst derived from 
compound 3 as ligand only resulted in a racemic mixture. This preliminary study 
suggests that the DNA has a positive effect on the enantioselectivity of the reaction. It 
could be possible that the DNA binds to arginine transferring the chirality to the 
reaction or that the aptamer interacts with the copper precursor forming a metal 
complex which is active in this reaction.  
 
5.3 Conclusion 
A bipyridine modified L-arginine was synthesized and analyzed by chiral HPLC. This 
ligand was tested with and without an aptamer in copper catalyzed Diels-Alder 
reaction resulting in 13% ee when the aptamer is used. This suggests that DNA 
induces enantioselectivity of the reaction. Further studies could be focused on the 
optimization of the catalytic reaction by changing the concentration of the aptamer 
used and also by partially changing the structure of the aptamer to improve binding 
affinity. Also, the binding affinity of the aptamer toward the bipyridine modified 
arginine could be analyzed by CD spectroscopy. 
 
 
 126 
5.4 Experimental 
General procedure 
All reactions were performed under argon using standard Schlenk techniques. 
Chemicals were purchased from Aldrich Chemical Company and Acros and used as 
received. CH2Cl2 and acetonitrile were distilled over CaH2; ethanol and methanol 
were distilled over Mg/I2; THF and Et2O were distilled over sodium /benzophenone 
and all the distillations were performed under nitrogen atmosphere, N-
methylmorpholine was distilled over sodium. DMF was purchased “Extra dry” and 
stored over molecular sieves (4 Å) under argon. Thin Layer Chromatography (TLC) 
was performed on silica plates (Polygram 0.2 mm silica gel with fluorescent indicator 
UV254). Silica gel 60 particle size 0.063-0.2 mm from Fluka was used for flash 
chromatography. NMR spectra were recorded at room temperature with Bruker 
Avance spectrometers (300, 400, and 500 MHz). Positive chemical shifts () are 
given (in ppm) for high-frequency shifts relative to a TMS reference (
1
H and 
13
C) or 
an 85% H3PO4 reference (
31
P). 
13
C and 
31
P spectra were measured with 
1
H 
decoupling. The following abbreviations have been used in the description of the 
spectra: s, singlet; d, doublet; t, triplet; m, multiplet. Mass spectrometry: electrospray 
mass spectra were recorded on waters, micromass LCT time of flight mass 
spectrometer coupled to a Waters 2975 HPLC. HPLC purification of Arginine 
bipyridine was carried out in a Waters machine equipped of a Waters 2700 sample 
manager, Waters 600 controller and Waters 2487 dual absorption detector. The 
reverse phase column used was a Phenomenex, Clarity
®
 C18 5 μ oligo-RP, 250 x 
21.20. Chiral HPLC analyses of the Diels-Alder product was carried out on an 
Agilent Technologies 1200 Series apparatus equipped with a UV-Vis photodiode 
array detector. The measurements were performed at 215 nm, with an injection 
volume of 1 µl. Chiral HPLC analysis of Arginine bipyridine was carried on a Varian 
ProStar with an auto sampler Model 410. 
N-Hydroxysuccinimide-2,2'-bipyridine-5-carboxylate 
(2)
29
 
Compound 2 was prepared following literature procedure. 
Yield: 210 mg, 70 %  
Characterization of the product fully agreed with data from 
literature.  
1
H NMR (400 MHz, CDCl3): δ = 9.30-9.29 (m, 1H), 8.68-8.66 (m, 1H), 8.56-8.53 (m, 
1H), 8.47-8.42 (m, 2H), 7.81 (dt, 1H, J = 1.8 Hz, 7.7 Hz), 7.35-7.32 (m, 1H), 2.88 (bs, 
4H) 
13
C NMR (100.6 MHz, CDCl3): δ = 169.0, 161.0, 160.9, 154.4, 151.1, 149.4, 138.8, 
137.3, 125.1, 122.3, 121.1, 120.8, 25.7 
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Ethyl 2-([2,2-bipyridine]-5-carboxamido)-5-guanidinopentanoate (3) 
Compound 2 (100 mg, 0.336 mmol, 1 eq), L-arginine 
ethyl ester·HCl (92 mg, 0.336 mmol, 1 eq), and N-
methylmorpholine (81 μl, 0.740 mmol, 2.2 eq), were 
mixed together in DMF (5 ml) and stirred overnight. 
Afterwards the reaction mixture was concentrated to 
dryness, dissolved in 50:50 solution of 
water:methanol, filtered again and purified by 
Preparative HPLC using A: 0.1 mM TEAA 
(triethylamine acetic acid) buffer, B: methanol. 
Gradient 20 →55% B in 40 min. tR 25.40 min. Yield: 
14.6 mg, 11% 
1
H NMR (400 MHz, D2O): δ = 8.73 (m, 1H), 8.44 (m, 1H), 8.09-8.06 (m, 1H), 7.91-
7.80 (m, 3H), 7.36 (m, 1H), 4.49-4.45 (m, 1H), 4.15 (q, 2H, J = 7.1 Hz), 3.13 (t, 2H, J 
= 6.7 Hz), 1.95-1.89 (m, 1H), 1.85-1.74 (m, 1H), 1.66-1.60 (m, 2H), 1.17 (t, 3H, J = 
7.4 Hz) 
13
C NMR (75.5 MHz, MeOD): δ = 168.3, 159.7, 158.8, 156.2, 150.5, 149.6, 138.8, 
137.6, 130.9, 125.9, 123.1, 121.9, 62.6, 54.0, 41.9, 29.5, 26.6, 14.5  
MS (ES+): 384.91 (M+), HRMS calculated for C19H25N6O3 (acetic acid salt); 
385.1988, found 385.1987 
mp: 42-45  
[α] = +13.5 (c = 1, methanol) 
Chiral HPLC analysis using a CHIRACEL OD-H column, hexane:ipropanol 90:10 
plus 1% TFA, eluted the desired compound at tR 53.55min.  
Compound 5 was synthesized following the procedure of compound 3 using racemic 
arginine ethylester. Yield: 3.6 mg, 10%.  
1H NMR (400 MHz, MeOD): δ = 9.1 (m, 1H), 8.70 (m, 1H), 8.47-8.43 (m, 2H), 8.38-
8.35 (m, 1H), 7.98 (dt, 1H, J = 7.8 Hz, 1.8 Hz), 7.51-7.48 (m, 1H) 4.70-4.66 (m, 1H), 
4.26 (q, 2H, J = 7.1 Hz), 3.29-3.25 (m, 2H), 2.10-2.04 (m, 1H), 2.00-1.88 (m, 1H), 
1.80-1.71 (m, 2H), 1.31 (t, 3H, J = 7.4 Hz) 
Chiral HPLC analysis using a CHIRACEL OD-H column, hexane:ipropanol 90:10 
plus 1% TFA, eluted the desired compound at tR (D)33.38 min, tR (L) 50.78 min.  
Crystals suitable for X-ray crystal structure analysis were obtained by slow 
evaporation with acetonitrile. Both enantiomers were found in the crystal structure. 
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DL-Arninine ethyl ester(4)
30
 
Compound 5 was synthesized according to literature 
procedure resulting in a white powder. Yield: 1.2 g, 
77% 
Characterization of the product fully agreed with data 
from literature.  
1
H NMR (400 MHz, MeOD): δ = 4.32 (q, 2H, J = 7.0 Hz), 4.10 (t, 1H, J = 6.5 Hz), 
3.29 (t, 2H, J = 6.9 Hz), 2.08-1.94 (m, 2H), 1.85-1.68 (m, 2H), 1.34 (t, 3H, 7.1 Hz) 
General procedure for Diels-Alder reactions
29
 
Aptamer 5’-GATCGAAACGTAGCGCCTTCGATC-3’ (30 μl, 30 nmol, 2.6 eq),  
compound  3 (10 μl, 15 nmol, 1.3 eq), and Cu(NO3)2·3H2O (120 μl, 12 nmol) in 
MOPS buffer (20 mM, pH 6.5) were added together and cooled for 1.5 h at 0˚C. 
Azachalcone (3 μl, 296 nmol, 25 eq) and freshly distilled cyclopentadiene (1 μl, 10.9 
μmol, 363 eq), were added and the reaction mixture was shaken for 3 days at 4˚C. 
Then the reaction mixture was extracted with Et2O which was evaporated by a flow of 
air. The products were analyzed by chiral HPLC using an OD-H column and 
hexane:iPrOH 99:1 with a flow rate of 0.5ml/min. 15.4, 18.6 (exo isomer), 22.0, 30.1 
(endo isomer)  
ClHHN N
H
NH
NHHCl
O
O
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Conclusion and Future Work 
 
This thesis focuses on the development of metalloDNAzymes for the application in 
asymmetric catalytic reactions. Two methods are presented; the covalent and 
noncovalent approach. The covalent approach consists of introducing modified 
nucleosides with thiol or amine functionalities into oligonucleotides. This thesis 
reports the synthesis of several modified nucleosides, their introduction into 
oligonucleotides and their coupling to phosphine moieties. Thiol functionalized 
oligonucleotides were the initial target with the aim to form thioesters with phosphine 
moieties. Thioester bonds can be cleaved easily and therefore have high potential for 
the recycling of DNA ligands. The functionalization of thiol modified 
oligonucleotides proved troublesome due to unwanted reactions of the free thiol group 
during the deprotection step. These difficulties prompted us to change the strategy and 
use a less reactive linker for the introduction of phosphine moieties into DNA strands. 
Two amine modified nucleosides were successfully introduced into oligonucleotides. 
Ortho-, meta-, and para-diphenylphosphinobenzoic acids were successfully coupled 
to amine modified nucleosides and the resulting ligands were used as models for 
DNA strands in Pd-catalysed allylic substitution reactions. Although no 
enantioselectivity was observed, four of the ligands gave complete conversions in this 
reaction. Longer amine modified oligonucleotides could also be functionalized with 
phosphine moieties and a 
31
P NMR spectra of a 15-mer modified with para-
diphenylphosphinobenzoic acid and its metal complex with a Pd allylic moiety was 
successfully obtained. The method developed in this thesis enables the synthesis of 
several phosphine modified oligonucleotides as ligands for asymmetric catalytic 
reactions.  
To circumvent the problem of phosphine oxidation another covalent method is 
presented in this thesis, which consists of the synthesis of a sulfur protected phosphine 
moiety coupled to PNA strands. PNA is a stable achiral mimic of DNA. Chirality in 
PNA can be easily introduced by placing DNA as complementary strand. PNA 
strands can be synthesized with modified monomers already containing the ligand 
functionality. Since the PNA backbone is resistant to sulfur deprotection conditions, a 
protected phosphine moiety can be introduced in a PNA strand during its synthesis. 
Unfortunately, the preparation of long modified PNA strands was found troublesome 
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although a PNA 5-mer containing a bidentate sulfur protected phosphine could be 
successfully prepared. Further work on this method will allow the introduction of 
protected phosphine moieties into PNA strands during its synthesis and therefore 
easing ligand purification.  
As an alternative to the covalent approach, a preliminary study in using aptamers as 
chiral scaffold has also been presented in this thesis. Several aptamers have been 
reported to bind to L-arginine, which has been chosen as the target molecule to couple 
to a transition metal coordinating ligand. A 2,2’-bipyridine modified L-arginine was 
successfully synthesized and tested with and without an aptamer in a copper catalyzed 
Diels-Alder reaction, resulting in 13% ee when the aptamer was used. This suggests 
that the DNA aptamer induces enantioselectivity in the reaction.  
The successful preparation of phosphine modified oligonucleotides developed in this 
thesis is a promising starting point for using phosphine modified “DNAzymes” as 
ligands for enantioselective transition-metal catalyzed reactions. This thesis contains 
the ground work to obtain DNA modified phosphines, which in the future can be 
tested in several different catalytic reactions. In addition, different complementary 
strands can be used to change the local environment of the substrate (Scheme 1); 
different transition metals can be used such as Rh, Pd, and Ir; and different types of 
phosphines bearing a carboxylic acid moiety can be coupled to the DNA, as shown by 
Jäschke
1
 (Scheme 2), increasing the variety of ligands that can be synthesized in a 
relatively short period of time.  
 
 
Scheme 1. Coupling of a phosphine moiety to a DNA strand and introduction of 
complementary strands. Introduction of a complementary strand also containing a phosphine 
moiety results in a bidentate (a), mismatches in the complementary strand sequence can give 
rise to loops in the complementary strands (b) in the modified strand (c), or in a self 
complementary strand (d), addition of a fully complementary strand (e) produces yet another 
environment. 
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Scheme 2. DNA strands containing different phosphine ligands.
1
 
 
In future work the use of thiol functionalities, which provide a convenient reversible 
thioester linkage between the DNA and the phosphine functionality, can be carried 
out by synthesizing nucleosides which do not contain a reactive alkynyl functionality. 
A few examples of such monomers can be found in the work of Glick
2
 and Eritja
3
 
(Scheme 3). 
 
 
Scheme 3. Nucleosides containing a thiol linker.
2, 3
 
 
PNA is a biomolecule with high potential as ligand in catalytic reactions. This thesis 
shows the successful introduction of protected phosphine moieties in short PNA 
strands. In future work Dde instead of Fmoc protecting group can be used to avoid 
problems during strand synthesis. PNA binds more strongly to DNA than DNA does 
with itself and therefore shorter strands can be synthesized to simplify the syntheses. 
Phosphine deprotection was unsuccessful therefore different phosphine moieties that 
might be more prone to sulfur deprotection or the use of a phosphorous scavenger 
such as tributylphosphine
4
 can also be tested. As with DNA, PNA ligands could be 
modified by changing the complementary DNA strands, using different types of 
ligand functionalities and different transition metals.  
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Finally, the preliminary study presented in this thesis demonstrates that the arginine 
aptamer plays a role in the enantioselectivity of a Diels-Alder reaction. This method 
will allow the easy synthesis of ligands without the need to apply modifications to the 
DNA structure and without the need of anaerobic conditions. Further studies can be 
focused on the optimization of the catalytic reaction by changing the concentration of 
the aptamer used and by partially changing the structure of the aptamer or arginine to 
improve binding affinity. In addition, the binding affinity of the aptamer toward the 
2,2’-bipyridine modified arginine can be analyzed by CD spectroscopy. For a better 
insight on the catalytic reaction, the racemic arginine bipyridine ligand can be used in 
the catalytic reactions to understand the importance of the chirality of the arginine 
ligand for binding to the aptamer. In addition, catalytic runs with only DNA and 
copper are necessary to understand whether the enantioselectivity observed is 
generated from the aptamer/arginine ligand or from the aptamer alone interacting with 
the copper precursor. 
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Appendix: Crystallographic Data 
 
The complete crystallographic data (.cif file) for the compounds bellow can be found 
in the CD accompanying this thesis.  
 
Table 1. Crystal data and structure refinement for compound 5 (Chapter 2). 
Identification code  10 
Empirical formula  C15 H17 N3 O5 S 
Formula weight  351.38 
Temperature  93(2) K 
Wavelength  0.71075 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 5.2132(11) Å α = 90°. 
 b = 9.1903(18) Å β = 90°. 
 c = 32.342(7) Å γ = 90°. 
Volume 1549.5(6) Å3 
Z 4 
Density (calculated) 1.506 Mg/m3 
Absorption coefficient 0.242 mm-1 
F(000) 736 
Crystal size 0.15 x 0.10 x 0.01 mm3 
Theta range for data collection 2.30 to 25.33°. 
Index ranges -6<=h<=5, -11<=k<=10, -38<=l<=38 
Reflections collected 15517 
Independent reflections 2831 [R(int) = 0.0252] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction multiscan 
Max. and min. transmission 0.9976 and 0.9646 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2831 / 0 / 217 
Goodness-of-fit on F2 1.119 
Final R indices [I>2sigma(I)] R1 = 0.0567, wR2 = 0.1607 
R indices (all data) R1 = 0.0576, wR2 = 0.1618 
Absolute structure parameter -0.01(15) 
Largest diff. peak and hole 0.691 and -0.296 e.Å-3 
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Table 2. Crystal data and structure refinement for compound 11 (Chapter 2). 
Identification code  2 
Empirical formula  C20 H20 N2 O6 S 
Formula weight  416.44 
Temperature  173(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 4.8756(4) Å α = 90°. 
 b = 16.2429(13) Å β = 90°. 
 c = 23.7663(19) Å γ = 90°. 
Volume 1882.1(3) Å3 
Z 4 
Density (calculated) 1.470 Mg/m3 
Absorption coefficient 1.902 mm-1 
F(000) 872 
Crystal size 0.20 x 0.20 x 0.03 mm3 
Theta range for data collection 3.30 to 68.00°. 
Index ranges -5<=h<=5, -19<=k<=19, -28<=l<=28 
Reflections collected 20497 
Independent reflections 3104 [R(int) = 0.0521] 
Completeness to theta = 68.00° 93.9 %  
Absorption correction multiscan 
Max. and min. transmission 0.9451 and 0.7022 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3104 / 0 / 263 
Goodness-of-fit on F2 1.003 
Final R indices [I>2sigma(I)] R1 = 0.0651, wR2 = 0.1734 
R indices (all data) R1 = 0.0686, wR2 = 0.1766 
Absolute structure parameter 0.05(4) 
Largest diff. peak and hole 0.567 and -0.303 e.Å-3 
 
 
 
 
 
 
 
 
 
 137 
Table 3. Crystal data and structure refinement for compound 19 (Chapter 2). 
Identification code  1 
Empirical formula  C13 H16 N2 O5 S 
Formula weight  312.34 
Temperature  93(2) K 
Wavelength  0.71070 Å 
Crystal system  Monoclinic 
Space group  C2 
Unit cell dimensions a = 20.69(5) Å α = 90°. 
 b = 6.819(16) Å β = 111.36(6)°. 
 c = 11.35(4) Å γ = 90°. 
Volume 1491(7) Å3 
Z 4 
Density (calculated) 1.391 Mg/m3 
Absorption coefficient 0.240 mm-1 
F(000) 656 
Crystal size 0.35 x 0.11 x 0.01 mm3 
Theta range for data collection 2.11 to 25.44°. 
Index ranges -24<=h<=24, -8<=k<=8, -13<=l<=13 
Reflections collected 7338 
Independent reflections 2715 [R(int) = 0.3862] 
Completeness to theta = 25.44° 98.9 %  
Absorption correction multiscan 
Max. and min. transmission 0.9976 and 0.9208 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2715 / 1 / 92 
Goodness-of-fit on F2 1.495 
Final R indices [I>2sigma(I)] R1 = 0.2236, wR2 = 0.4824 
R indices (all data) R1 = 0.2379, wR2 = 0.5160 
Absolute structure parameter -1.0(4) 
Largest diff. peak and hole 1.080 and -1.200 e.Å-3 
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Table 4. Crystal data and structure refinement for compound 15 (Chapter 3). 
Identification code  4 
Empirical formula  C12 H15 N3 O5 
Formula weight  281.27 
Temperature  93(2) K 
Wavelength  0.71069 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 6.633(3) Å α = 90°. 
 b = 10.934(5) Å β = 90°. 
 c = 17.203(8) Å γ = 90°. 
Volume 1247.7(10) Å3 
Z 4 
Density (calculated) 1.497 Mg/m3 
Absorption coefficient 0.118 mm-1 
F(000) 592 
Crystal size 0.30 x 0.10 x 0.03 mm3 
Theta range for data collection 3.29 to 28.14°. 
Index ranges -6<=h<=8, -13<=k<=14, -16<=l<=22 
Reflections collected 7432 
Independent reflections 2606 [R(int) = 0.1290] 
Completeness to theta = 28.14° 90.7 %  
Absorption correction multiscan 
Max. and min. transmission 0.9965 and 0.9654 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2606 / 0 / 182 
Goodness-of-fit on F2 0.991 
Final R indices [I>2sigma(I)] R1 = 0.1225, wR2 = 0.2564 
R indices (all data) R1 = 0.1904, wR2 = 0.2910 
Absolute structure parameter 2(4) 
Largest diff. peak and hole 0.518 and -0.436 e.Å-3 
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Table 5. Crystal data and structure refinement for compound 37 (Chapter 3) 
Identification code  agpk5 
Empirical formula  C31 H32 N3 O6 P 
Formula weight  573.57 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 8.2680(15) Å α = 90°. 
 b = 12.254(2) Å β = 92.063(5)°. 
 c = 13.839(3) Å γ = 90°. 
Volume 1401.2(4) Å3 
Z 2 
Density (calculated) 1.359 Mg/m3 
Absorption coefficient 0.148 mm-1 
F(000) 604 
Crystal size 0.1000 x 0.1000 x 0.1000 mm3 
Theta range for data collection 2.22 to 25.37°. 
Index ranges -8<=h<=9, -12<=k<=14, -12<=l<=16 
Reflections collected 8867 
Independent reflections 4839 [R(int) = 0.0272] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.9836 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4839 / 5 / 387 
Goodness-of-fit on F2 0.715 
Final R indices [I>2sigma(I)] R1 = 0.0479, wR2 = 0.1285 
R indices (all data) R1 = 0.0500, wR2 = 0.1326 
Absolute structure parameter 0.19(11) 
Largest diff. peak and hole 1.388 and -0.358 e.Å-3 
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Table 6. Crystal data and structure refinement for compound 38 (Chapter 3) 
Identification code  agpk3 
Empirical formula  C31 H32 N3 O6 P 
Formula weight  573.57 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 8.321(2) Å α = 75.93(2)°. 
 b = 10.6140(19) Å β = 88.69(3)°. 
 c = 18.263(6) Å γ = 68.52(3)°. 
Volume 1451.9(6) Å3 
Z 2 
Density (calculated) 1.312 Mg/m3 
Absorption coefficient 0.143 mm-1 
F(000) 604 
Crystal size 0.1500 x 0.0800 x 0.0500 mm3 
Theta range for data collection 2.13 to 25.37°. 
Index ranges -10<=h<=9, -10<=k<=12, -21<=l<=21 
Reflections collected 9047 
Independent reflections 6748 [R(int) = 0.0774] 
Completeness to theta = 25.00° 96.7 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.9748 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6748 / 11 / 764 
Goodness-of-fit on F2 0.981 
Final R indices [I>2sigma(I)] R1 = 0.0792, wR2 = 0.1737 
R indices (all data) R1 = 0.1114, wR2 = 0.2032 
Absolute structure parameter 0.1(2) 
Largest diff. peak and hole 1.029 and -0.376 e.Å-3 
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Table 7. Crystal data and structure refinement for compound 5 (Chapter 5). 
Identification code  9 
Empirical formula  C19 H24 N6 O3 
Formula weight  384.44 
Temperature  173(2) K 
Wavelength  1.54187 Å 
Crystal system  Orthorhombis 
Space group  Pbca 
Unit cell dimensions a = 30.217(6) Å α = 90°. 
 b = 16.724(3) Å β = 90°. 
 c = 9.365(2) Å γ = 90°. 
Volume 4732.8(17) Å3 
Z 8 
Density (calculated) 1.079 Mg/m3 
Absorption coefficient 0.621 mm-1 
F(000) 1632 
Crystal size 0.30 x 0.01 x 0.01 mm3 
Theta range for data collection 2.92 to 68.07°. 
Index ranges -36<=h<=36, -19<=k<=20, -11<=l<=11 
Reflections collected 57858 
Independent reflections 4289 [R(int) = 0.2367] 
Completeness to theta = 67.00° 99.9 %  
Absorption correction multiscan 
Max. and min. transmission 0.9938 and 0.8356 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4289 / 0 / 130 
Goodness-of-fit on F2 1.942 
Final R indices [I>2sigma(I)] R1 = 0.2212, wR2 = 0.5181 
R indices (all data)    R1 = 0.2631, wR2 = 0.5468 
Largest diff. peak and hole 2.612 and -1.010 e.Å-3 
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Table of Abbreviations 
AdaOH  adamantane acetic acid 
CAST   combinational active-site saturation test  
Cbz   carbobenzyloxy 
CDI   1,1′-carbonyldiimidazole 
CS   commercial strand 
Bhoc   benzhydryloxy carbonyl 
Boc   tert-butyloxycarbonyl 
BSA   (N,O-bis(trimethylsilyl)acetamide) 
DBU   1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC   N,N′-dicyclohexylcarbodiimide 
DCM   dichloromethane  
Dde   1-(4,4-dimethyl-2,6-dioxacyclohexylidene)ethyl 
DMF   dimethylformamide 
DMT-Cl  4,4'-dimethoxytrityl chloride 
DNA   deoxyribonucleic acids 
dppba    diphenylphosphine benzoic acid 
EDC   N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
EPA   environmental protection agency  
FMN   flavin mononucleotide  
Fmoc   9-Fluorenylmethyloxycarbonyl 
FPLC   fast protein liquid chromatography 
15-mer  oligonucleotide 15 bases long 
Trimer  oligonucleotide 3 bases long 
HMBC  heteronuclear multiple bond correlation 
HOBT  1-hydroxybenzotriazole 
HPLC   high performance liquid chromatography 
IPEA   diisopropylethylamine 
IU   5-iodo-2’-deoxyuridine  
MW   molecular weight 
MMT-Cl  4-Methoxytriphenylmethyl chloride 
NHS   N-hydroxysuccinimide 
NMR   nuclear magnetic resonance 
nt   nucleotides  
PCR   polymerase chain reaction 
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SELEX  systematic evolution of ligands by exponential enrichment  
TCEP   tris(2-carboxyethyl)phosphine hydrochloride 
TEA   tryethylamine  
TEAA  triethylamine acetic acid  
TFA   trifluoroacetic acid  
THF   tetrahydrofuran 
TIS   triisopropylsilane 
VEGF   endothelial growth factor  
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